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Abstract 
Characterization of serum amyloid P and Fe gamma receptor: a critical engagement 
implicated in fibrosing diseases 
by 
Jeffrey Crawford 
Fibrotic diseases have a poor prognosis with no FDA approved therapies. 
Monocyte-derived, fibroblast-like cells called fibrocytes participate in the formation of 
fibrotic lesions. The conserved pentraxin protein serum amyloid P (SAP) inhibits 
fibrocyte differentiation in cell culture, and injections of SAP significantly reduce fibrosis 
in several animal models. SAP binds to the receptors for the Fe portion of 
immunoglobulin G (FcyR), and has been crystallized bound to FcyRIIa. The in vivo 
activity of SAP appears to be dependent on the common y chain (FcRy) of activating Fe 
receptors. The goal of my project is to elucidate the functional domains of SAP and the 
receptor responsible for SAP bioactivity, which could lead to refinements for SAP as a 
therapeutic agent and additional drug targets. 
I found that mutagenesis of the residues critical for SAP binding to FcyRIIa only 
moderately decreases SAP's ability to inhibit fibrocyte differentiation. In murine cells, 
deletion of FcRy or FcyRI significantly reduced sensitivity to SAP. Deletion of the 
combination of FcyRIIb/FcyRIIIa!FcyRIV did not significantly affect sensitivity to SAP, 
while deletion of just the inhibitory receptor FcyRIIb increased sensitivity to SAP. In 
human cells, siRNA-mediated reduction of FcRy or FcyRI levels significantly decreased 
sensitivity to SAP, while reduction ofFcyRIIb levels increased sensitivity to SAP. These 
observations suggest that SAP, at least in part, uses FcyRI and FcRy to inhibit fibrocyte 
differentiation. 
I am also interested in how SAP functions in various disease states. SAP is 
known to be elevated in Alzheimer's disease (AD) and binds to amyloid plaques in the 
brain, a key hallmark of AD. There is a significant population of individuals that have 
key hallmarks of AD but show no signs of cognitive impairment, termed non-demented 
with AD neuropathology (NDAN). I evaluated SAP levels in post mortem samples of 
hippocampus and frontal cortex in age-matched controls, AD, and NDAN individuals. 
AD individuals had significantly increased SAP levels, while NDAN samples had no 
significant difference in SAP levels compared to controls. These results suggest that low 
levels of SAP in plaques marks the brains of individuals that escape dementia despite the 
presence of beta amyloid plaques. 
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Chapter 1: Fibrocytes in fibrosing diseases and potential regulation by serum 
amyloid P. 
1.1 Fibrosing diseases. 
1 
Fibrosis is an aberrant condition involving repeated tissue injury and 
inflammation, resulting in scar-like lesions composed primarily of extracellular matrix 
(ECM) proteins such as collagen and fibronectin (Kumar et al., 2005). This excess 
buildup of scar tissue leads to tissue dysfunction and eventual organ failure. 
Fibrosing diseases are characterized by a chronic and severely debilitating 
condition with a high mortality rate. Idiopathic pulmonary fibrosis is one such disorder 
with a 70% mortality rate within 5 years of diagnosis due to the excessive remodeling of 
the lung and collagen deposition (Perez et al., 2003). Other fibrosing diseases include 
scleroderma, hypertrophic scarring, chronic kidney disease, liver fibrosis, and a major 
killer in the US, congestive heart failure (Lupher et al., 2006). There are currently no 
FDA approved therapies so there is a serious unmet medical need (Bouros et al., 2005). 
Increasing evidence suggests that fibroblast-like cells termed fibrocytes are implicated in 
the formation of fibrotic lesions and can potentially differentiate into or activate existing 
fibroblasts into a more active cell type involved in collagen production, the 
myofibroblasts (Lupher, et al., 2006; Herzog et al., 2010). My project deals with 
determining how a potential therapeutic for fibrosing diseases, serum amyloid P, 
functions in its ability to regulate fibrocyte differentiation, which could lead to new and 
even more effective therapeutics. 
2 
1.2 Fibrocytes are involved in wound healing and implicated in fibrosing diseases. 
To heal wounds, several cell types help form new tissue. Local fibroblasts 
migrate to the source of the wound and proliferate (Clark, 2001). In addition, circulating 
monocytes can leave the blood, enter the wound, and differentiate into spindle-shaped, 
fibroblast-like cells called fibrocytes (Bucala eta!., 1994; Abe eta!., 2001 ). At the site of 
a wound, fibrocytes secrete extracellular matrix proteins such as collagen to rebuild 
tissue, secrete inflammatory cytokines, stimulate angiogenesis, and promote wound 
closure (Chesney et a!., 1998; Hartlapp et a!., 2001). In addition to their beneficial 
effects, fibrocytes have been implicated in the formation of the scar tissue-like lesions in 
a variety of fibrosing diseases such as pulmonary fibrosis, congestive heart failure, 
cirrhosis of the liver, renal fibrosis, and nephrogenic systemic fibrosis (Cowper et a!., 
2003; Phillips et a!., 2004; Haudek et a!., 2006; Kissel eva et a!., 2006; Mehrad et a!., 
2007; Sakai eta!., 2010). Fibrocytes have also been detected in bronchial asthma and 
hypertrophic scarring (Schmidt eta!., 2003; Yang eta!., 2005). 
Fibrocytes derive from a subset of CD14+ monocytes in human peripheral blood, 
and mature fibrocytes express markers of both hematopoietic cells (CD34, CD45, LSP-1, 
MHC Class II) and stromal cells (collagen I and Ill, fibronectin) (Bucala et a!. 1994; Abe 
eta!., 2001; Gomperts eta!., 2007; Pilling eta!., 2009b). Fibrocyte differentiation is 
inhibited by the serum protein serum amyloid P (SAP) as well as cross-linked lgG 
(Pilling eta!., 2003, 2006). 
3 
1.3 Serum Amyloid P as a regulator of fibrocyte differentiation. 
The regulation of fibrocytes is essential for proper wound repair; thus, a factor is 
present in the serum to regulate fibrocyte differentiation. The Gomer lab has identified 
serum amyloid P (SAP), a member of the pentraxin family of proteins, as the factor that 
prevents the rapid appearance of fibrocytes in a human peripheral blood mononuclear cell 
culture (Pilling et al., 2003). SAP is a glycoprotein that is secreted by the liver into the 
blood and has 51% amino acid homology to C-reactive protein (CRP), another member 
of the pentraxin family (Pepys et a!., 1983 ). The pentraxin family is characterized by a 
planar disc arrangement of five, non-covalently associated monomers (Figure 1.1; Woo et 
al., 1985; Thompson et al., 2002). SAP monomers have a mass of 25.46 kDa and are 
folded as a two-layered ~-sheet with a jelly roll topology (Thompson et al., 2002; 
Aquilina et al., 2003). On one side of the roll is an alpha helix, and on the opposite side 
are two calcium binding sites. As a pentamer, the SAP disc-like structure consists of an 
"A face" with five alpha helixes and a "B face" that binds calcium (Figure 1.1; 
Thompson et al., 2002). 
SAP is a pattern recognition protein that binds a variety of ligands in a calcium 
dependent manner, including pathogen components like bacterial lipopolysaccharide 
(LPS), and autoimmune I apoptotic components like chromatin, histones, and 
phosphoethanolamine (Emsley et al., 1994; Pepys et al., 1997). CRP binds to similar 
ligand types, but the exact role of SAP and CRP within the body remains unclear (Pepys 
et al., 1997). Both proteins likely play a role in the initiation and clearance of an immune 
response because SAP and CRP can opsonize cells for phagocytosis to eliminate 
4 
A B 
Figure 1.1: Crystal structure of SAP. MMDB ID: 2151. Visualized with Pymol 
(Delano, 2002). (A) Side view of SAP "disc". The "A" face is purported to bind the Fey 
receptor, the "B" face binds ligands such as bacterial lipopolysaccharide, chromatin, and 
phosphoethanolamine. (B) Overhead view of SAP "A" face. 
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pathogens and cellular debris (Bharadwaj et al., 2001). It has been proposed that SAP 
and CRP opsonize cells by binding to a ligand (such as bacteria or an apoptotic cell) on 
the B face, and then binding through its A face to a Fey receptor (FcyR) on a phagocytic 
cell (Figure 1; Bharadwaj et al., 2001; Bodman-Smith et al., 2002; Mold eta/., 2002). 
However, SAP and CRP likely have distinct roles in vivo because of differences in their 
biology and structure. For instance, SAP levels remain relatively constant within the 
blood, while CRP levels increase up to 1 000 fold during an immune response and CRP 
can activate innate immunity through the complement cascade (Pepys et al., 1978 & 
1983; Mold et al., 1999). Another difference is that SAP is glycosylated with aN-linked 
biantennary oligosaccharide at Asn32, while CRP is not glycosylated in serum except in 
some pathological conditions (Emsley et al., 1994). 
One of the proposed roles of SAP in vivo is the regulation of fibrocyte 
differentiation within the circulation and peripheral tissues (Pilling et al., 2003). During 
resolution of an immune response, serum proteins are often cleared from the site of 
infection (Haslett et al., 1988). Within a wound, SAP may no longer be present due to 
such clearance or SAP's binding to other ligands to clear cellular debris. Without the 
presence of SAP to inhibit fibrocyte differentiation, monocytes can differentiate into 
fibrocytes and initiate wound repair. However, the monocyte will likely not immediately 
differentiate into a fibrocyte and close the wound, since closing an infected wound could 
result in gangrene and further cell death (Ferreira et a/., 2006). Instead, aggregated 
immunoglobulin, which binds pathogens and also inhibits fibrocyte differentiation, will 
6 
prevent premature appearance of fibrocytes until the wound is clear of pathogens (Pilling 
et at., 2006). 
Because fibrocytes participate and help regulate wound healing, manipulating 
SAP levels could also be beneficial to promote wound healing (Mori et at., 2005). 
Fibrocytes are present in hypertrophic scars, and the ability to manipulate SAP levels 
could potentially reduce scarring (Yang et at., 2005). Altering SAP levels could also 
potentially help diabetics who have slow wound healing. SAP-depleting bandages have 
been used to accelerate wound healing in pigs, and local and systemic injections of SAP 
slow woun healing in mice (Naik-Mathuria et at., 2008; Gomer et at., 2009). 
In addition, smce fibrocyte dysregulation has been associated with fibrotic 
diseases and SAP can inhibit fibrocyte differentiation in vitro (Pilling et at., 2003), SAP 
has been tested as a therapeutic in a number of fibrosing disease model systems. We 
found that injections of SAP significantly reduced the levels of fibrosis in bleomycin-
induced pulmonary fibrosis in a mouse and rat model system (Pilling et. at, 2007). We 
hypothesize that SAP prevents fibrosis by inhibiting fibrocyte differentiation. SAP has 
also successfully been used to treat model systems of ischemic cardiomyopathy, 
Aspergillus fumigatus-induced allergic airway disease, radiation-induced oral mucositis, 
renal fibrosis, and kidney fibrosis (Haudek et at., 2006; Castano et at. 2009; Moreira et 
al., 2010; Murray et at., 2010). Additionally, SAP is undergoing Phase II clinical trials 
tests to inhibit scar formation in ocular surgery by Promedior (Malvern, P A). In these 
disease model systems, SAP appears to have acted through the reduction of fibrocytes 
7 
(Haudek et al., 2006; Pilling et at., 2007) or inhibition of pro-fibrotic inflammatory M2 
macrophages (Castano et at., 2009; Moreira et at., 2010). Understanding how SAP 
functions could be beneficial not only for developing therapies for fibrosing diseases but 
also for promoting wound healing. My project could potentially impact both fields by 
allowing for fine tuned manipulation of SAP and its receptor. 
1.4 SAP binds to Fey receptors (FcyR), key receptors in mediating the immune 
response. 
To determine the functional domain of SAPs we will examine how SAP interacts 
with its receptor, FcyR. However, FcyR are known for mediating the immune response 
through the binding of immunoglobulin (IgG) antibodies. FcyRs are found on a variety 
of hematopoietic cells and bind the Fe portion of IgG antibodies (Ravetch et at., 2001). 
Once aggregated IgG cross-links multiple receptors, a signaling cascade is activated 
through tyrosine kinases to initiate an immune response (Daeron, 1997). There are four 
activating Fey receptors: FcyRI (CD64), IIa (CD32a), Ilia (CD16a), and IIIb (CD16b). In 
contrast, FcyRIIb (CD32b) triggers an inhibitory signaling pathway to help modulate the 
immune response (Nimmerjahn et al., 2008). The signaling cascades initiated by the 
receptors can be initiated directly by FcyRIIa and FcyRIIb, while FcyRI and IIIalb require 
an accompanying gamma chain (FycR) to initiate the signal (see figure 1.2). The 
signaling pathways initiated by the different receptors are quite similar. After the 
receptors are crosslinked, the tyrosine in the IT AM domain is phorphorylated by kinases 
of the SRC cellular activation. It is interesting to note that the binding of SAP to FcyRs 
initiates a family (Ravetch 2003). This leads to recruitment of the SYK family of 
A 
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Figure 1.2: The family of Fey receptors in (A) humans and (B) mice. 
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Green 
represents IT AM activating dotnains, red the ITIM inhibitory domain. Parenthesis around 
IgG subtypes indicates that the subtypes can bind in vitro to the FcyR but does not require 
the receptor in vivo to function. Adapted from Nimmerjahn et al. (2008). 
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kinases, followed by the activation of downstream pathways such as RAS-RAF-MAPK, 
important for similar but not identical pathway. SAP utilizes the SRC family of kinases 
but does not appear to rely on SYK since a SYK-agonist failed to block the bioactivity of 
SAP (Pilling et al., 2006). 
FcyRs are also defined by their affinity for binding monomeric or aggregated lgG. 
FcyRI is the high affinity receptor for both monomeric and aggregated lgG, while the 
remaining receptors bind only aggregated IgG with low to medium affinity. The 
extracellular region of the Fe receptors is composed of two domains containing 
immunoglobulin-like folds, termed D1 and D2, with IgG binding to D2. Additionally, 
FcyRI has a third extracellular domain D3, which accounts for its ability to bind IgG with 
high affinity (Hullet et al., 1998; figure 1.2). IgG will intercalate into the groove formed 
by the two different extracellular domains, forming an asymmetrical contact between the 
single FcyR and the Fe binding portion of IgG, which prevents a second receptor from 
binding to the same Fe portion of IgG (Nimmerjahn et al., 2008). Therefore, a single 
lgG molecule cannot cross-link multiple receptors and elicit an immune response. It 
requires multiple IgGs to form an immune complex by binding to an antigen like a 
pathogen or by heating lgGs to cause them to self aggregate. 
The activating and inhibitory Fey receptors work together to modulate an immune 
response. This is further complicated by the fact that there are four specific IgG 
subtypes that also bind with varying affinity and specificity to the FcyRs to elicit specific 
responses (Dijstelbloem et al., 2001; see Figure 1.2). As another complication, the 
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biology of the FcyRs is not consistent across species. A significant portion of my studies 
are in the murine system with distinct FcyR biology. Similar to humans, there are both 
activating and inhibitory FcyRs. In mice, the activating FcyRs are FcyRI, III, and IV, and 
all three require the accompanying gamma chain for signaling (Nimmerjahn et al., 2008). 
The inhibitory receptor is FcyRIIb, similar to humans, while mice lack FcyRIIIb, an 
activating receptor unique to human neutrophils (Ravetch et al., 1991). Based on 
sequence similarity of the extracellular domain, mouse FcyRIII is most closely related to 
human FcyRIIa, while FcyRIV is most closely related to human FcyRIIIa (Hughes et al., 
1996). Additionally, the affinity for specific IgG subtypes by murine FcyRs is much 
higher than those found in humans. These differences should be taken into account 
when trying to extrapolate any results from mice to humans. 
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Chapter 2: Determining the functional domains of SAP through mutagenesis. 
2.1 Introduction 
There are no FDA approved therapies for the treatment of fibrosing disorders. 
Because SAP is a potential therapeutic for such diseases and is currently undergoing 
Phase II trials, there is great interest in understanding how SAP functions. To determine 
the functional domains of SAP, residues were altered by site-directed mutagenesis. For 
the initial mutagenesis, residues were selected that could potentially bind to the SAP 
receptor, FcyR. There are multiple reasons why we are focusing on SAP's ability to bind 
FcyR in trying to determine the functional domain of SAP. The bioactivity in question is 
SAP's ability to inhibit monocytes from becoming fibrocytes. SAP was previously 
found to bind to monocytes, monocytes express all three main classical subtypes ofFcyR, 
SAP has been found to initiate a signaling cascade consistent with FcyR ligation, and 
SAP has been crystallized bound to FcyRIIa (Bharadwaj et al., 2001; Grage-Griebenow 
et al., 2001; Chi et al., 2002; Macdonald et al., 2006; Lu et al., 2008). Additionally, 
SAP's ability to inhibit fibrosis in mouse models of pulmonary and kidney fibrosis was 
dependent on activating FcyRs (Haudek et al., 2008; Castano et al., 2009). 
To select residues for mutagenesis, I initially compared SAP to two conserved 
regions of IgG, 234L(F)LGGPS239 and 327ALPAPe33, that contact the FcyR when IgG 
binds to the receptor (Radaev et al. 2001 ). Assuming that there is functional homology in 
having a similar amino acid motif, I selected residues 178-183 of SAP, which closely 
resembles the 327 ALP API333 sequence from IgG (See table 2.1 ). C-reactive protein 
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(CRP), a pentraxin and serum protein that also binds FcyRs, is known to have a sequence 
that resembles the IgG 234L(F)LGGPS239 region (Bang et al., 2005). CRP has distinct 
bioactivity from SAP and does not inhibit fibrocyte differentiation, and this difference in 
IgG-like binding domains could account for this. 
A second region was also selected for mutagenesis based on a published SAP-
FcyRIIa crystal structure, which suggests a completely separate region to focus upon. Lu 
et a/.(2008) crystallized SAP binding to the extracellular domain of the human FcyRIIa 
receptor to 2.8 A resolution. For crystallization, SAP was purportedly dissociated into 
monomers and mixed with a 1:1 molar ratio of E.coli expressed ecto-domain ofFcyRIIa. 
The resulting complex suggests that one FcyRIIa molecule would bind across the face of 
one SAP pentamer with the D 1 and D2 domains of the receptor contacting 2 subunits of 
the pentraxin (see Figure 2.1, contacts between 2 SAP monomers). SAP binds to the 
receptor along the ridge helix region (Pro 166 to Gin 174) with key residues being Tyr 
173 and Gin 174 (Figure 2.1, highlighted red spheres). Additionally, the C-terminus 
residues near the SAP pentamerization domain (Srinivassan et al., 1994) come in contact 
with the Dl and D2 domains ofthe receptor. 
In this chapter, I show that recombinant SAP produced both in bacteria and 
human cells is bioactive. The bacterially expressed SAP displays some interesting 
biology such as promoting fibrocyte differentiation when altering reside 182, while 
reducing differentiation when residue 180 was mutagenized. However, only the SAP 
expressed by human tissue cultured cells retains native structure as a pentamer, which 
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Table 2.1: Sequence homology between SAP, CRP, and IgG binding regions. 
SAP sequence 173 174 175 176 177 178 179 180 181 182 183 
Human SAP y Q G T p L p A N L 
Human CRP y L G G p F s p N L 
HumanlgGl L L G G p L p A p E 
Human IgG2 v A G p p p E 
HumanigG3 L L G G p L p A p E 
Human IgG~ F L G G p s s E 
IgG seguence (EU sys) 234 235 236 237 238 328 329 330 331 332 333 
Comparison of SAP to two different IgG binding regions 234L(F)LGGPS239 and 
327 ALP API333 (Bang eta!. , 2005). SAP closely resembles the 327-333 lgG sequence. 
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Figure 2.1: Crystal structure of SAP-FcyRIIa complex. MMDB ID: 67886 (Lu eta/. 
2008). Only the SAP monomers that come in contact with FcyR are shown. The FcyR is 
highlighted as multi-colored dotted spheres, the interface residues on SAP are highlighted 
as red spheres, and the purported lgG-like 234L(F)LGGPS239 region is highlighted as blue 
spheres (initial site selected for mutagenesis). 
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ensures that any change in bioactivity when mutagenized is due to the alteration of a 
specific amino acid residue rather than a change in gross structure. Mutagenesis of the 
IgG like domain does not significantly alter SAP bioactivity, while mutagenesis of key 
residues from the SAP-FcyRIIa crystal structure only had a modest effect on SAP 
bioactivity. This suggests that these regions do not play a major role in the effect that 
SAP has on fibrocyte differentiation. 
2.2 Methods 
2.2.1 Construction ofpTriEx vector & expression in E. coli. 
The serum amyloid P (SAP) mature peptide coding region (Genbank Accenssion 
number 18375514) was amplified via PCR using a commercial human liver eDNA 
library as the template source (Agilent). The PCR primers contained restriction sites for 
Nco I (forward) and Xho I (reverse) for insertion into plasmids- Forward: 5'CAT GCC 
ATG GGC CAC ACA GAC CTC AGT GGG 3 '; Reverse: 5'CCG CTC GAG GAC CCA 
CAC CAA GGG TTT G 3' (Invitrogen, Carlsbad, CA). A Geneamp PCR kit (Applied 
Biosystems) was used to amplify the eDNA, and the sequence was cloned into the 
pTriEx-3 Neo Vector (EMD Chemicals, Gibbstown, NJ). 
The TriEx vector containing SAP eDNA was transformed into Tuner (DE3) pLaci 
competent cells (EMD Chemicals) and expressed following the manufacturer's protocol 
with a 4 hour induction time at 37° C with 0.5 mM IPTG. 
2.2.2 Protein purification for pTriEx vector 
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Cell pellets were resuspended in 20 mM Tris, 200 mM NaCl buffer pH 8.0 with 
protease inhibitors (Roche), run twice through an Avestin Emulsiflex-C5 homogenizer, 
and the inclusion body was collected by centrifugation for 30 minutes at 20,200 x g (r. 
avg., Sorvall SS-34 rotor). Inclusion bodies were dissolved in 8M urea, 20 mM Tris, 
200 mM NaCl, pH 8.0 and clarified by centrifugation at 125,000 x g (r. avg., Beckman 
45Ti rotor) for 30 min at 4° C. The supernatant was loaded onto an AKTA FPLC and 
applied to a His-binding HiTrap column (Amersham). Protein was refolded slowly on 
the column and eluted with a linear 0 to 500 mM imidazole gradient at a rate of 1 mllmin. 
The eluted protein was exchanged to 20 mM sodium phosphate, pH 7.4, using a spin 
concentrator (Amicon). When samples needed additional purification to remove 
contaminants, the procedure in 2. 2. 6 was followed with bead purification. 
2. 2. 3 Construction of pBad vector & expression in E. coli 
The eDNA was originally cloned into a pTriEx expression vector (EMD 
Chemicals), but was subsequently transferred to the pBad giiiA vector (Invitrogen). 
The pBadlgiiiA vector containing SAP eDNA was transformed into Top10 competent 
cells (Invitrogen) and expressed following the manufacturer's protocol with a 4 hour 
induction time at 3 7° C with 0.1% arabinose. 
2. 2. 4 Protein purification for pBad vector 
Cell pellets were resuspended in 20 mM sodium phosphate, 150 mM NaCl buffer 
pH 8.0 with protease inhibitors (Roche), run twice through an Avestin Emulsiflex-C5 
homogenizer, and the homogenized pellet was mixed with a final concentration of 5% n-
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lauroylsarcosine (sarcosyl) for 2 hours at room temperature. The homogenized cell mix 
was clarified by centrifugation at 125,000 x g (r. avg., Beckman 45Ti rotor) for 30 min at 
4° C. The supernatant was loaded onto a Bio-Rad Biologic FPLC and applied to a His-
binding HiTrap column (GE Lifesciences, Piscataway, NJ) at a rate of 0.2 ml/min. 
Protein was slowly washed overnight in a 25 mM imidazole Tris wash buffer, and eluted 
with a 500 mM imidazole, 50 mM Tris, pH 8, 150 mM NaCl, 5% glycerol buffer. The 
sample was dialyzed overnight in a Slide-a-Lyzer dialysis cassette with 1 Ok MWCO 
(Pierce). 
2.2.5 Construction ofpcDNA3.1- vector & expression in HEK293 cells 
The serum amyloid P (SAP) coding region (Genbank Accession number 
18375514), including the secretion signal, was amplified via PCR using a commercial 
human liver eDNA library (Agilent). The eDNA was cloned into the pcDNA3.1(-) 
plasmid (Invitrogen) using Not I and Age I restriction sites, with an RNA export 
enhancer element cloned in 3' to SAP (Pacl to Eco Rl). The vector with SAP was 
generously donated by Promedior. 
The SAP-pcDNA3.1(-) vector was transfected into Freestyle 293F cells 
(Invitrogen) using Lipofectamine 2000 (Invitrogen) following the manufacturer's 
protocol. Cells were grown at 37° C with 5% C02 in Freestyle 293 media (Invitrogen), 
supplemented with 2 mM glutamine and 0.75 mg/ml Geneticin to select for the vector. 
After 5 days, conditioned media were collected for protein purification. 
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2. 2. 6 Protein purification from HEK293 cells 
20 ml of conditioned medium from the SAP-expressing 293F cells were clarified 
by centrifugation at 900 x g for 10 minutes at room temperature (R T). 1 M CaCh was 
added to a final concentration of 2 mM, and the conditioned medium was then mixed 
with 1 ml of 50% slurry of Sepharose Fast Flow (GE Healthcare BioSciences, 
Piscataway, NJ) for 1 hour at RT using an end-over-end mixer (in the presence of Ca ++, 
SAP binds strongly to Sepharose; Pepys et al., 1977). The Sepharose beads were 
collected by centrifugation at 900 x g for 1 minute at RT. The beads were washed five 
times with 15 ml of 20 mM Tris pH 7.4/ 140 mM NaCl/ 2 mM CaCh buffer. Bound 
protein was eluted overnight at 4° C with 400 !Jl of 20 mM Tris pH 7.4/ 140 mM NaCl/ 
50 mM EDT A. The eluted protein was dialyzed in a 500 !Jl, 1 OkDa MWCO dialysis 
cassette (Thermo Scientific Pierce, Rockford, IL) using 1.5 L of 20 mM NaP04 pH 
7.4/10% glycerol overnight at 4° C. The protein was further dialyzed in 20 mM NaP04 
pH 7.4 buffer six times with a minimum 3 hour period between buffer exchanges. 
Protein was filter sterilized with a 0.2 !Jm acrodisc syringe filter (Millipore, Billerica, 
MA) and concentration was checked via Western blot as previously described (Pilling et 
al., 2003; Pilling et al., 2007) with the exception that samples were run on 4-15% Tris-
Glycine gels (Bio-Rad, Hercules, CA) and the detection antibody was a 1 :20,000 dilution 
of rabbit anti-SAP polyclonal antibody (Epitomics, Burlingame, CA). The purity of the 
SAP was also checked by Coomassie or silver stain. 
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2.2. 7 Construction ofpMT/BiPIV5-His vector, expression, and purification of SAP 
The SAP eDNA was originally cloned into a pTriEx expression vector (Novagen), 
but was subsequently transferred to the pMT/BIPN5-His vector (Invitrogen). The 
pMT/BIPN5-His vector containing SAP eDNA was cotransfected with pCoHygro vector 
(Invitrogen) into S2 cells with calcium phosphate and selected for with hygromycin in 
Schneider's Drosophila medium (Invitrogen) with 10% FBS. Cells were grown at 23· C 
in air. Before induction, the medium was changed to serum free medium, and SAP 
expression was induced with 500 J.!M copper sulfate. SAP was purified from the media 
as per 2.2.6. 
2.2.8 Generation ofSAP mutants 
Using the SAP-pTriEx, SAP-pBad, and SAP-pcDNA3.1(-) vectors as templates, 
the primers in Table 2.2 were used to generate point mutations in the SAP sequence. 
The PCR reaction and transformation was carried out using a QuikChange II Site-
Directed Mutagenesis Kit (Stratagene, La Jolla, CA), following the manufacturer's 
protocol. The resulting plasmids were sequenced to confirm the point mutations and 
absence of other mutations. Transfection and expression were then carried out as 
described above. 
2. 2. 9 Circular dichroism 
Samples were prepared by placing the protein in 20 mM sodium phosphate, 150 
mM NaCl buffer at a volume of 400 J.!l and a concentration of at least 2 J.!M (250 Jlg/ml). 
400 J.!l of the 20 mM Na phosphate, 150 mM NaCl buffer was used as the "blank" 
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Table 2.2: List of primers for mutagenesis. 
Mutant 
R38A 
S171A 
Y173A 
Q174A 
Sl71A/Y173A/Q174Aa 
Y173A/Q174A/T176Vb 
L178A 
P179A 
A180G 
AI 80S 
N181A 
I182A 
I182N 
I182V 
I182L 
L183A 
D184A 
Forward/Reverse Primer 
5'ACCTTGTGTTTTGCAGCCTATAGTGATCTC3' 
5'GAGATCACTATAGGCTGCAAAACACAAGTT3' 
S'GAA AAT ATCCTG GCT GCCTATCAGGGTACC 3' 
5'GGTACCCTGATAGGCAGCCAGGATATTTTC3' 
5'ATCCTGTCTGCCGCTCAGGGTACCCCTCTC3' 
5'GAGAGGGGTACCCTGAGCGGCAGACAGGAT3' 
5'CTGTCTGCCTATGCGGGTACCCCTCTC3' 
5'GAGAGGGGTACCCGCATAGGCAGACAG3' 
5' ATCCTGGCTGCCGCTGCGGGTACCCCTCTC 3' 
5'GAGAGGGGTACCCGCAGCGGCAGCCAGGAT3' 
5'TCTGCCGCTGCGGGTGTCCCTCTCCCTGCC3' 
5'GGCAGGGAGAGGGACACCCGCAGCGGCAGA3' 
S'CAGGGTACCCCTGCCCCTGCCAATATC 3' 
5'GATATTGCCAGGGGCAGGGGTACCCTG3' 
5'GGTACCCCTCTCGCTGCCAATATCCTG3' 
5'CAGGATATTGCCAGCGAGAGGGGTACC3' 
5'GGTACCCCTCTCCCTGGCAATATCCTGGAC3' 
5'GTCCAGGATATTGCCAGGGAGAGGGGTACC3' 
5'GGTACCCCTCTCCCTTCCAATATCCTGGAC3' 
5'GTCCAGGATATTGGAAGGGGAGAGGGGTACC3' 
5'CCTCTCCCTGCCGCTATCCTGGACTGG3' 
5'CCAGTCCAGGATAGCGGCAGGGAGAGG3' 
5'CTCCCTGCCAATGCCCTGGACTGGCAG3' 
5'CTGCCAGTCCAGGGCATTGGCAGGGAG3' 
5'CTCCCTGCCAATGTCCTGGACTGGCAG3' 
5'CTGCCAGTCCAGGACATTGGCAGGGAG3' 
5'CTCCCTGCCAATGTCCTGGACTGGCAG3' 
5'CTGCCAGTCCAGGACATTGGCAGGGAG3' 
5'CTCCCTGCCAATCTCCTGGACTGGCAG3' 
5'CTGCCAGTCCAGGAGATTGGCAGGGAG3' 
5'CCTGCCAATATCGCGGACTGGCAGGCTCTG3' 
S'CAGAGCCTGCCAGTCCGCGATATTGGCAGG 3' 
5'GCCAATATCCTGGCCTGGCAGGCTCTG3' 
5'CAGAGCCTGCCAGGCCAGGATATTGGC3' 
a S171A eDNA was used as the template. 
b Y173A eDNA was used as the template. 
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control. The spectra of protein samples were obtained from a CD Spectrometer model 
62ADS (Aviv, Lakewood NJ), measuring a wavescan from 200 to 250 nm, every 1 nm. 
Each sample was measured three times. 
For thermal denaturation studies, samples in sodium phosphate buffer were heated 
from 25 to 100" C in 1 degree increments at 220 nm with a 3 second averaging time and 
1.5 minute equilibration time. 
2. 2.10 HEK Blue LPS detection, temperature denaturation, and proteinase-K digestion 
To ensure that recombinant SAP bioactivity was not due to bacteria 
contamination, bacterially-expressed SAP was tested for LPS contamination using the 
HEK-Blue LPS detection kit (Invivogen), as per the manufacturer's protocol. 
Additionally, bacterially-expressed SAP was heated at 98" C for 20 minutes. 
Bacterially-expressed SAP was also digested with a 1:20 ratio of Proteinase-K (Sigma-
Aldrich) (5 J..Lg/ml proteinase K per 100 J..Lg/ml SAP) for 16 hours at 37" C. Proteinase K 
was deactivated by mixing the proteinase K digest with equimolar concentration of 
Pefabloc SC (AEBSF, Sigma Aldrich). The digest was checked by silver staining on a 4-
15% SDS-PAGE gel. The heat denatured and digested SAP were tested for bioactivity 
using the fibrocyte differentiation assay in 2. 2.13. 
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2. 2.11 Gel filtration 
Conditioned media from SAP-expressing 293F cells was filtered with a 0.2 J..L 
acrodisc syringe filter (Millipore) and diluted in running buffer (20 mM Tris, 140 mM 
NaCI, 10 mM EDTA, pH 7.4). 300 J..Ll of sample was loaded onto a Superose 12 100/300 
GL column (GE Healthcare) using an AKTA Purifier UPC-10 with a flow rate of 0.3 
ml/min at 4° C. 300 J..Ll fractions were collected and analyzed by Western blots for the 
presence of SAP. The apparent molecular weight of SAP was estimated by comparing 
the fractions to the elution profile of gel filtration standards (Bio-Rad), run in the same 
buffer. 
2. 2.12 Detection of SAP mutants by ELISA 
Maxisorb 96-well plates (Thermo Scientific Nunc, Rochester, NY) were coated 
overnight at 4° C with anti-SAP monoclonal antibody CBL304 (Millipore) or SAP-5 
(Sigma) at a 1:1000 dilution in PBS. Plates were washed 3 times with PBS/0.05% 
Tween-20. Plates were blocked in PBS-4% BSA for 1 hour at 37° C. Recombinant SAP 
and mutants were diluted to 5 J..Lg/ml in PBS-4% BSA and incubated in the plates for 1 
hour at 37° C. The presence of SAP was detected as described previously (Pilling eta/., 
2003), using a rabbit polyclonal anti-SAP antibody (EMD Calbiochem, San Diego, CA). 
For bacterially-expressed SAP, the SAP and mutants were bound directly to the plate and 
then detected as described above. 
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2. 2.13 Fibrocyte Differentiation Assay 
Human peripheral blood was collected into heparin vacutainer tubes 
(#367874; BD Bioscience, Franklin Lakes, NJ) with written consent from healthy 
adult volunteers and with specific approval of Rice University's or Texas A&M's 
Institutional Review Board. Peripheral blood mononuclear cells (PBMC) were 
isolated by Ficoll-Paque Plus (GE Healthcare Biosciences, Piscataway, NJ), as 
previously described (Pilling et al., 2009). PBMCs were cultured in serum-free medium 
(SFM) as described previously using Fibrolife basal media (LifeLine Cell Tech, 
Walkersville, MD) (Pilling et al., 2009). 5x RPM! medium was prepared by mixing 2.5 
ml of 1 Ox RPM! (Sigma Aldrich) with 250 fll of each supplement described previously 
(Pilling et al., 2009), 833 fll of 6% NaHC03, and 170 fll of H20. Recombinant SAP was 
added to flat-bottomed, 96-well, tissue-culture plates and diluted as follows. 0.8 flg 
recombinant SAP in 20 mM NaP04 pH 7.4 or an equal volume of buffer, was added to 
the first column of wells along with a 114th volume of 5x RPM! medium. The wells were 
brought to 200 fll with SFM. 100 fll was removed from the first column and serially 
diluted with an equal volume of SFM across the plate to achieve the indicated SAP 
concentrations. 100 fll ofPBMCs at 5x105 cells/ml in SFM was then added to each well. 
After a 5 day incubation period, the plate was air dried, fixed with methanol, and stained 
with Hema 3 stain (Fisher Scientific, Hampton, NH). For each well, fibrocytes were 
counted in five different 900 f.tm diameter fields, with fibrocytes defined as adherent, 
elongated spindle-shaped cells with oval nuclei (Pilling et al., 2003 and 2006; Shao et al., 
2008). 
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2.3 Results 
2. 3.1 Bacterially-expressed SAP is bioactive. 
To perform mutagenesis to determine SAP's functional domains, I first needed to 
express recombinant SAP that was bioactive and retained its native structure. I initially 
expressed SAP in the pTriEx vector in E.coli and human CHO cells, experiencing low 
yields, especially in the mammalian system. For the E.coli expressed SAP, all of the 
protein was in the inclusion body, which required urea denaturation to extract the protein, 
followed by dialysis and refolding (Figure 2.2A). I was able to obtain approximately 50 
J..lg protein from a 500 ml culture of LB broth. However, to avoid refolding from the 
inclusion body, I also tried expressing SAP in the baculovirus system, which failed. 
Finally, I expressed SAP in the pBAD vector in E. coli and was able to extract the protein 
using Sarkosyl detergent in 2-3 times larger yields than the TriEx vector without having 
to refold the protein from the inclusion bodies (Figure 2.2B). 
TriEx and pBad expressed SAP significantly reduced the number of fibrocytes, 
signifying bioactivity (Figure 2.3), and had IC50s that were statistically indistinguishable 
from native SAP (Table 2.4). Additionally, mock expression of both vectors were 
carried out, purified, and tested for bioactivity. Neither mock expression showed 
bioactivity (Figure 2.3 and data not shown). 
2.3.2 The observed bioactivity of bacterially-expressed SAP is due to expressed protein 
rather than bacteria components or detergent. 
Bacterial components such as lipoteichoic acid (L TA) inhibit fibrocyte 
differentiation, so one worry is that any observed effect of the bacterially-expressed SAP 
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A 
Figure 2.2: Purification of SAP from pTriEx and pBAD vectors. (A) Purification of 
recombinant SAP expressed from pTriEx. Lane 1 - cell pellet, Lane 2 -urea extract 
from inclusion body, Lane 3 - elution off His beads. (B) Purification of pTriEx 
expressed SAP with agarose beads. Lane 1 - M, Lane 2- SAP after dialysis, Lane 3-
flow through off agarose beads, Lane 4 - elution off agarose beads. (C) Purification of 
recombinant SAP expressed from pBAD. Lane 1 - blank, Lane 2 - M, Lane 3 - final 
elution off nickel column (his tag), Lane 4- final SAP after dialysis in phosphate buffer 
+ 150 mM NaCl. 
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Figure 2.3: Recombinant SAP from pTriEx and pBAD vectors have bioactivity 
similar to native SAP. PBMCs at 2x 1 as cells/ml were cultured for 5 days in the 
presence of SAP or an equal volume of serum-free medium/buffer. Results are 
normalized to the number of fibrocytes per 2.5 x 1 as cells/ml in serum-free medium only 
wells, and the results are expressed as the mean percentage ± SEM. Recombinant SAP 
expressed from pTriEx (n=3) and pBAD (n=5) vectors were compared to native SAP 
(n=4), buffer only, and eluent from a mock purification of empty TriEx vector (n=3). 
Recombinant SAP significantly reduced the number of fibrocytes compared to buffer 
controls as, determined by Student's t-test. **, p < a.a1 
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was due to contamination (Maharjan et. a/, 201 0). I initially checked for 
lipopolysaccharide (LPS) contamination with the HEK-Blue LPS detection kit 
(Invivogen), and there was no contamination in recombinant SAP or the mutants. 
Although LPS does not inhibit fibrocyte differentiation, LPS contamination would be a 
general indicator of other bacterial component contamination (Maharjan eta/., 201 0). 
A common method to inactivate proteins and test contamination is through heat 
denaturation. Recombinant SAP was heated at 98° C for 20 minutes, but the sample still 
retained full bioactivity (Figure 2.4A). To determine if the result was due to 
contamination or due to the thermastability of SAP, I performed thermal denaturation 
studies using circular dichroism. The secondary structure of SAP was not significantly 
altered when heated from 25 to 100° C, indicating that SAP is a very stable protein 
(Figure 2.4B), while the closely related pentraxin CRP was fully denatured by 80° C 
Figure 2.4C). Because SAP is not readily denatured at 98° C like most proteins, the 
bioactivity observed in 2.4A could still be from recombinant SAP instead of a non-
protein contaminant. 
As an alternative approach to check for bacterial contamination, recombinant 
protein can be digested by proteolysis and measured for bioactivity. However, SAP is 
known to be highly resistant to proteolysis (Kinoshita et a/., 1992), so I selected a potent 
serine protease, proteinase K, that has broad selectivity (Elbeling et al., 1974) and tested 
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Figure 2.4: Bacterially-expressed SAP retains bioactivity after being heated to 98° C 
and is thermally stable as determined by circular dichroism. (A) Bacterially-
expressed SAP was heated at 98° C for 20 minutes. PBMCs at 2x105 cells/ml were 
cultured for 5 days in the presence of SAP, heat denatured SAP, or an equal volume of 
serum-free medium/buffer. Results are normalized to the number offibrocytes per 2.5 x 
105 cells/ml in serum-free medium only wells, and the results are expressed as the mean 
percentage± SEM (n=2). Heat denatured SAP did not lose bioactivity. (B and C) The 
thernial stability of SAP and the closely related pentraxin CRP were measured by circular 
dichroism at 220 nm while heating the sample from 25 to 100° C in 1 degree increments. 
SAP does not readily denature even when reaching 98° C, while CRP readily denatures 
by 75 ° C. 
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Figure 2.5: Proteinase K fully digests SAP in a 1:20 ratio, and digested recombinant 
SAP has no bioactivity. (A) Proteinase K was added to 100 !J.g/ml native SAP and 
incubated overnight at 3 7° C. Digestion of SAP was checked via Coomassie. M - MW 
marker, lane 1 - empty, lane 2 - SAP control 100 !J.g/ml, lane 3 - SAP + 20 !J.g/ml 
proteinase K, lane 4 - SAP + 1 0 !J.g/ml proteinase K, lane 5 - SAP + 5 !J.g/ml proteinase 
K, lane 6 - SAP + 2 !J.g/ml proteinase K, lane 1 - SAP + 1 !J.g/ml proteinase K. Arrow 
indicates very light band in lanes 6 and 7 at this location, indicating low levels of native 
SAP still present that is undigested. (B) 1 00 !J.g/ml of recombinant WT SAP was mixed 
with 5 !J.glml of proteinase K and incubated overnight. AEBSF proteinase K inhibitor 
was added in equimolar amounts to the SAP digest and buffer control containing 
proteinase K. PBMCs at 2x 105 cells/ml were cultured for 5 days in the presence of 
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recombinant SAP, proteinase K-digested SAP, or inactivated proteinase K in buffer 
control. Results are normalized to the number of fibrocytes per 2.5 x 105 cells/ml in 
serum-free medium only wells, and the results are expressed as the mean percentage± 
SEM (n=2). The proteinase K digested SAP had significantly less bioactivity compared 
to recombinant WT SAP, as determined by Student's t test. *, p < 0.05. 
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for digestion at various protease:SAP ratios (Figure 2.5A). I found that to fully digest 
SAP, it requires a 1 :20 ratio. Recombinant SAP was digested with proteinase K, checked 
for complete digestion with a silver stain (data not shown), and then the proteinase K was 
inactivated with AEBSF. As a control, buffer with proteinase K was also inactivated 
with AEBSF. The digest was cultured along with the deactivated proteinase K control 
with PBMCs to measure fibrocyte inhibition. The proteinase K-digested recombinant 
SAP had no bioactivity, while recombinant SAP significantly inhibited fibrocyte 
differentiation, as determined by Student's t test (Figure 2.5B). The lack of activity by 
the proteinase K digest indicates that the observed bioactivity was due to the presence of 
a protein. Because the recombinant SAP sample did not show additional protein 
contaminants when stained via Coomassie and the fact that a mock purification of empty 
vector did not inhibit fibrocyte differentiation (Figure 2.3), this suggests that the observed 
bioactivity is due to recombinant SAP. 
One additional source of contamination was the use of lauroylsarcosine sodium 
salt (sarcosyl) to purify recombinant SAP from the bacteria cell pellet. This method 
resulted in higher yield and did not require isolating and refolding protein from the 
inclusion body using 8M urea. However, if sarcosyl is not fully removed by dialysis, 
low levels of detergent could remain in the samples and alter the bioactivity. Therefore, 
the bioactivity of SAP purified using 8M urea was compared to that of SAP purified 
using sarcosyl (Figure 2.6). Both recombinant SAPs were bioactive, as they significantly 
reduced the number of fibrocytes found in culture compared to buffer-only controls. As 
there was little difference in the bioactivity between recombinant SAP purified with urea 
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Figure 2.6: Purifying recombinant SAP with sarcosyl does not affect bioactivity. 
PBMCs at 2x 1 as cells/ml were cultured for 5 days in the presence of SAP or an equal 
volume of buffer. Results are expressed as number of fibrocytes per 2x 1 as cells/mi. 
Recombinant WT SAP using the pBad expression system was purified from inclusion 
bodies with urea, followed by protein refolding during dialysis. Recombinant SAP was 
also purified by solubilizing the cell pellet with sarcosyl. Purifying the protein with 
sarcosyl had no significant difference in its bioactivity compare to SAP purified with 
urea, as determined by Student's t-test. 
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and sarcosyl, the sarcosyl either had no affect on fibrocyte differentiation or was fully 
removed by dialysis. Therefore, the purification method could continue to be utilized. 
2. 3. 3 Bacterially-expressed SAP and mutants have secondary structure similar to native 
SAP, but appear to mostly be aggregates in solution. 
To elucidate the functional domains of SAP, I mutagenized a region of SAP that 
bears resemblance to the region of IgG which comes in contact with the FcyR, the 
purported SAP receptor. IgG residues 327 ALPAPe33 have similarity to SAP region 178-
182 (Table 2.1). To ensure that any observed changes in bioactivity of SAP mutants are 
due to the change in the amino acid residue rather than a gross change in structure, I 
measured the physical characteristics of the recombinant SAP and mutants by circular 
dichroism, native antibody binding, and size exclusion chromatography. I initially tried 
analytical ultracentrifugation and size exclusion chromatography to determine protein 
size to see if the recombinant SAP was a pentamer at 13 5 kDa rather than 25 kDa 
monomers or some sort of aggregate. However, the initial runs failed to either show 
recombinant protein or give measurable data. I later rectified the problem with size 
exclusion chromatography through the use of a Tris-EDTA buffer on a fresh Superose-12 
column. Before that breakthrough, I relied on CD to determine if the recombinant SAP 
had similar secondary structure as native SAP. Native and recombinant SAP had very 
similar circular dichroism spectra, while the mutants such as SAP I182A showed slightly 
more disorder while retaining similar alpha helix and beta sheet structure (Table 2.3). 
These results suggest that the recombinant SAP folded properly but it does not give 
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Table 2.3: Comparison of2° structure between native and recombinant SAP. 
Hl: H2: Sl: S2: Distorted Distorted Sample a Helix p strand Turns Unordered 
a Helix p strand 
Native SAP 0.28 0.19 0.12 0.15 0.13 0.13 
Recomb. WT 0.27 0.19 0.11 0.15 0.13 0.15 
SAP I182A 0.28 0.16 0.13 0.10 0.13 0.19 
Ellipticity of bacterially-expressed SAP was compared to native SAP. Standard 
wavelength scans were performed with an Aviv 62A DS Circular Dichroism 
Spectrometer from 200 to 250 nm using a 1 mm path length (Starna 21-Q-1 quartz 
cuvette) with a 3 second averaging time. All measurements were taken at 25° C in 20 
mM sodium phosphate buffer, pH 7.4, 150 mM NaCl. Recombinant SAP percent 
structure was calculated using CDPro with the CDSSTR Fit algorithm and the SMP56 
( 43 soluble and 13 membrane protein reference set). 
2.0· 
E 1.8· 
t: 1.6· ~ 
0 
L() 1.4· ~'-: ~ llil ~ ;l, (]) 1.2· t (.) k 
t: 1.0• ~ 
co ~ ~ ; 
.c 0.8· ~ * 
L.. 
' 
·" 0 0.6· I en I fu 
.c I I ~ 0.4· I I 
0.2· ~ ~ ~ nPJ 
"· 
nm 0.0 I 
' ·~e ~ .... ~0),. ~~ ·~'lj '$>' q_~ 0~ 
<J;-eCi 
rn 
~ 
' :~ 
~ 
~~- ~-
0: ~ 
' 
~~ 
,,, ~·-
~ 
n, ill; 
~0 ~ ,. 
SAP 
ill 
~m 
I l· ·~ 
~ 
Flm i 
'b~ 
'" 
nm 
. 
~ ~'b 
' 
~ 
CJ SAP-5 mAb 
I2ZI CLB304 mAb 
Ill SAP polyclonal 
36 
Figure 2.7: Recombinant SAP and mutants expressed in bacteria do not bind anti-
SAP monoclonal antibodies that only recognize native SAP. Wells were coated with 
capture antibodies Sap-5 mAb (Sigma) or CBL304 mAb (Millipore). The presence of 
SAP bound to the capture antibodies was detected using a rabbit anti-SAP polyclonal Ab 
(Calbiochem). Both of the capture antibodies only bind native SAP. Alternatively, SAP 
was bound directly to the plate and then detected throught the use of rabbit anti-SAP 
polyclonal Ab (Calbiochem). Biotinylated goat anti-rabbit was used as the secondary 
antibody. Blank control had all the antibodies added, but no SAP was added. The plate 
was developed with Extravidin-conjugated peroxidase. 
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Figure 2.8: pBAD-expressed SAP mutants are predominantly aggregates in solution. 
Recombinant SAP was fractionated by size exclusion chromatography on a Superose 12 
10/300 GL column and compared to native SAP and CRP. The two recombinant 
mutants ran near the void volume, suggesting a molecular weight greater than 670,000. 
Graph provided by Rick Caimi of Promedior. 
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information about whether the SAP was pentameric. Since the protein was not grossly 
misfolded, I bioassayed the mutant SAPs, further discussed in section 2. 3. 4. 
I further characterized the bacterially expressed SAP through the use of 
monoclonal antibodies that bind only native protein, as per the manufacturer's 
instructions, SAP-5 mAb (Sigma Aldrich) and CBL304 mAb (Millipore). Wells of an 
ELISA plate were coated with recombinant SAP and mutants, the plate was blocked, and 
the presence of SAP was detected with the monoclonal antibodies or a rabbit polyclonal 
(EMD Chemicals) that can also bind denatured SAP, as per the manufacturer's 
instructions. The recombinant SAP and mutants failed to bind to the monoclonal 
antibodies and were only detected with the rabbit polyclonal antibody (Figure 2. 7). 
These results suggest the possibility that the recombinant protein is not in its native 
structure. 
Finally, we successfully analyzed the bacterially-expressed mutants by size-
exclusion chromatography with the assistance of Promedior (Malvern, P A). The 
bacterially expressed SAP mutants ran as aggregates near the void volume, suggesting a 
molecular weight greater than 670,000 (Figure 2.8). Therefore, any observed biological 
effects of the mutants could be due to SAP aggregation. 
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2.3.4 Bacterially-expressed SAP mutants AJBOG and L183A has reduced bioactivity 
while /182A has a proliferative effect. 
After mutagenizing these residues, I found that altering residues 174, 178, and 
179 had little effect on the ability of SAP to inhibit fibrocyte differentiation (Table 2.4). 
Residues A180G and L183A had reduced bioactivity, with A180G showing a statistically 
significant decrease compared to WT, as determined by ANOVA with Dunnett's test (p < 
0.05) (Figure 2.9 and Table 2.4). Reduced bioactivity would suggest that these residues 
are part of SAP's functional domain. Additional mutations of these residues, including a 
double mutant, would need to be done to answer this question. However, the bacterially-
expressed SAP mutants were found to predominantly be aggregates in solution (Figure 
2.8), so this was not pursued further. 
Although the recombinant mutants were mostly aggregates in solution, mutations 
in residue 182 gave interesting effects (Figure 2.9B and Table 2.4). Mutants 1182N and 
1182V appeared to be more bioactive than WT SAP, although this was not a statistically 
significant change by one-way ANOV A. I 182A actually resulted in a proliferative effect 
resulting in an increase in fibrocyte number above that of serum free controls. This 
effect was obtained when expressed from either pTriEx or pBad vector, although no such 
effect was observed for n=2 out of a total of n=7. 
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Figure 2.9: Bacterially-expressed SAP mutants have altered bioactivity in their 
ability to inhibit fibrocyte differentiation. PBMCs at 2x 105 cells/ml were cultured for 
5 days in the presence of SAP or an equal volume of serum-free medium/buffer. Results 
are normalized to the number of fibrocytes per 2.5 x 105 cells/ml in serum-free medium 
only wells, and the results are expressed as the mean percentage ±SEM. (A) SAP 
mutants A180G (n=5 , pBad and pTriEx expressed) and L183A (n=3 , pBad only) were 
compared to buffer only control and commercial SAP. The A180G and L183A mutants 
did not significantly inhibit fibrocyte differentiation as determined by Student' s t-test, 
although both mutants did retain some bioactivity. (B) SAP mutant 1182A (n=7, pBad 
and pTriEx expressed) was compared to buffer control. At concentrations between 1 and 
4 nM, SAP I 182A increased the number of fibrocytes compared to buffer control, but this 
change was not statistically significant due to variance between assays. 
40 
Table 2.4: IC50 values for bacterially-expressed SAP mutants inhibiting fibrocyte 
differentiation. 
Sample IC50, nM 
Native SAP 3.3 ±0.2 
Rec. SAP (pTriEX) 2.5 ± 0.6 
Rec. SAP (pBad) 1.7 ± 0.5 
Q174A 4.5 ± 0.5 
L178A 3.0± 0.8 
P179A 3.3 ± 0.8 
A180G 14±7.1* 
1182A 6.5 ±2.5 
1182V 0.9± 0.2 
1182N 1.1±0.3 
L183A 8.1±3.1 
ICso was calculated as the concentration at which the inhibitor, SAP, reduces fibrocyte 
number by half. Bacterially-expressed (rec.) SAP and mutants had similar ICso as native 
SAP. ICso levels were obtained by fitting a sigmoidal dose response curve with 
normalized response and variable slope, using normalized fibrocyte levels compared to 
serum-free controls (n=3 except n=5 for native SAP and A180G,n=4 for pBad SAP and 
SAP P179A). For Il82A, four sets of data failed to converge so they were excluded. 
ICso values were compared to native SAP and recombinant SAP for significance using 
ANOV A with Dunnett's post-test. *, p < 0.05. 
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2.3.5 Human cell culture expressed SAP is pentameric and bioactive. 
I initially utilized bacterially-expressed SAP because I was not able to express 
SAP in human cell culture using the pTriEx vector in CHO cells. However, the 
bacterially-expressed SAP was not an appropriate choice for mutagenesis because any 
observed changes in SAP bioactivity could be due to the fact that the recombinant SAP 
formed aggregates instead of a native pentamer structure. Therefore, I looked to 
alternative expression systems with a focus on human cell lines, as native SAP is 
glycosylated and has a native secretion signal that could be utilized by mammalian cells. 
I was able to express SAP using the pcDNA3.1(-) vector in HEK293 human cell culture. 
As the coding region contained SAP's native secretion signal, the SAP was secreted into 
the media and readily purified by binding to Sepharose beads. The resulting SAP was 
highly pure (Figure 2.1 OA) with yields between 5-40 Jlg from 10 ml of conditioned 
media. To try to increase the yield, I expressed SAP in different cell lines using the 
same procedure as the HEK293 system. I tried K562, HL-60, THP-1, U937, CHO K1, 
and NSO cells. SAP expression was only observed in HEK293 and CHO K1 cells, and 
the expression levels in the two cell lines were not significantly different (data not 
shown). 
To determine if the HEK293-expressed SAP was pentameric, I performed size 
exclusion chromatography. The recombinant SAP was predominantly in fractions 38-41 
as a wide peak of approximately 135 kDa (Figure 2.1 OB), as determined by the peaks of 
molecular weight standards. The recombinant WT SAP had no apparent aggregation 
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Figure 2.10: Recombinant SAP secreted from HEK293 cells can be readily purified 
and is predominantly a pentamer. (A) Purified recombinant SAP expressed from 
HEK293 cells. Fractions were analyzed by SDS-PAGE on a 4-15% reducing gel and 
stained with Coomassie. Lane 1 - marker, Lane 2 - recombinant SAP , Lane 3 -
recombinant SAP mutant S171A/Y173A/Q174A, lane 4 - native SAP control. (B) 
Recombinant SAP was fractionated by size exclusion chromatography on a Superose 12 
10/300 GL column. Fractions were analyzed by Western Blot using a rabbit anti-SAP 
primary antibody (Epitomics). The first two lanes contain native SAP controls. The 
remaining lanes represent 300 J.!l fractions collected off the column. Arrows indicate the 
molecular weight of known standards (Pierce) previously run on the column. 
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(fractions 25-29), and there was only a small amount of monomers (27 kDa, fractions 45-
46). This suggests that the 293-expressed SAP was predominantly pentameric with no 
apparent aggregates. To further demonstrate that the recombinant SAP was folded 
properly, I determined by ELISA that a monoclonal antibody that can only bind native 
SAP was able to bind the HEK293-expressed SAP (Figure 2.11). The CBL304 
(Millipore) antibody did not bind the bacterially-expressed SAP aggregates (Figure 2. 7), 
while it was able to bind the 293-expressed SAP. 
I tested for bioactivity using an in vitro fibrocyte differentiation assay. The 
HEK293-expressed SAP significantly reduced the number of fibrocytes, signifying 
bioactivity (Figure 2.12), and had an IC50 that was statistically indistinguishable from 
native SAP (Table 2.5). 
2.3.6 SAP mutants expressed from human cells retain bioactivity similar to native SAP. 
To elucidate the functional domains of SAP, I mutagenized two regions of SAP 
potentially involved in FcyR binding. For the first region, SAP region 178-182 was 
mutagenized similar to the bacterially-expressed SAP in section 2.3.3, as the IgG-like 
region. Although the bacterially expressed SAP did not show these residues as critical, 
the results are suspect due to the bacterially-expressed SAP mainly being composed of 
aggregates. For the second region, residues were selected that were critical for SAP 
binding to the extracellular domain of FcyRIIa in a published crystal structure (Lu et a/., 
2008). The crystal structure indicated that SAP residues 38, 171-176, and 200-205 are 
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Figure 2.11: Recombinant SAP and mutants expressed by HEK293 cells can bind to 
anti-SAP monoclonal antibodies, that only bind native SAP. Wells were coated with 
a capture antibody as indicated. The presence of SAP bound to the capture antibodies, 
Sap-5 mAb (Sigma) or CBL304 mAb (Millipore ), was detected using a rabbit anti-SAP 
polyclonal Ab (Calbiochem). Both of the capture antibodies only bind native SAP. 
Biotinylated goat anti-rabbit was used as the secondary antibody. Blank control had all 
the antibodies added, but no SAP was added. The plate was developed with Extravidin-
conjugated peroxidase. 
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Figure 2.12: HEK293-expressed SAP inhibits fibrocyte differentiation of PBMCs. 
PBMCs at 2x 105 cells/ml were cultured for 5 days in the presence of SAP or an equal 
volume of buffer in serum-free medium (SFM). Results are normalized to the number of 
fibrocytes per 2.5 x 105 cells/ml in SFM only wells, and the results are expressed as the 
mean percentage ±SEM (n=3). Recombinant SAP at and above 4 nM significantly 
reduces fibrocyte differentiation compared to buffer only control, as determined by 
Student's t-test. **, p < 0.01; ***, p < 0.001. 
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the key contacts for SAP binding to FcyRIIa; however, residues 200-205 were not 
mutagenized as they are near the SAP pentamerization domain and could interfere with 
native structure formation. A series of single and multiple point mutations were made in 
these two regions of SAP and the mutagenized protein was subsequently expressed by 
HEK293 cells, except for SAP 1182A which was not secreted into the media. Instead, 
SAP 1182A was expressed in S2 cells, as well as WT SAP as a control. Size exclusion 
chromatography performed as described in Figure 2.10 indicated that all the resulting 
SAP variants were pentameric and could bind the native antibody CBL304. However, 
~ 10% of SAP 1182A was determined to be aggregates, while still predominantly 
pentameric. 
Altering residues in the two selected regions of SAP had a modest effect at best 
on the ability of SAP to inhibit fibrocyte differentiation (Table 2.5). Mutagenizing 
residues in the IgG-like region did not significantly alter SAP bioactivity (Table 2.5 and 
data not shown), while a slight reduction in bioactivity was observed for the residues 
implicated in the SAP-FcyRIIa crystal structure (Figure 2.13). Altering residue 171 did 
not significantly reduce SAP bioactivity due to assay variability (Figure 2.13A). Altering 
residues 173 and 174 and removing the hydrogen bonding potential from residues 173, 
174, and 176 reduced SAP bioactivity (Figure 2.13B-D). Focusing only on mutants 
derived from the SAP-FcyRIIa crystal structure, no significant differences were observed 
compared to native SAP (Figure 2.13E) unless the highly variable results of mutant 
S171A were excluded from the analysis. Excluding the S171A data, mutants Y173A and 
Q174A showed a significant increase in IC50 compared to native hSAP, suggesting that 
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Table 2.5: ICso values for HEK293-expressed SAP mutants inhibiting fibrocyte 
differentiation. 
Sample ICso, nM 
Native SAP 2.9± 0.3 
Rec. SAP 2.6± 0.7 
S2SAP 2.9± 0.6 
R38A 2.7 ± 0.1 
S171A 6.8 ± 4.3 
Y173A 5.9 ± 1.4 
Q174A 5.6±0.6 
S171A/Y173NQ174A 3.5 ± 0.5 
Y173F/Q174Lff176V 5.0 ± 0.4 
L178A 4.1 ± 0.5 
P179A 3.5 ± 0.5 
A180G 4.3 ± 0.4 
A180S 2.2± 0.3 
N181A 2.7 ± 0.3 
I182A 3.7 ± 0.5 
D184A 3.5 ± 0.4 
IC5o was calculated as the concentration at which the inhibitor, SAP, reduces fibrocyte 
number by half. No significant change in IC5o was observed for HEK293-expressed 
(rec.) SAP, S2-expressed SAP, or SAP mutants compared to native SAP (1-way 
ANOV A, Dunnett's test). ICso values were obtained by fitting a sigmoidal dose 
response curve with normalized response and variable slope, using normalized fibrocyte 
levels compared to serum-free controls (n=3 except n= 12 for native SAP, n=5 for S 171 A, 
A180S, and N181A; n=4 for Y173A and 173/174/176). 
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Figure 2.13: Human SAP mutants Y173A, Q174A, and Y173F/Q174L/T176V have 
reduced bioactivity compared to native SAP. PBMCs were cultured for 5 days in the 
presence of hSAP or an equal volume of serum-free medium/buffer. Results are 
normalized to the number of fibrocytes in serum-free medium, and the results are 
expressed as the mean percentage ± SEM. n= 12 for native, n = 5 for S 1 71 A, n=4 for 
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Y173A and 173/174/176, and n=3 for Q174A. (A) hSAP S171A did not have 
significantly reduced bioactivity compared to native hSAP due to the significant variance 
between assays (2 assays showed reduced bioactivity, 3 assays showed a response similar 
to that of native SAP). (B- D) hSAP Y173A, Q174A, and Y173F/Q174LIT176V at 7.4 
nM have significantly reduced bioactivity compared to native hSAP, as determined by t-
test. *, p < 0.05; ***, p < 0.001. (E) IC50 values for SAP mutants focusing on the residues 
critical in the SAP-FcyRIIa crystal structure. No significant differences were observed in 
the IC50s between the mutants and native SAP (1-way ANOVA, Dunnett's test). If 
mutant S171A is excluded from the ANOVA analysis, mutants Y173A and Q174A have 
significantly increased IC50 values compared to native hSAP, suggesting reduced hSAP 
bioactivity (p < 0.01; 1-way ANOVA, Dunnett's test). 
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the mutants have reduced activity (Figure 2.13E). However, when these residues were 
changed to alanine in a triple 1711173/174 mutant, the bioactivity of the mutant was 
similar to that of native hSAP (Figure 2.13E). Additionally, the IC 50 of R38A was 
similar to that of hSAP (Figure 2.13E). The data suggest that hSAP residues 173 and 174 
may mediate some but not all of SAP bioactivity. 
2.4 Discussion 
To elucidate the functional domains of SAP, residues were mutagenized that were 
believed to be critical for SAP signaling through its receptor, FcyR. Bioactive SAP was 
expressed both from bacteria and human cells. Initially, human SAP was expressed in 
bacteria because of the extremely low yields when the recombinant protein was expressed 
in human cells. The bacterially-expressed SAP appeared to have folded properly as 
determined by circular dichroism and digestion of the protein eliminated all bioactivity, 
suggesting any observed effect was not due to bacterial contamination. However, the 
bacterially-expressed proteins were eventually found to be predominately aggregates 
after refining the size exclusion chromatography assay to include EDTA in the buffer. 
Therefore, any observed biological effect could be purely due to SAP being aggregated 
rather than a specific change to its primary structure. Nonetheless, aggregated proteins 
in general do not inhibit fibrocyte differentiation. Specifically, heat aggregated lgG, 
which acts through the same receptor as SAP, inhibits fibrocyte differentiation, while 
other heat aggregated immunoglobulins have no effect on fibrocyte differentiation 
(Pilling et al., 2006). Additionally, the observed biological effects are not just a generic 
aggregation effect because different mutations gave interesting results, including 1182A 
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promoting fibrocyte number, while A180G and L183A had reduced bioactivity. 
However, these results did not carry over when the same mutations were expressed in 
human cells, although L183A was not expressable in HEK293 or S2 cells. Finally, the 
bacterially-expressed SAP results should not necessarily be discounted because protein 
aggregation was not measured immediately, so these recombinant proteins could be 
pentameric when immediately assayed after purification. Additionally, the bacterially-
expressed protein could be predominantly pentameric when diluted down to nM 
concentrations utilized in the bioassays. 
Although the key functional domain of SAP was not found, I was able to 
successfully express recombinant SAP and mutants that retain SAP's native pentameric 
structure. The pentameric SAP was expressed in human HEK293 cells, which has the 
benefit of glycosylating the protein, as SAP has a single glycosylation site at Asn32 
(Emsley et al., 1994). We were able to discern additional aspects of SAP's biology, 
including the fact that SAP is highly thermostable, unlike CRP which has 51% sequence 
identity, and that SAP requires a very high 1:20 ratio for full proteinase K digestion. 
Additionally, two specific regions were eliminated for future studies in determining 
SAP's functional domain. Altering the sequence with similarity to IgG 327 ALPAPe33 
had no significant effect on SAP bioactivity when the mutants were expressed by human 
HEK293 cells. Altering residues critical for SAP binding to FcyRIIa in the Lu et al. 
(2008)'s crystal structure only had a very modest effect on SAP bioactivity. Residues 
173 and 1 7 4 may mediate some but not all of SAP bioactivity and do not appear to be a 
critical part of SAP's functional domain. 
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A possible explanation regarding the lack of success with mutagenizing the ridge 
helix region (Pro 166 to Gin 174) suggested by the Lu et a/. (2008) crystal structure, is 
that the crystal structure may not be biologically relevant. The Lu paper states that SAP 
was dissociated into monomers and then crystallized, whereas biologically relevant SAP 
is pentameric. The crystal structure published at NCBI (MMDB ID: 67886) only shows 
4 out of 5 SAP monomers on the same plane as a partial pentamer. 
Even if the crystal structure is biologically relevant, SAP could act through a 
different receptor or predominantly through a different FcyR subtype. While FcyRIIa 
and III have similar structure, FcyRI contains an additional immunoglobulin D3 domain 
that accounts for its high affinity to IgG (Hullet et al., 1998) and could potentially 
interact with SAP. For instance, the closely related pentraxin CRP was mutagenized at 
residues critical for FcyRIIa binding, which disrupted the binding of CRP to FcyRIIa and 
III but not to FcyRI, which contains the additional D3 domain (Lu eta/., 2008). 
Finally, because SAP is part of the pentraxin family that is highly conserved 
across species and the closely related CRP does not inhibit fibrocyte differentiation, for 
any future mutagenesis we will be looking towards residues on the surface of SAP that 
are conserved in humans, mice, and rats (human, mouse, and rat SAP's inhibit fibrocyte 
differentiation) and are different than the residues found in CRP (Baltz et a/., 1982; 
Pilling eta/., 2003). 
Chapter 3: Potential characterization of SAP's functional domain through SAP 
peptides and receptor binding 
3.1 Introduction 
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In addition to mutagenesis of residues, we can also determine the active domain 
of SAP by producing peptides containing the critical regions of SAP. The peptide could 
not only tell us which residues are sufficient for SAP bioactivity but also have potential 
as a therapeutic since peptides are preferred over whole protein for their cheaper cost and 
are easier to manipulate. The two regions we selected for mutagenesis in Chapter 2 are 
also the regions we focused on for the peptides (Figure 3.1 ). 
Although our initial mutagenesis study did not find any residues critical for SAP 
bioactivity, any future critical residues will need to be further characterized. We will 
need to determine if the recombinant and mutant SAP are still binding to the F cy 
receptors to fully understand any biological effects the mutants have on PBMC cultures. 
If the binding of SAP to FcyR is essential for bioactivity, any SAP mutants that fail to 
inhibit fibrocyte differentiation will likely fail to bind to the FcyRs or bind with different 
affinity so that the mutant no longer activates the FcyR. Also, mutants that are bioactive 
might be found that no longer bind to any FcyR, which would suggest that the other 
receptors and/or ligands are involved in regulating differentiation. 
SAP has previously been found to bind to FcyRs through the use of cells 
expressing only specific receptors, as well as through surface plasmon resonance (SPR); 
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A 
B 
Figure 3.1: SAP peptide locations along the pentamer and Bethyl peptide position 
relative to the SAP-FcyRIIa complex crystal structure. (A) SAP was visualized 
with Pymol (Delano, 2002). Residues were highlighted by peptide with blue 
representing the peptide 171 SA YQGTPLPANILDWQ 186, yellow representing the 
178LPANILDWQALNYEIRGY 195, green representing 163VLPPENILSAYQGTPLPA179, 
and red representing 6 1LLVYKERVGEYSLYIGRHK79, which is found on the opposite 
face of the SAP planar disc. (B) The SAP monomer and FcyRIIa complex is 
represented as a cartoon and colored by their secondary structure (Lu et a/. , 2008). The 
SAP peptide comprises residues 165PPENILSAYQGT 176 and its location within a SAP 
monomer is represented as stick figures. The peptide is at the interface of the SAP-
FcyRIIa complex. 
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however, significantly different affinities were reported (Lu et al., 2008; Castano et al., 
2009). To evaluate SAP mutants, we need a quick, efficient, and relatively inexpensive 
method to test the binding of our mutants to the receptor. The most successful method 
for SAP receptor binding was surface plasma resonance (SPR), but that process is 
expensive due to the Biacore machine and due to the fact that you need a significant 
amount of protein. Additionally, to get SPR to work, Castano et al. (2009) had to bind 
SAP in the presence of calcium to a dextran ligand present on a Biacore CM5 chip. In a 
typical SPR run, you bind the receptor to the chip and have the ligand flow over the chip. 
Having to bind SAP to the chip would make it very inconvenient and costly to analyze 
multiple mutants. Therefore, we focused on binding SAP through ELISAs using the 
recombinant extracellular domain ofFcyR. 
In this chapter, I show that peptides based off areas we mutagenized do not have 
bioactivity except at 500x molar excess, which makes it irrelevant as a potential 
therapeutic and suspect as biologically relevant. I also show that receptor binding 
ELISAs do not require having SAP bound to a ligand like dextran, suggesting that Ca ++ 
dependent ligand binding is not necessary for FcyR engadgment. Additionally, IgG is 
found to be a poor competitor to use against SAP in a competitive ELISA assay, 
suggesting that IgG and SAP bind to different locations on the FcyRs. Finally, I show 
that the optimum binding conditions for SAP occurs when the receptor is not bound 
directly to an ELISA plate, suggesting that proper orientation is critical for efficient SAP 
binding in an ELISA receptor assay. 
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3.2 Methods 
3.2.1 SAP f(ab 'h antibody preparation. 
A SAP polyclonal antibody was made by Bethyl Laboratories in a goat against the 
human SAP peptide 165PPENILSAYQGT176. The nonspecific Fe portion ofthe antibody 
was removed via papain digestion using a Fab preparation kit (Pierce), as per 
manufacturer's instructions. The digestion was checked via Western blot and compared 
to goat Fab (Abeam), the full length SAP antibody, and full length goat IgG (Jackson 
Immunoresearch) as controls. Fab fragments and full-length antibodies were detected 
using a biotinylated donkey anti-goat F(ab')2 (Jackson ImmunoResearch), along with 
Extravidin-HRP (Sigma Aldrich). 
3.2.2 SAP Fab antibody fibrocyte differentiation assay. 
PBMCs were prepared and cultured as described in 2.2.13. The. SAP Fab 
antibody and goat Fab control antibody (Abeam) were mixed at 40 and 10 nM with 7.7 
nM (1 j..lg/ml) SAP (EMD Chemicals) or buffer control in a final200 Ill volume with 2.5 
x 105 cells/ml PBMCs. Additionally, serum-free only wells and SAP only wells at 7.7 
nM were plated with the same concentration of PBMCs. After 5 days, cells were fixed 
and stained as previously described (Pilling et al., 2003). 
3. 2. 3 Biotinylation of peptide and SAP 
The 165PPENILSAYQGT176 peptide was biotinylated using NHS-PEG4-Biotin 
(Thermo Scientific), following the manufacturer's protocol. The biotinylated peptide 
was purified via size exclusion gravity chromatography with Sephadex G 15 (GE 
Healthcare) column bedding at room temperature. Fractions were collected via gravity 
57 
in 300 J.ll fractions, and peptide concentration was measured via Bradford protein assay. 
Biotinylation of fractions was confirmed by ELISA. The fractions were incubated 
overnight in a Maxi sorb 96-well plates (Thermo Scientific Nunc), blocked with TBS-4% 
BSA for 1 hour, and washed 3 x in TBS-0.05% Tween 20. Biotinylated peptide was 
detected using Extravidin Peroxidase (Sigma-Aldrich). Undiluted peroxidase substrate 
3,3,5,5-tetramethylbenizidine (Sigma-Aldrich) was incubated for 4 minutes at room 
temperature before stopping the reaction with 1 N HCl, and the plate was read at 450 nm 
(Biotek Instruments, Winooska, VT). 
SAP was biotinylated using the Pierce EZ-Link Micro Biotinylation kit (Pierce), 
following the manufacturer's protocol, and the degree of biotinylation was checked via 
depletion using neutravidin beads (Pierce). Biotinylated SAP in the presence and 
absence of neutravidin beads were assayed via electrophoresis on 4-15% Tris-glycine 
gels (Bio-Rad laboratories) and stained with Coomassie blue dye. 
3. 2. 4 Peptide fibrocyte differentiation assay 
PBMCs were prepared and cultured as described in 2. 2.13. Biotinylated peptides 
were generated by Biomer Technology (Pleasanton CA), or from 3.2.3 using the Bethyl 
peptide. The peptides were resuspended in ddH20 or 20 mM sodium phosphate buffer, 
pH 7.4. Biotinylated peptides were plated in serum-free media at 10 J.!M, as well as 
doubling dilutions ranging from 1 J.!M to 7.8 nM. Additionally, the biotinylated peptides 
were conjugated with neutravidin (Pierce) at 114th molar concentration by mixing for 1 
hour at room temperature in an end-over-end mixer before plating in serum-free media. 
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As a control, neutravidin was plated by itself in serum free media. Originally, the 
neutravidin was added at much higher concentration based on the estimated binding 
capability via weight, but these high concentrations were toxic to the cells. For the 
Bethyl 165PPENILSAYQGT176 peptide, biotin (Sigma-Aldrich) was also added to the 
neutravidin + peptide, neutravidin-only, and buffer control wells at 5x molar 
concentrations to the neutravidin. 
3.2.3 Detection ofSAP binding to FcyR by ELISA 
Maxisorb 96-well plates (Thermo Scientific Nunc, Rochester, NY) were coated 
overnight at 4° C with 2 !J.g/ml of the extracellular domain of recombinant Fey receptor 
(R&D Systems). Plates were washed 3 times with PBS/0.05% Tween-20. Plates were 
blocked in PBS-4% BSA for 1 hour at 37° C. SAP (EMD Chemicals) was diluted to 0.5-
50 j.lg/ml in PBS-1% BSA and incubated in the plates for 1 hour at 37° C. Alternatively, 
SAP was pre-incubated in a 20 mM Tris, 140 mM NaCl, 2 mM CaCh binding buffer in 
the presence or absence of equimolar carboxymethyl dextran (GE Healthcare) for 30 
minutes, followed by incubation in the receptor-coated plates for 1 hour, 2 washes with 
PBS-Tween-20, and fixation with ice-cold 4% PF A-PBS. The presence of SAP was 
detected as described previously (Pilling eta/., 2003), using a mouse monoclonal anti-
SAP antibody (SAP-5, Sigma Aldrich or CBL304, Millipore) or a rabbit polyclonal 
(Calbiochem). Bound SAP was detected using biotinylated goat F(ab')2 anti-mouse lgG 
or goat F(ab')2 anti-rabbit IgG (Southern Biotech), followed by Extravidin peroxidase 
(Sigma-Aldrich). Undiluted peroxidase substrate 3,3,5,5-tetramethylbenizidine (Sigma-
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Aldrich) was incubated for 4 minutes at room temperature before stopping the reaction 
with 1 N HCl, and the plate was read at 450 nm (Biotek Instruments, Winooska, VT). 
Biotinylated SAP was also tested for binding to the Fey receptor. The same 
procedure as above was followed, except the SAP that was added was biotinylated. 
Additionally, biotinylated human IgG (Jackson ImmunoResearch) was heated 45 minutes 
at 60 °C to aggregate the IgG, and the aggregated IgG was added to the wells at 50 Jlg/ml 
as a positive control. Bound lgG or SAP was detected with Extravidin peroxidase 
(Sigma-Aldrich). 
An indirect ELISA for SAP binding was performed through competitive binding 
with IgG. Wells were coated with 2 Jlg/ml of receptor overnight. The wells were 
blocked with PBS-4% BSA. Human IgG (Jackson ImmunoResearch) was heated 45 
minutes at 60 °C to aggregate the IgG, and the aggregated lgG was added to the wells at 
50 Jlg/ml along with SAP at concentrations between 0.3 - 30 Jlg/ml in PBS-1% BSA. 
Bound lgG was detected with a biotinylated mouse F(ab')2 anti-human lgG (Jackson 
Immunoresearch), followed by Extravidin peroxidase (Sigma-Aldrich). 
Alternatively, rabbit anti-his (1: 1 000) was coated overnight on the 96 well plates, 
the plates were washed twice the next day and blocked with PBS-4% BSA, and the 
recombinant Fey receptors were incubated at 2 Jlg/ml for 1 hour. The remaining 
procedure was as above, except SAP was incubated in a PBS-1% BSA solution with 2 
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mM CaCh. Bound SAP was detected with a mouse monoclonal anti-SAP antibody 
(CBL304, Millipore ), followed by Extra vi din peroxidase (Sigma-Aldrich). 
3.2.4 Detection of SAP binding to FcyR bound to Tosyl beads 
Alexa-594 conjugated SAP and albumin were kindly donated by Promedior 
(Malvern, P A) and was prepared using an Alexa Fluor 488 kit (Invitrogen) on human 
SAP (EMD Chemicals) and albumin (Sigma-Aldrich), as per the manufacturer's protocol. 
Dynabeads M-280 Tosylactivated (Invitrogen) were prepared as per the 
manufacturer's instructions binding 5 1-1g/ml of recombinant extracellular domain of the 
Fey receptors (R&D Systems) in a 0.1 M Na-phosphate buffer, pH 7.4. The beads were 
mixed overnight at 3 T C, blocked the next day in phosphate buffer-0.1% BSA two times 
for 5 minutes, and finally blocked with 0.2 M Tris, pH 8.5 with 0.1% BSA for 4 hours at 
3 T C. Due to nonspecific binding by SAP, the blocking step was later changed to 
include washes with sodium phosphate-3% BSA and 0.5 M Tris, pH 8.5 with 1% BSA. 
Alexa-594 conjugated SAP or BSA were incubated with 8 ~-tl of bead slurry per protein 
concentration in a 20 mM Tris, 140 mM NaCl, 2 mM CaCh, 0.1% BSA binding buffer in 
the presence or absence of equimolar carboxymethyl dextran (GE Healthcare) for 1 hour 
at 3T C. The beads were placed on a Dynal magnet (Invitrogen) and washed twice with 
PBS-0.5% Tween-20. The beads were resuspended in 60 ~-tl PBS-1% BSA and 30 ~-tl 
were placed in a black 96 well plate (Nunc), and the fluorophore was excited at 594 nm 
and read at 620 nm using a Tecan plate reader (Durham, NC) and Magellan data analysis 
software. 
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3.3 Results 
3.3.1 Anti-SAP Fab that recognizes an epitope near the purported FcyR binding region 
blocks SAP bioactivity. 
We had a goat polyclonal antibody made against SAP and the sequence selected 
just happens to be in the same region that SAP binds FcyRIIa in the Lu et al. (2008) 
crystal structure (Figure 3.1B). Therefore, I decided to try to block SAP bioactivity 
through the binding of the antibody. Since the SAP pentamer acts like a planar disc with 
one side binding ligands like bacteria, while the opposite side binds the FcyR (Figure 
1.1A), we would expect this antibody to block SAP bioactivity if our hypothesis for SAP 
receptor binding holds true. First, I digested the goat polyclonal with papain to remove 
the Fe constant region that could nonspecifically bind to monocytes in culture and 
interfere with fibrocyte differentiation (Figure 3.2A). SAP bioactivity was significantly 
reduced in the presence of the Fab anti-SAP fragment as expected (Figure 3.2B & 3.2C). 
This helps confirm that SAP's active domain is on the "A" face of the planar disc (Figure 
1.1A). 
3.3.2 SAP peptides based around the two purported FcyR binding regions do not have 
significant bioactivity or block the action of SAP. 
To help determine the functional domain of SAP, I tested peptides based around 
the purported FcyR binding regions from Chapter 2, the IgG-like domain and the 
FcyRIIa-SAP crystal structure (Figures 2.1 & 3.1 ). I initially selected 3 biotinylated 
peptides near the IgG-like domain and a 4th peptide on the opposite face of the SAP 
pentamer as a negative control (Table 3.1, Figure 3.1A). The peptides weren't bioactive, 
A B 
c 
Fab 40 nM Fab 40 nM 
+SAP 
lgG Control Fab 
Fab 10 nM 
+SAP 
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Figure 3.2: Goat anti-SAP Fab blocks SAP bioactivity. SAP antibody was made by 
Bethyl in a goat against the human SAP peptide165PPENILSA YQGT176. To assay the 
blocking activity of the antibody, we removed the nonspecific Fe portion of the antibody 
via papain digestion. 
(A) Papain digestion of goat anti-SAP antibody gives rise to Fab fragments, as 25-
26 kDa dimers. Fab fragments and full-length antibodies were detected using a 
biotinylated donkey anti-goat F(ab')2 (Jackson ImmunoResearch), along with Extravidin-
HRP (Sigma). Lane 1 - Goat anti-SAP Fab 1 :50 dilution, lane 2- goat Fab control 1:100 
dilution, lane 3- goat anti-SAP Fab 1 :200, lane 4 - goat Fab control 1 :500, lanes 5-7 -
full length goat anti-SAP antibody, lanes 8-10- full length goat IgG. 
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(B and C) SAP inhibits fibrocyte differentiation in the presence of nonspecific goat 
IgG Fab, but SAP's bioactivity is significantly reduced in the presence of goat anti-
SAP Fab. PBMCs at 2x105 cells/ml were cultured for 5 days in the presence of 5.5 nM 
SAP and/or Fab, or an equal volume of buffer in serum-free medium (SFM). Results are 
normalized to the number of fibrocytes per 2.5 x 105 cells/ml in SFM only wells, and the 
results are expressed as the mean percentage± SEM (n=3). SAP significantly reduced 
the fibrocyte level in IgG Fab treated wells, but not in wells treated with goat anti-SAP 
(1-way ANOVA, Dunnett's test). *, p < 0.05; **, p < 0.01; ***. SAP's bioactivity was 
significantly decreased in wells treated with goat anti-SAP compared to wells treated 
with nonspecific IgG Fab (1-way ANOVA, Dunnett's test). 
Table 3.1: SAP peptides tested for bioactivity. 
Biomer Technology Peptides: 
Peptide Location 
Biotin- centered around 327 ALP APP33 IgG-
171SAYQGTPLPANILDWQ186 like domain 
Biotin-
I78LPANILDWQALNYEIRGYI9s Shifted towards c-terminus 
Biotin- Shifted towards n-terminus, 
I63VLPPENILSAYQGTPLPAI79 contains residues critical in SAP-
FcyRIIa crystal structure 
Biotin- Opposite side of protein, 
61LLVYKERVGEYSL YIGRHK79 LPS/agarose binding domain 
Bethyl peptide: 
165PPENILSAYQGT176 
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The first three peptides were selected to cover the entire region around the 327 ALP API333 
IgG-like domain (see Table 1, Figure 3). The fourth peptide was selected as a negative 
control since the sequence lies on the opposite side of the SAP planar disc (Figure 1.1 ), 
where SAP can opsonize bacteria and still bind to Fey receptors. The Bethyl peptide was 
available since our lab had an antibody synthesized, and the sequence contains residues 
critical in the SAP- FcyRIIa crystal structure (Figure 2.1). 
65 
as they failed to inhibit fibrocyte differentiation beyond buffer controls (Figure 3.3). 
Because SAP is pentameric in its native state and activates receptors via crosslinking, I 
also cross-linked the biotinylated peptides with a streptavidin-derivative (neutravidin) 
and tested for bioactivity. Initially, too high of neutravidin concentration was used, 
which depleted the biotin from the medium and resulted in cell death. Using a 
significantly lower neutravidin concentration as well as treating all samples with 5x 
excess biotin, I was able to mostly eliminate this effect except at the highest 
concentrations. However, the limited amount of peptide prevented me from pursuing 
further with the neutravidin binding assays. 
Our lab had an anti-SAP antibody synthesized, and the peptide utilized for this 
synthesis happened to be centered around the FcyRIIa-SAP crystal structure residues 
(Figure 3.1B, Table 3.1). Therefore, I tested this peptide for bioactivity as a monomer 
and cross-linked. To be able to crosslink the peptide, I first biotinylated the peptide and 
then purified it (Figure3.4A - C). The monomeric form of the peptide failed to inhibit 
fibrocyte differentiation, nor did it block SAP's bioactivity (Figure 3.4D). Upon 
crosslinking with neutravidin, the cross-linked peptide still failed to block SAP 
bioactivity (data not shown), but the cross-linked peptide did manage to significantly 
inhibit fibrocyte differentiation (p < 0.5; 1-way ANOVA, Dunnett's test) when at 500 x 
molar excess compared to the bioactivity of SAP. At such high concentrations, the use 
of this peptide would not be biologically relevant and would be of no use as a potential 
therapeutic. Therefore, I did not further pursue the peptide studies. 
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Figure 3.3: SAP peptides did not significantly alter fibrocyte differentiation. 
PBMCs at 2x105 cells/ml were cultured for 5 days in the presence of the indicated 
peptide, neutravidin only, or a mixture of neutravidin and peptide. Results are 
normalized to the number of fibrocytes per 2.5 x 105 cells/ml in SFM only wells, and the 
results are expressed as the mean percentage± SEM (n=3). All peptides, including the 
control 61 LLVYKERVGEYSL YIGRHK79, reduced the number of fibrocytes across most 
concentrations without crosslinking. The presence of neutravidin crosslinker was 
initially found to be toxic to the cells. When added in 1/4th equimolar amounts compared 
to peptide, neutravidin only had a slight effect on the cells, and the cross-linked peptide-
neutravidin complex did not appear to alter fibrocyte differentiation (n=l only, ran low 
on peptide). 
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Figure 3.4: Biotinylation of 165PPENILSAYQGT176 peptide and bioactivity. SAP 
peptide was biotinylated via available amine groups using NHS-PEG4-Biotin (Thermo 
Scientific) and purified on a Sephadex G15 column (GE Healthcare). 
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(A) ELISA confirms biotinylation of the peptide with streptavidin-conjugated 
detection. Fractions off the Sephadex G 15 column were tested on an ELISA plate for 
the ability of the newly attached biotin on the peptide to bind a streptavidin-conjugated 
peroxidase, which was then read at 450 run on a plate reader. 
(B) Biotinylation of the peptide results in two major peaks when collected off a 
Sephadex G 15 column. Protein concentration was determined by Bradford. Fractions 
1 0-15 composed the first, smaller peak, which was identified as biotinylated peptide 
through ELISA in (A). 
(C) Biotinylated peptide binds neutravidin as seen by a shift in molecular weight. 
Neutravidin (Thermo Scientific) strongly binds up to 4 biotins and was mixed with 
biotinylated-peptide for 1 hour. The results were visualized on a Western blot using the 
goat anti-SAP antibody (Bethyl), with the neutravidin-bound biotinylated peptide shifted 
up from biotinylated-peptide only. Lane 1 -peptide, lane 2- biotinylated peptide, lane 3 
- biotinylated peptide bound to neutravidin, lane 4 - neutravidin. 
(D) SAP peptide does not inhibit fibrocyte differentiation and does not compete with 
SAP bioactivity. PBMCs at 2x105 cells/ml were cultured for 5 days in the presence of 
peptide and/or 7.5 nM SAP, or an equal volume of buffer in serum-free medium (SFM). 
Results are normalized to the number of fibrocytes per 2.5 x 105 cells/ml in SFM only 
wells, and the results are expressed as the mean percentage± SEM (n=3). 
(E &F) Neutravidin-conjugated SAP inhibits fibrocyte differentiation at 500x 
concentration compared to SAP. Neutravidin and PBS were premixed with biotin, 
biotinylated peptide was mixed initially with neutravidin and then with biotin. PBMCs 
at 2x105 cells/ml were cultured for 5 days in the presence of neutravidin-bound 
biotinylated peptide, neutravidin-only, or an equal volume of buffer in serum-free 
medium (SFM). Results are normalized to the number of fibrocytes per 2.5 x 105 
cells/ml in SFM only wells, and the results are expressed as the mean percentage ± SEM 
(n=4). Although neutravidin-only reduced the fibrocyte levels, the biotinylated peptide 
conjugated to neutravidin significantly reduced fibrocyte differentiation compared to 
buffer and neutravidin-only controls (1-way ANOV A, Dunnett's test). *, p < 0.05. 
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3.3.3 The binding of SAP to recombinant FcyRI can be detected via a direct ELISA. 
We want to be able to test a variety of mutants for their ability to bind FcyRs. 
Therefore, I optimized a direct binding ELISA where the extracellular domain of the Fey 
receptor was bound to the plate, then mixed with SAP, and any bound SAP was 
visualized with anti-SAP antibodies and Extravidin-peroxidase. The recombinant FcyRs 
were bioactive, as they bound aggregated IgG, along with monomeric IgG for FcyRI 
(Figure 3.5A). I also determined that the rabbit anti-SAP polyclonal antibody 
(Calbiochem) and any antibody based on mouse IgG2 subtype like the SAP-S 
monoclonal (Sigma-Aldrich) nonspecifically binds to FcyRI (Figure 3.5A & 3.5B). 
Therefore, one should avoid using any such antibodies for future assays. I also tested for 
SAP binding to the FcyRs using the SAP CBL304 mAb (Millipore). SAP was only 
detected binding to FcyRI, even though SAP has a higher affinity for FcyRIIa and III 
(Figure 3.5C; Castano eta/., 2009). I tried to improve upon SAP binding to the FcyRs by 
mimicking how SAP can opsonize apoptotic material, where SAP initially binds to a 
ligand like cellular debris on the "B" face of SAP and then binds to the FcyR with SAP's 
"A" face to elicit an immune response. (Figure 1.1A; Bharadwaj eta/., 2001; Mold et 
al., 2002). To mimic this approach, I initially bound SAP to dextran in the presence of2 
mM CaCh, and then tried binding the complex to FcyRs. However, no difference in 
binding affinity was observed (Figure 3.5C). I also tried to fix any bound SAP to the 
receptor using 4% paraformaldehyde, but no improvement was observed (Figure 3.5C). 
For future ELISA experiments, I decided to use a PBS-1 %BSA plus CaCh binding 
buffer. The closely related pentraxin CRP requires Ca ++ to bind to its receptor on a 
Biacore chip (Bodman-Smith et a/., 2002), and SAP requires Ca ++ and 
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Figure 3.5: Receptor binding ELISA controls and SAP binding. Wells were coated 
with recombinant FcyR extracellular domains at 2 J.lg/ml. (A & B) Biotinylated human 
lgG was heated 45 minutes at 60 oc to heat aggregate. 30 J.lg/ml aggregated IgG and 
monomeric lgG were added to the wells as a positive control, along with the indicated 
negative control antibodies. The FcyRs all bind aggregated IgG as a functional control. 
The rabbit anti-SAP antibody and any mouse antibodies based on lgG2 subtype 
nonspecifically bind to FcyRI. Data are representative of 2 different experiments. (C) 
Native SAP was added to the wells at 30 J.lg/ml. SAP was preincubated with the dextran 
ligand when indicated. After binding SAP to the receptors on the plate, wells were 
washed, and when indicated fixed with 4% paraformaldehyde. Bound SAP was detected 
with the anti-SAP mAb CBL304 (Millipore), followed by Extravidin peroxidase (Sigma-
Aldrich). SAP weakly bound FcyRI, while the remaining receptors showed no binding 
(lib and III not shown). Fixing bound SAP to the receptor with 4% PFA, or pre-
incubating SAP with a ligand such as dextran did not alter the ELISA read out. Data are 
representative of 3 different experiments. 
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dextran for receptor binding in surface plasmon resonance (Castano et a/., 2009). 
Although dextran did not improve the ELISA signal when assayed, BSA could 
potentially have made the dextran unnecessary since albumin is a weak ligand for SAP 
that can help stabilize the protein in the presence of Ca ++ (Hutchinson et a/., 2000). 
3.3.4 Biotinylated lgG binds to FcyRs and competes with "cold" lgG, while biotinylated 
SAP fails to do either. 
In order to properly measure mutant SAP binding to the FcyRs, one should not 
use an anti-SAP antibody directly on the mutant. The reason is that a mutation could be 
in the same epitope that the antibody was raised against. Therefore, I performed an 
indirect competitive assay where I competed "hot" labeled protein with cold unlabeled 
protein such as the various SAP mutants. Aggregated biotinylated IgG was able to bind 
to the FcyRs (Figure 3.6A) as well as compete with cold IgG (Figure 3.6B). However, 
biotinylated SAP failed to do either when we were at least expecting to see the 
biotinylated SAP bind to FcyRI. The assay was repeated with 10 fold excess biotinylated 
SAP in case the biotinylation reduced SAP's ability to bind, but again no signal was 
observed (data not shown). Therefore, alternative competitors were assayed. 
3. 3. 5 Aggregated IgG does not compete with SAP for receptor binding by ELISA. 
As an alternative competition assay, SAP was tested for its ability to block 
aggregated IgG from binding to the FcyRs. After binding SAP and IgG to FcyRs, the 
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Figure 3.6: Biotinylated SAP is not detectable in receptor binding ELISA or 
competitive ELISA. Wells were coated with recombinant FcyR at 2 ~J-g/ml. 
Biotinylated human IgG was heated 45 minutes at 60 °C to aggregate IgG. (A) Heat 
aggregated IgG was added to the wells at 50 ~J-g/ml as a positive control. Biotinylated 
SAP was added to separate wells in concentration range of 0.5 - 50 J..tg/ml. Bound IgG or 
SAP was detected with streptavidin-conjugated peroxidase. (B) Biotinylated IgG or 
SAP were added to the wells at 50 ~J-g/ml. Unlabeled "cold" IgG and SAP were added at 
the indicated concentrations to compete with biotinylated version of itself. The binding 
of biotinylated proteins was detected with Extravidin peroxidase (Sigma-Aldrich). 
Unlabeled aggregated IgG reduced the binding of aggregated biotinylated IgG, but no 
SAP binding was observed. Data are representative of 3 separate experiments. 
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amount of bound IgG was measured to determine if SAP lowered the degree of binding. 
SAP failed to compete against aggregated IgG in three out of four assays (Figure 3.7), 
and even in the 4th assay the competition was rather weak (data not shown). Therefore, 
a competitive assay between IgG and SAP is not a viable method to indirectly measure 
SAP's binding affinity. This also suggests that IgG and SAP may not bind to the same 
region on the FcyRs, as there was little to none competition between the two for the same 
receptor. 
3.3.6 Improved ELISA signal when the FcyR extracellular domains are not bound to the 
plate. 
To further optimize the ELISA assays, the orientation of the FcyRs was adjusted. 
The recombinant receptor's binding affinity could be altered when it randomly binds to 
an ELISA plate in an incorrect orientation. Therefore, the plates were coated with a 
rabbit anti-his capture antibody, and the his-tagged FcyR extracellular domains were then 
bound to the antibody. The signal was significantly improved and SAP binding to 
FcyRIIa was observed for the first time (Figure 3.8). However, the negative control 
wells had a high background signal that overshadowed the lowest concentrations of SAP. 
This method is the most promising but further optimizations would be needed for future 
measurements. 
Alternatively, I tried a different coupling method for the receptor. Instead of 
binding the receptor to the plate, the receptor was cross-linked to tosylated Dyna beads 
through a free amine group. This method has the advantage of providing more surface 
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Figure 3.7: SAP does not compete with lgG binding to FcyRs. Human IgG was 
heated for 45 minutes at 60 oc to aggregate IgG. Wells were coated with recombinant 
FcyR at 2 1-1g/ml. SAP was added to each well in concentrations shown and was 
incubated for 15 minutes. Heat aggregated IgG at 50 1-1g/ml was added to the wells 
already containing SAP and then incubated for 45 minutes. The amount of human IgG 
bound to FcyR was detected with a biotinylated mouse anti-human IgG F(ab')2 and a 
streptavidin-conjugated peroxidase. Data are representative of 3 separate experiments. 
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Figure 3.8: The receptor binding ELISA assay for SAP is improved when the 
receptor is not directly bound to the plate. Wells were coated with rabbit anti-his 
antibody. The his-tagged FcyRs were incubated the next day at 2 ~g/ml for 1 hour, 
followed by SAP at the indicated concentrations in a PBS-1% BSA, 2 mM CaCb buffer. 
Bound SAP was detected with a mouse monoclonal anti-SAP antibody (CBL304, 
Millipore ), followed by Extravidin peroxidase (Sigma-Aldrich). Representative of n=2. 
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area for receptor binding, and the magnetic beads allowed for more efficient cleaning in 
reduced amounts. However, the blocking conditions had to be altered to reduce 
nonspecific SAP binding, by increasing the Tris and BSA concentrations. Promedior 
donated SAP conjugated with Alexa-594, which will allow for competitive binding 
assays. Therefore, we tested the binding of Alexa-594 SAP to FcyRI while competing 
with cold SAP and CRP. Cold SAP but riot CRP was able to compete with the Alexa-
SAP (Figure 3.9). This method will work for any future competitive binding assays, but 
the blocking step can be inconsistent, where one sometimes sees SAP binding in the 
absence of any bound receptor. 
3.4 Discussion 
To further elucidate the functional domain of SAP, peptides were tested that 
contained sequences from the two purported FcyR binding domains in Chapter 2. The 
peptides failed to block SAP activity and did not inhibit fibrocyte differentiation except 
in 500 fold molar excess. This negative result does not rule out these areas, but taken 
within the context of the mutagenesis study and the peptide analysis, we will need to look 
elsewhere for SAP's functional domain. 
I was able to establish conditions that will allow us to measure the binding of 
mutant recombinant SAP to FcyRI and potentially FcyRIIa, although the system could 
use further refinement to reduce nonspecific binding. For the binding assay, coupling 
SAP with dextran was not necessary to obtain a signal, nor did it improve receptor 
binding. Previously, the coupling of SAP to dextran was necessary to measure receptor 
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Figure 3.9: CRP does not compete with SAP binding to FcyRI when the 
receptor is bound to tosyl magnetic beads. 5 J..Lg/ml of FcyRI extracellular 
domain was bound to tosylactivated M-280 dynabeads (Invitrogen) overnight at 
37° C. The beads were blocked with sodium phosphate-3% BSA and 0.5 M Tris, 
pH 8.5 with 1% BSA. 50 J..Lg/ml Alexa-594 conjugated SAP was mixed with cold 
SAP or CRP for 1 hour at 37° C at the indicated concentrations. After washes, 
beads were placed in a black 96 well plate (Nunc), and the fluorophore was 
excited at 594 nm and read at 620 nm using a Tecan plate reader (Durham, NC). 
Representative of 4 separate experiments. Negative controls were inconsistent 
across plates, where SAP was detected in the absence of FcyRI in 2 out of 4 
experiments. 
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binding through surface plasmon resonance (Castano et al., 2009). The binding of 
dextran would mimic how SAP can opsonize apoptotic material on one side of SAP's 
planar disc and then induce phagocytosis by binding to FcyRs on the opposite face 
(Bharadwaj et al., 2002; Mold et al., 2002). The prediction was that SAP could not 
efficiently bind to FcyRs unless SAP first bound a ligand in its Ca ++-dependent pattern 
recognition site. One possible explanation why pre-incubation with dextran did not 
improve receptor binding is that the assays were carried out in the presence of Ca ++ and 
BSA, and BSA is a weak ligand for SAP that can help stabilize the protein (Hutchinson et 
al., 2000). 
In trying to develop a competition assay to indirectly measure SAP mutant 
binding, I found that SAP is not competitive with lgG or CRP for FcyRI binding. The 
lack of competition with IgG is consistent with the finding that monomeric IgG does not 
compete with SAP bioactivity in vitro and that there are distinct differences in the 
signaling cascade produced by SAP or IgG upon engagement to the receptor (Pilling et 
al., 2006). However, Lu et al. (2008) found that SAP competes with IgG for binding to 
FcyRs through surface plasmon resonance (SPR). The contrasting results could be due 
to methodology or sensitivities in the assays, and Lu (2008) did not specifically look at 
FcyRI for SPR. Additionally, CRP likely did not compete because the FcyRI receptor is 
a lower affinity receptor for CRP, although a successful competition may be viable when 
using the high affinity receptor FcyRIIa (Bharadwaj et al., 1999). For future competition 
assays, we can use fluorophore labeled SAP instead, either using the ELISA system with 
the rabbit anti-his capture antibody or the tosyl bead system. 
Chapter 4: Improved serum-free culture conditions for spleen-derived murine 
fibrocytes 
4.1 Introduction 
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Fibrocyte biology has been extensively studied in humans, but to delve further 
into how fibrocytes are involved in diseased states we need to find alternative cell sources 
from diverse genetic backgrounds. Thus, we can look to mouse disease model systems 
and murine genetic knock outs to see how fibrocyte differentiation is influenced. 
However, to do so efficiently, we need a quick, viable fibrocyte differentiation assay 
where we can eliminate outside influencing factors like the various components of serum. 
In addition to human peripheral blood mononuclear cells (PBMCs), fibrocytes 
have also been cultured from murine PBMCs, although monocytes are only 1-4% of 
murine peripheral blood PBMCs compared to 10% for humans (Abe et al., 2001; Kile et 
al., 2003). However, a large reservoir of monocytes has recently been found in the 
subcapsular red pulp of the spleen, and these can be mobilized for wound repair (Swirski 
et al., 2009). Niedermeier et al. (2009) recently used this splenic reservoir to show that 
fibrocytes differentiate from a subpopulation of CD 11 b+ CD 115+ Gr 1 + monocytes under 
the control of activated CD4+ T -cells. Their protocol involved culturing the cells in the 
presence of 10% FBS in RPMI for 14 days. 
We previously found that culturing human and murine PBMC in serum-free 
medium results in fibrocytes appearing within 5 days (Pilling et al., 2003, 2006, 2009a). 
In this chapter, I show that mouse spleen cells can differentiate into fibrocytes in serum 
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free conditions within 5 days. Conditions are determined where a large number of 
fibrocytes can be produced from a single mouse spleen, which will allow for future 
studies testing the effect of multiple factors on murine fibrocyte differentiation (Crawford 
et al., 2010). 
4.2 Methods 
4. 2.1 Isolation of murine SAP 
Murine SAP was purified from murme serum (Gemini Bio-products, West 
Sacramento, CA) using calcium-dependent binding to phosphoethanolamine-conjugated 
agarose, as described previously (Haudek et al .• 2006; Pilling et al., 2007), with the 
exception that Amicon Ultra-15 centrifugal filters (Millipore, Billerica, MA) were used 
for the 20 mM phosphate buffer exchange. 
4. 2. 2 Cell fractionation 
Human peripheral blood was collected into heparin vacutainer tubes 
(#367874; BD Bioscience, Franklin Lakes, NJ) with written consent from healthy 
adult volunteers and with specific approval of Rice University's Institutional Review 
Board. Peripheral blood mononuclear cells (PBMC) were isolated by Ficoll-Paque 
Plus (GE Healthcare Biosciences, Piscataway, NJ), as previously described (Pilling et al., 
2009a). 
4-6 week male C57BL/6J mtce (Jackson Laboratories, Bar Harbor, ME or 
Taconic, Hudson, NY) were used in this study. All work was done under Rice and Texas 
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A&M IACUC approved protocols. Murine peripheral blood was drawn by cardiac 
puncture using heparin-coated syringes, and mononuclear cells were purified by density 
centrifugation using Lympholyte-Mammal (Cedarlane, Burlington, NC), following the 
manufacturer's protocol. Spleens were harvested (~70-100 mg each) and cells were 
isolated by digesting in a cocktail of 450 U/ml collagenase I (EMD, San Diego, CA), 60 
U/ml DNase I, and 60 U/ml hyaluronidase (Sigma-Aldrich, St. Louis, MO) in 1 ml RPMI 
(Sigma-Aldrich) for 30 minutes at 37°C. Alternatively, spleen cells were isolated by 
forcing diced spleen fragments through a 100 1-1m cell strainer (BD Biosciences, San Jose, 
CA) using the plunger of a 3 ml syringe (BD Medical, Franklin Lakes, NJ) and 5 ml of 
RPMI. Finally, some spleen cells were isolated with a combination of digest cocktail, 
followed by the use of a cell strainer. After digest or passage through a cell strainer, the 
cells were resuspended in 10 ml RPMI and collected by centrifugation at 300 x g for 10 
minutes. Cells were further purified using ammonium chloride, potassium bicarbonate 
(ACK) lysis buffer (0.15 M NH4Cl, 10 mM KHC03, 0.1 mM Na2EDTA; Kruisbeek, 
2000), or by density centrifugation using Lympholyte-Mammal or Ficoll-Paque Plus (GE 
Lifesciences, Piscataway, NJ). For ACK lysis, spleen cells were resuspended in 940 !J.l 
lysis buffer for 3 minutes at room temperature, and the reaction was stopped by the 
addition of 14 ml PBS. The cells were collected by centrifugation at 200 x g for 10 
minutes, and the PBS wash step was repeated 3 additional times. A final wash was 
carried out by resuspending the cells in 1.5 ml Fibrolife basal media (Lifeline Cell 
Technology, Walkersville, MD) with the supplements listed below, and the cells were 
collected by centrifugation at 300 x g for 5 minutes at 4° C. For density centrifugation, 
spleen cells were resuspended in 1 0 ml RPMI and fractionated following the 
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manufacturer's protocol. The mononuclear fraction was then diluted to 14 ml with PBS 
and cells were collected by centrifugation at 300 x g for 10 minutes. The resuspension 
and centrifugation was repeated three times. The cells were resuspended in 1.5 ml 
Fibrolife basal media with supplements and collected by centrifugation at 300 x g for 5 
minutes at 4° C. 
4.2.3 Culture conditions andfibrocyte differentiation assay 
PBMC and spleen cells were resuspended in 1 ml Fibrolife basal media (Lifeline 
Cell Technology), supplemented with 10 mM HEPES (Sigma-Aldrich), 2 x non-essential 
amino acids (Sigma-Aldrich), 2 mM sodium pyruvate (Sigma-Aldrich), 4 mM glutamine 
(Invitrogen, Carlsbad, CA), 100 U/ml penicillin, 100 g/ml streptomycin (Sigma-
Aldrich), 2 x ITS-3 (Sigma-Aldrich), and 50 Jlm 2-mercaptoethanol (EMD). For some 
experiments, spleen cells were cultured in the presence or absence of 50 ng/ml murine 
IL-13 and 25 ng/ml murine M-CSF (Peprotech, Rocky Hill, NJ). Additionally, murine 
IL-4 (Peprotech), IL-13, and M-CSF were tested alone and in combination at the 
indicated concentrations. PBMC and spleen cells were cultured in flat-bottomed 96 well 
tissue culture plates (353072, BD Biosciences) at 200 Jll per well at the indicated cell 
densities in a humidified incubator containing 5% C02 at 3 7° C. On day 3 of the 
incubation, wells with IL-13 and M-CSF were further supplemented with 5 Jll of a 
cocktail containing 1 Jlg/ml IL-13 and 0.5 Jlg/ml M-CSF in Fibrolife SFM. After 5 days, 
plates were air dried, fixed with methanol, and stained with Hema 3 stain (Fisher 
Scientific, Hampton, NH). Fibrocytes were counted in five different 900 Jlm diameter 
fields of view for each well of a 96 well plate, using the following criteria: an adherent 
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cell with elongated spindle-shaped morphology and an oval nucleus (Pilling et al., 2003, 
2006, and 2009a; Shao et al., 2008). The total number of fibrocytes per 105 input cells 
for each well was then calculated. 
4. 2. 4 Immunohistochemistry 
Mouse spleen cells, isolated by combination of digest cocktail, cell strainer, and 
ACK lysis, were cultured in 8 well glass slides (177402, Lab-tek, Nalge-Nunc, 
Naperville, IL) or 8 well CC2 glass slides (154941, Nalge-Nunc) at 4 x 106 cells/ml and 
250 f.!l per well for 5 days in the presence or absence ofiL-13 and M-CSF. Slides were 
air dried overnight, fixed in acetone, and stained as described previously (Pilling et al., 
2009a) with the following modifications. Slides were stained for CD34 (clone RAM34, 
rat IgG2a, eBioscience, San Diego, CA), CD11c (clone 223H7, rat IgG2a, MBL Int., 
Woburn, MA), CDllb (clone Ml/70, rat IgG2b, BioLegend, San Diego, CA), CD45 
(clone 30-Fll, rat IgG2b, BD Biosciences), syk (sc-1077, rabbit polyclonal, Santa Cruz 
Biotech., Santa Cruz, CA), or collagen I (600-401-103-01, rabbit polyclonal, Rockland, 
Inc., Gilbertsville, PA). Negative controls were rat IgG2a and IgG2b (BioLegend) and 
rabbit IgG (Jackson Immunoresearch, West Grove, PA). Primary antibodies were 
incubated at 5 f.!g/ml in PBS/BSA for 1 hour, except anti-CD34 was incubated at 10 
f.!g/ml. Slides were then washed in 5 changes of 50 ml PBS over 15 minutes and 
incubated for 30 minutes in PBS/BSA with 2.5 f.!g/ml biotinylated mouse F(ab')2 anti-rat 
IgG (Jackson Immunoresearch) or 2.5 f.!g/ml biotinylated goat F(ab')2 anti-rabbit IgG 
(Southern Biotech, Birmingham, AL). The slides were then washed and developed as 
previously described (Pilling et al., 2009a). 
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4.2.5 Flow cytometry 
For fibrocyte collagen analysis, spleen cells were cultured for 5 days in the 
presence of IL-13 and M -CSF. Adherent cells were dislodged with a 1 0 minute 
incubation in trypsin-EDTA (Sigma-Aldrich) at 37° C. Cells were washed with 14 ml 
PBS/1 0% mouse serum (Gemini) and collected by centrifugation at 300 x g for 10 
minutes. The cells were resuspended in 100 J.tl ice-cold PBS containing 10% rat serum 
(Sigma-Aldrich), and incubated on ice for 15 minutes. Cells were collected by 
centrifugation at 300 x g for 5 minutes, and resuspended in 100 J.tl of PBS/4% BSA 
containing 2.5 J.tg/ml PE-conjugated anti-CDllb antibody (clone M1/70, rat IgG2b, 
eBioscience ). After a 30 minute incubation on ice, the cells were washed twice with 1.4 
ml ice-cold PBS and fixed with 100 J.tl of 4% paraformaldehyde in PBS for 15 minutes at 
room temperature. The cells were washed twice with 1.4 ml ice-cold PBS/4% BSA and 
permeabilized by resuspension in 100 J.tl PBS/4% BSA/0.1% saponin (Invitrogen). After 
a 15 minute incubation on ice, the cells were washed once with 1.4 ml ice-cold PBS/0.1% 
saponin, collected by centrifugation at 300 x g for 5 minutes, and then stained with 
antibodies against collagen type I (ab292-100, rabbit polyclonal, Abeam, Cambridge, 
MA), collagen type III (600-401-105-.1, rabbit polyclonal, Rockland), or syk (Santa 
Cruz) at 5 J.tg/ml in 100 J.tl PBS/4% BSA/0.1% saponin. After a 30 minute incubation 
on ice, cells were washed twice with 1.4 ml ice-cold PBS/0.1% saponin, and resuspend in 
100 J.tl of PBS/4% BSA/0.1% saponin containing 2.5 J.tg/ml FITC-conjugated goat 
F(ab')2 anti-rabbit IgG (Southern Biotech). After a 30 minute incubation on ice, cells 
were washed twice with 1.4 ml ice-cold PBS, resuspended in 100 J.tl PBS/BSA/saponin, 
and staining was analyzed using a C6 flow cytometer (Accuri, Ann Arbor, MI). 
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For monocyte analysis, mouse spleen cells were subjected to flow analysis as 
described previously (Pilling et a/., 2009a) with the following modifications. Cells were 
stained for Ly6G (clone 1A8, rat lgG2a, BioLegend). The secondary antibody was a 
FITC-conjugated mouse F(ab')2 anti-rat IgG (Jackson Immunoresearch), used at 2.5 
j..tg/ml. After incubating the cells with the secondary antibody and washing, the cells 
were resuspended in 100 j..tl ice-cold PBS containing 10% rat serum (Sigma-Aldrich), and 
incubated on ice for 30 minutes. Cells were collected by centrifugation at 300 x g for 5 
minutes, and resuspended in 100 j..tl ofPBS/4% BSA containing 2.5 j..tg/ml PE-conjugated 
anti-CDllb antibody (clone M1/70, rat IgG2b, eBioscience). After a 30 minute 
incubation on ice, cells were washed twice with 1.4 ml ice-cold PBS, resuspended in 100 
j..tl ice-cold PBS/BSA, and then analyzed using a C6 flow cytometer (Accuri). 
4. 2. 6 Monocyte enrichment and CD 11 b depletion of spleen cells 
Mouse spleen cells were isolated by the combination of digest cocktail, cell 
strainer, and ACK lysis. Monocytes were enriched from spleen cells using an EasySep 
mouse monocyte negative selection kit (Stemcell Technologies, Vancouver, BC), 
following the manufacturer's protocol. Alternatively, CD11 b+ cells were depleted from 
spleen cells using the EasySep Mouse CD 11 b positive selection kit (Stemcell 
Technologies), following the manufacturer's protocol. The CD11 b-depleted cells were 
then subjected to ACK lysis. The purity of the cells was checked by morphology, with a 
monocyte defined as a large cell (1 0-15 IJ.m) with a kidney-shaped nucleus. Cytospins 
were prepared by centrifugation at 400 rpm for 5 minutes in a Shandon Cytospin 2 
(Thermo Scientific, Waltham, MA) and stained with a Hema 3 kit (Fisher). The purity 
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was also checked by staining for CDll b and Ly6G using flow cytometry, as described 
above. The cells were cultured for 5 days as described above, except the monocyte-
enriched cells were plated at 5 x 1 05 cells/ml while the unfractionated spleen cells and 
CD 11 b-depleted cells were plated at 3 x 1 06 cells/mi. 
4.2. 7 Determining the effect of SAP and IgG on fibrocyte differentiation 
Lympholyte-Mammal isolated murine PBMCs were cultured at 2.5 x 106 cells/mi. 
Spleen cells, isolated by the combination of digest cocktail, cell strainer, and ACK lysis, 
were cultured at 3.5 x 106 cells/mi. Murine and human SAP (EMD-Calbiochem) in 20 
mM sodium phosphate buffer, pH 7.4, was added to the cells at the indicated 
concentrations. The cells were then cultured for 5 days, and fibrocytes were counted as 
described above. 
Spleen cells were also tested for sensitivity to IgG. Chromopure murine IgG 
(Jackson Immunoresearch) was clarified by centrifugation at 14,000 x g for 15 minutes at 
4° C to remove aggregates. Mouse spleen cells at 5 x 106 cells/ml in 500 J.tl were 
incubated with 100, 10, 1, or 0 J.tg/ml IgG for 30 minutes at 4° C. Cells were washed 
with 1.4 ml ice-cold Fibrolife medium and collected by centrifugation at 300 x g for 5 
minutes at 4° C. Cells were resuspended in 500 J.tl Fibrolife medium and incubated with 
500 ng/ml goat F(ab')2 anti-mouse IgG (Southern Biotech) for 30 minutes at 4° C. 
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Cells were washed with 1.4 ml Fibrolife, collected by centrifugation at 300 x g 
for 5 minutes, and resuspended to 500 fll. Cells were counted and diluted to 3.5 x 106 
cells/mi. The cells were then cultured for 5 days, and fibrocytes were counted. 
4.3 Results 
To study factors that regulate the differentiation of monocytes to fibrocytes, 
peripheral blood mononuclear cells can be isolated from blood and cultured in vitro. 
When murine PBMCs are utilized, the cells must be cultured at higher densities due to 
the low percentage of monocytes found in mouse blood (Wirth et a/., 1982; Kile et a/., 
2003); therefore, the blood from multiple mice must be pooled together to obtain enough 
cells for a single experiment (Pilling eta/, 2009a). Murine spleens have recently been 
shown to contain a monocyte population that can be mobilized for wound repair (Swirski 
et a/., 2009), and spleen cells have been shown to differentiate into fibrocytes, although 
this process requires serum and an incubation period of 14 days (Niedermeier et a/., 
2009). Therefore, I tested if cultured mouse spleen cells can differentiate into fibrocytes 
in serum free conditions. 
4. 3.1 Spindle-shaped cells that appear in cultures of spleen cells express fibrocyte 
markers 
We previously observed the appearance of spindle-shaped cells in 5 day serum-free 
cultures of human and murine PBMCs (Pilling et a/., 2003, 2006, 2009a; Shao eta/., 
2008). These cells showed positive staining for markers that have been used to classify 
cells as fibrocytes, including the general leukocyte marker CD45, the stem cell marker 
CD34, the monocyte marker CD 11 b, and the matrix biosynthesis marker collagen I 
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(Bucala eta/., 1994; Abe eta/., 2001, Pilling eta/., 2003). To assess the viability of 
culturing mouse spleen cells to study fibrocyte differentiation, I first confirmed the 
presence of fibrocytes in mouse spleen cell cultures. Mouse spleen cells were initially 
isolated by passage through a cell strainer and further purified by density centrifugation. 
After a 5 day incubation in serum-free media, we observed spindle-shaped cells in the 
culture. To confirm the identity of the spindle-shaped cells, I stained the cells for a 
variety of markers. The spindle-shaped cells were positive for well-known markers of 
fibrocytes, including CDllb (Figure 4.1D), CD45 (Figure 4.1E), and weakly positive for 
collagen I (Figure 4.1H). The cells also stained positive for CD34 (Figure 4.1A) with 
variable expression levels, similar to the variability found in human fibrocytes (Pilling et 
a/., 2003 and 2009b; Phillips et a/., 2004). Fibrocytes are known to produce low levels 
of collagen (Wang eta/., 2007; Pilling eta/., 2009b), but to further confirm the presence 
of collagen, we measured the intracellular levels of collagen on 5 day cultured spleen 
cells by flow cytometry. The overall cell population (Figure 4.2A) showed little to no 
staining for collagen (Figure 4.2C), but CDllb+ cells (Figure 4.2B) stained positive for 
both collagen I and III (Figures 4.2D and 4.2E). Similar to the immunohistochemistry 
results, the CD 11 b+ cells only stained weakly positive for collagen I with a median 
fluorescent intensity of 3.4 x 103 ± 0.1 x 103 compared to 5.8 x 104 ± 0.6 x 104 for the 
positive control Syk (Figure 4.2D). To confirm that the spindle-shaped cells were not 
dendritic cells, I stained by immunohistochemistry for CD 11 c, a marker for dendritic 
cells (Shortman eta/., 2002). The cells in culture with a dendritic shape stained strongly 
for CD 11 c, while the spindle-shaped cells were either negative or very weakly positive 
(Figure 4.1B). This suggests that the spindle-shaped cells are fibrocytes rather than 
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Figure 4.1: Cultured mouse spleen cells express markers of fibrocytes. Isolated 
spleen cells were cultured for 5 days at 4 x 106 cells/ml on 8 well CC2 slides, then air 
dried, fixed, and stained with antibodies against (A) CD34, (B) CDllc, (C) rat IgG 2a 
control for A and B, (D) CDll b, (E) CD45, (F) rat lgG 2b control forD and E, (G) syk, 
(H) collagen I, and (I) rabbit lgG control for G and H. Cells were counterstained with 
hematoxylin to identify nuclei . Bar is 50 J.tm, and arrow in A indicates a fibrocyte. 
Images are representative of four independent experiments. 
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Figure 4.2: Expression of collagen by 5 day cultured spleen cells. ACK-treated 
spleen cells were cultured for 5 days at 3.5 x 105 cells per well in the presence of IL-13 
and M-CSF. Adherent cells were removed by trypsin-EDT A treatment and stained for 
the presence of CD 11 b. The cells were then fixed, permeabilized, stained with rabbit 
polyclonal antibodies, and analyzed by flow cytometry. A) Forward and side scatter 
characteristics of 5 day cultured spleen cells. (B) Forward and side scatter analysis of 
CD 11 b+ cells. C and D) Histograms show fluorescence intensity of FITC-conjugated 
goat F(ab ' )2 anti-rabbit 2° (black line) compared to collagen I (red line), collagen III (blue 
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line), and as a positive control syk (yellow line). Flow cytometry plots are representative 
of 3 independent experiments. C) When gating the entire live cell population Rl (from 
A), collagen was nearly undetectable, but when gating (D) for CDllb+ cells and region 
PI (from A and B) there was an increase in the levels of both collagen I and III. E) 
Compared to FITC control, CD 11 b+ cells had a significant increase in median 
fluorescent intensity for collagen I and III staining (1-way ANOVA, Dunnett's test). ** 
p<O.Ol; ***,p<O.OOl. 
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dendritic cells. Together, these observations suggest that murine spleen cells cultured 
for 5 days in serum-free media can differentiate into fibrocytes. We can therefore use 
murine spleen cells to further study conditions that affect differentiation. 
4.3.2 Effect of purification method on fibrocyte differentiation. 
Murine splenocytes are typically isolated either by passage through a cell strainer 
or by digestion with enzymes (Swirski et al., 2009). Mononuclear cells are typically 
further purified by density centrifugation, and leukocytes are purified by lysis of red 
blood cells (Kruisbeek et al., 2000). I tested a variety of cell purification methods to 
optimize spleen cell recovery and fibrocyte differentiation. After removal of the spleen, 
cells were isolated by passage through a cell strainer, digestion with collagenase and 
DNase, or a combination of the two. The isolated spleen cells were further purified by 
density centrifugation with Lympholyte-Mammal or Ficoll, or by ACK lysis to remove 
red blood cells. For the initial isolation, the digest cocktail or the combination of cell 
strainer and digest resulted in the highest recovery of spleen cells (Figures 4.3A, 4.3C, 
and 4.3E). For the additional purification step, ACK lysis resulted in a significantly 
higher recovery of spleen cells compared to density centrifugation by Lympholyte-
Mammal or Ficoll (Figures 4.3A, 4.3C, and 4.3E). For fibrocyte yield, there was no 
significant difference between the initial isolation techniques (Figures 4.3B, 4.3D, and 
4.3F). However, for the additional purification step, ACK lysis showed a trend of 
increased fibrocyte differentiation compared to density centrifugation (Figures 4.3B, 
4.3D, and 4.3F). Additionally, the cultures prepared by ACK lysis and density 
centrifugation were checked for the presence of any contaminating fibroblasts by 
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Figure 4.3: Effect of spleen cell isolation and purification techniques on fibrocyte 
differentiation. A and B) After removal, the spleen was treated with collagenase 
/DNase, and the cells were further purified through ACK lysis or density centrifugation. 
C and D) After removal, the spleen was passed through a 100 ~m cell strainer, and the 
cells were further purified by ACK lysis or density centrifugation. E and F) After 
removal, the spleen was treated with collagenase/DN ase and then passed through a 1 00 
~m cell strainer. The cells were further purified by ACK lysis or Lympholyte-Mammal 
density centrifugation. For A, C, and E, the total number of cells recovered by the 
indicated purification technique was measured. ForB, D, and F, the purified spleen cells 
were cultured in SFM in the presence or absence of IL-13 and M-CSF for 5 days. Cells 
were air dried, fixed, stained, and the number of fibrocytes was counted. Results are 
mean± SEM (n=3). 
94 
morphology on day 1 and day 5 of the culture. The characteristic morphology of 
fibroblasts was never observed in the cultures, nor was there strong collagen staining of 
any cell in the culture, which would be indicative of a fibroblast. Finally, the influence of 
ACK lysis buffer on fibrocyte differentiation was examined to ensure that the higher 
fibrocyte yield compared to density centrifugation was not due to a biological effect by 
the ACK lysis buffer on the cells. Incubating Lympholyte-mammal (density 
centrifugation) purified cells with ACK lysis buffer did not significantly increase 
fibrocyte differentiation compared to density centrifugation alone (Figure 4.4), 
suggesting that the increased fibrocyte yield for ACK lysis is not due to the ACK lysis 
buffer directly promoting fibrocyte differentiation. Due to high spleen cell recovery and 
yielding the highest number of fibrocytes, the remaining experiments were performed 
using the digest cocktail plus cell strainer technique, followed by ACK lysis. 
4. 3. 3 Effect of culture conditions on fibrocyte difforentiation. 
We previously found that human fibrocyte differentiation was increased when 
PBMC were cultured with the pro-fibrotic cytokines IL-4 and IL-13 (Shao et al., 2008). 
Spleen monocytes have also been successfully cultured in the presence of GM-CSF and 
M-CSF (Swirski et al., 2009), and fibrocyte differentiation from murine spleen cells was 
markedly enhanced using conditioned media from CD4+ T cells (Niedermeier et al., 
2009). Therefore, I tested the effect of cytokines on spleen cell differentiation in our 
serum-free medium culture conditions. ACK-treated spleen cells were cultured in the 
presence of murine M-CSF to promote monocyte survival, along with IL-4 and IL-13 as 
pro-fibrotic cytokines, both individually and in combination. Both M-CSF alone and the 
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Figure 4.4: Treatment of spleen cells purified by density centrifugation with ACK 
lysis buffer does not enhance fibrocyte differentiation. After removal, the spleen was 
treated with collagenase/DNase and then passed through a 100 ~m cell strainer. The 
cells were further purified through ACK lysis, density centrifugation using Lympholyte-
Mammal (LM), or LM density centrifugation followed by a 3 minute incubation in ACK 
lysis buffer. Spleen cells were cultured in SFM in the presence or absence of IL-13 and 
M-CSF for 5 days at 3.5 x 105 cells per well. Cells were air dried, fixed, stained, and 
fibrocytes were counted. Cells purified by ACK lysis had increased fibrocyte 
differentiation compared to cells purified by density centrifugation (1-way ANOV A, 
Tukey' s test). *, p < 0.05; **, p < 0.01. Treatment of spleen cells that have already been 
purified by density centrifugation with ACK lysis buffer did not significantly alter 
fibrocyte differentiation compared to cells only isolated with density centrifugation. 
Results are mean± SEM (n=3). 
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combination of IL-13 and M-CSF increased the number of fibrocytes in culture, but M-
CSF alone tended to promote macrophage and dendritic-like cell differentiation as well as 
spindle-shaped, pseudo-fibrocyte cells that did not meet the criteria of a fibrocyte, i.e., an 
elongated spindle-shaped cell with an oval nucleus (Figure 4.5A). These pseudo-
fibrocytes tended to have round nuclei, shorter processes with increased width, and were 
not counted as fibrocytes. The addition ofiL-13 and M-CSF resulted in significantly 
more elongated spindle-shaped cells with oval nuclei (Figures 4.5B), which also express 
the same fibrocyte markers found in Figure 1 (data not shown). When added 
individually, IL-4, at concentrations above 12.5 ng/ml, significantly decreased the 
number offibrocytes, IL-13 had no effect on fibrocyte differentiation, and 25 ng/ml M-
CSF significantly increased the number of fibrocytes (Figure 4.5C). When used in 
combination, IL-13 and M -CSF showed a significant increase in fibrocyte number 
compared to M-CSF alone (Figure 4.5D) and compared to cells not treated with cytokines 
(Figures 4.3B, 4.3D, 4.3F; Figure 4.5D; Figure 4.6). When IL-4 was cultured with M-
CSF or in combination with M-CSF and IL-13, the number of fibrocytes was reduced to 
control levels, suggesting that the inhibitory effect of IL-4 counteracts the potentiating 
effects ofM-CSF and IL-13 on fibrocyte differentiation (Figure 4.5D). Together, these 
results suggest that IL-13 and M-CSF can be used to promote the differentiation of 
fibrocytes from ACK-treated spleen cells in serum-free culture. 
In vitro, human fibrocyte differentiation is dependent on cell density (Pilling et 
al., 2009a). Therefore, ACK-treated spleen cells were cultured at different cell densities 
to determine the optimal culture condition. The highest yield of fibrocytes was observed 
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Figure 4.5: The effect of cytokines on spleen fibrocyte differentiation. ACK-treated 
spleen cells were cultured for 5 days at 3. 5 x 1 05 cells per well in the presence of the 
indicated cytokines. Cells were air dried, fixed, stained, and the number of fibrocytes 
was counted. Wells treated with (A) M-CSF alone resulted in an increase of macrophage 
and dendritic-like cells (*) and pseudo-fibrocytes (white arrow), with round nuclei and 
shorter processes with increased width. Wells treated with (B) M -CSF and IL-13 in 
combination had more elongated, spindle-shaped cells with oval nuclei (black arrow). 
Bar is 100 j.lm, pictures are representative of 3 independent experiments. (C) IL-4, IL-
13 , and M-CSF were added to cultures individually to the indicated concentrations, or 
(D) in combination at 50 ng/ml for IL-4 and IL-13 and 25 ng/ml for M-CSF. Compared 
to SFM, ~ 25 ng/ml IL-4 significantly reduced fibrocyte differentiation, while 25 ng/ml 
M-CSF significantly increased fibrocyte differentiation (1-way ANOVA, Dunnett' s test). 
The combination of IL-13 and M-CSF significantly increased fibrocyte differentiation 
compared to M-CSF alone (1-way AN OVA, Dunnett's test). *, p < 0.05; ** , p < 0.01. 
Results are mean± SEM (n=3). 
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at 3.5x105 cells per well (Figure 4.6). For the remaining assays, cells were cultured at 3.5 
x 1 05 cells per well unless otherwise noted. 
4. 3. 4 Monocyte origin of spleen-derived fibrocytes. 
Fibrocyte precursors appear to differentiate from human CD14+ peripheral blood 
monocytes (Abe et al., 2001 Yang et al., 2002; Pilling et al., 2003 & 2006). Niedermeier 
et al. (2009) found that murine fibrocytes derive from a GR-1+, Ly6G- monocyte 
subpopulation using splenocytes cultured for 14 days in serum. To confirm the origin of 
the fibrocytes in our serum-free 5 day culture system, I isolated monocytes from ACK-
treated spleen cells. When the spleen cells were enriched for monocytes using an 
EasySep kit, the population of CD11b+, Ly6G- cells increased from less than 2.7% of 
total cells to more than 60% (Figures 4.7A, 4.7B, 4.7D, and 4.7E). Additionally, the 
monocyte-enriched population had an increase in the number of cells with kidney-shaped 
nuclei (Figures 4.7C and 4.7F) compared to spleen cell controls. The morphology of the 
cells along with the flow cytometry data suggests that the population was predominantly 
composed of monocytes. When cultured for 5 days, the monocyte-enriched population 
had a significant increase in fibrocyte differentiation (Figure 4.7G) compared to ACK-
treated spleen cultures. 
Niedermeier et al. (2009) found that the appearance of fibrocytes was dependent 
on CD 11 b+ monocytes. When monocytes and other CD 11 b+ cells were depleted from 
ACK-treated spleen cells using an EasySep CDllb kit, fibrocytes did not appear in our 
serum-free culture (data not shown). Together, the data suggest that the fibrocytes from 
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Figure 4.6: The effect of cell density on spleen fibrocyte differentiation. ACK-treated 
spleen cells were cultured in SFM in the presence or absence of IL-13 and M-CSF for 5 
days at a range of cell densities. Cells were air dried, fixed, stained, and fibrocytes were 
counted. Results are mean± SEM (n=3). 
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Figure 4.7: Enrichment of monocytes from spleen cells significantly enhances 
fibrocyte differentiation. Spleen cells were isolated through enzymatic digest, passed 
through a 100 J.lm cell strainer, and further purified by ACK lysis. The ACK-treated 
spleen cells were then enriched for monocytes through negative selection. ACK-treated 
spleen and monocyte-enriched cells were stained with rat monoclonal antibodies and 
analyzed by flow cytometry. Histograms show fluorescence intensity of isotype 
control antibody (black line) compared to the indicated antibody (red line). Compared to 
ACK -treated spleen cells (A and B), monocyte-enriched cells (D and E) had an 
increased number of CD 11 b+, Ly6G- cells. Flow cytometry plots are representative of 3 
independent experiments. ACK-treated spleen and monocyte-enriched cells were 
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analyzed for morphology. Monocyte-enriched cultures (F) showed an increased number 
of cells with kidney shaped nuclei (stained dark purple) compared to ACK-treated spleen 
cells (C). Bar is 20 Jlm. Pictures are representative of 3 independent experiments. G) 
ACK-treated spleen and monocyte-enriched cells were cultured for 5 days at 3.5 x 105 
cells per well and 0.5 x 105 cells per well, respectively, in the presence or absence ofiL-
13 and M-CSF. Cells were air dried, fixed, stained, and the number of fibrocytes was 
counted. Results are mean± SEM (n=3). Monocyte-enrichment significantly increased 
the number offibrocytes (t-test). *, p < 0.05; **, p <0.01. 
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our serum free 5 day culture are of monocyte origin, comparable to what has been 
observed in other systems (Abe et al., 2001; Pilling et al., 2003; Niedermeier et al., 
2009). 
4.3.5 SAP and cross-linked IgG inhibit the differentiation ofspleen-derivedfibrocytes. 
We previously found that a number of factors can regulate the differentiation of 
human PBMCs into fibrocytes (Pilling et al., 2003, 2006; Shao et al., 2008). For 
instance, SAP and aggregated IgG inhibit fibrocyte differentiation (Pilling et al., 2003, 
2006). To determine if purified murine spleen cells can also be used to test the 
bioactivity of such factors, I cultured ACK-treated murine spleen cells with different 
concentrations of SAP. At concentrations above 80 nM, SAP significantly reduced the 
number of fibrocytes compared to serum-free medium and buffer controls (Figure 4.8). 
The IC50 values for SAP inhibition of murine spleen cells are comparable to those of 
murine PBMCs treated with SAP (Table 4.1). For both murine PBMCs and spleen cells, 
human SAP was significantly more effective at inhibiting fibrocyte differentiation than 
murine SAP. Together, these results suggest that cultured spleen cells can give similar 
biological responses as peripheral blood mononuclear cells. Interestingly, in the presence 
of IL-13 and M-CSF, the addition of 480 nM murine SAP did not fully inhibit fibrocyte 
differentiation (Figure 4.8B); however, the IC50 of murine SAP was not significantly 
altered (1-way ANOVA, Tukey's test, Table 4.1). 
The differentiation of human PBMCs into fibrocytes is inhibited by cross-linked 
IgG (Pilling et al., 2006). To determine if murine spleen cells have a similar biological 
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Figure 4.8: Murine and human SAP inhibit fibrocyte differentiation of cultured 
spleen cells. Murine, ACK-treated spleen cells were cultured for 5 days at 3.5 x 105 
cells per well in the (A) absence or (B) presence of IL-13 and M-CSF, and the indicated 
mouse and human SAP concentrations. Cells were air dried, fixed, stained, and the 
number of fibrocytes was counted. Results are mean ± SEM (n=3 ). In the absence or 
presence of IL-13 and M-CSF, ~ 10 ~g/ml mouse SAP or ~ 1 ~g/ml human SAP 
significantly inhibited fibrocyte differentiation compared to buffer control (t-test). *, p < 
0.05 ; **' p < 0.01 ; *** ' p < 0.001. 
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Table 4.1: SAP IC50 values for the inhibition of fibrocyte differentiation in human 
and murine cell cultures. 
Cells Mouse SAP ICso Human SAP ICso 
nM nM 
HumanPBMC 5.8 ± 1.1 3.0 ± 0.3 * 
MurinePBMC 52.4 ± 7.4 11.8 ± 0.8 ** 
Murine Spleen 66.3 ± 15.7 9.6 ± 2.3 ** 
Murine Spleen + 113.2 ± 27.7 14.2 ± 2.2 ** Cytokines 
Human PBMCs, murine PBMCs, and murine spleen cells were cultured for 5 days at 5 x 
104 cells per well, 2.5 x 105 cells per well, and 3.5 x 105 cells per well, respectively, in 
the presence of human and murine SAP. Murine spleen cells were also cultured in the 
presence or absence of the cytokines IL-13 and M-CSF. Cells were air dried, fixed, 
stained, and enumerated by morphology. Using fibrocyte counts normalized to SFM 
controls, IC50 levels were calculated by fitting SAP bioactivity to a sigmoidal dose 
response curve with variable slope. Results are expressed as mean ± SEM (n=5 for 
spleens, n=3 for mouse PBMCs, n=6 for human PBMCs). For the inhibition of fibrocyte 
differentiation by murine SAP, no significant difference was observed between the IC50 
values for murine PBMCs and murine spleen cells (1-way ANOVA, Tukey's test). 
Human SAP was significantly more effective than murine SAP on both human cells 
(p<0.05) and mouse cells (p<0.01; t-test). *, p < 0.05; **, p < 0.01. 
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response, I cultured spleen cells in the presence or absence of monomeric and cross-
linked IgG. Monomeric murine IgG at concentrations up to 100 ~-tglml and goat-anti 
mouse IgG F(ab')2 crosslinker alone had no effect on fibrocyte differentiation (Figure 
4.9). The addition of goat F(ab'h anti-mouse IgG to monomeric IgG at concentrations as 
low as 10 ~-tglml led to a significant reduction in fibrocyte differentiation (Figure 4.9). 
Similar to the ability of SAP and cross-linked IgG to inhibit the differentiation of human 
PBMCs into fibrocytes, the differentiation of mouse spleen cells into fibrocytes is 
inhibited by both SAP and cross-linked IgG. Since the biological response is consistent 
with those observed from human PBMC cultures, mouse spleen cultures appear to be a 
viable alternative to peripheral blood for studying factors that affect fibrocyte 
differentiation. 
4.4 Discussion 
We previously found that we could culture both human and murine PBMCs in 
serum-free culture for 5 days to obtain fibrocytes and use this system to test for factors 
that affect fibrocyte differentiation (Pilling et al., 2003, 2006, 2009a; Shao et al., 2008). 
However, to obtain enough mouse PBMCs, we had to pool blood from multiple mice. I 
therefore explored alternative sources for mononuclear cells, including the spleen. The 
spleen has been shown to contain monocytes that can participate in wound repair, and 
spleen cells have been shown to differentiate into fibrocytes in a 14 day serum culture 
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Figure 4.9: Cross-linked but not monomeric IgG inhibit fibrocyte differentiation of 
spleen cells. Murine, ACK-treated spleen cells were incubated with the indicated 
concentrations of murine lgG for 30 minutes, followed by incubation in the presence or 
absence of 500 ng/ml goat F(ab')2 anti-mouse lgG cross-linker for 30 minutes. After 
washing the spleen cells, the cells were cultured for 5 days at 3.5 x 105 cells per well in 
the presence or absence ofiL-13 and M-CSF. Cells were air dried, fixed, stained, and the 
number of fibrocytes was counted. Results are mean ± SEM (n=5). Compared to 
controls, cross-linked lgG at 10 and 100 ~g/ml significantly reduced fibrocyte 
differentiation (1-way ANOVA, Dunnett's test). *, p < 0.05; **, p < 0.01; ***, p < 
0.001. 
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(Swirski et al., 2009; Niedermeier et al., 2009). In this chapter, I found that murine 
spleen cells can also be cultured in our serum-free system to obtain fibrocytes and test for 
factors that can affect fibrocyte differentiation. My study focused on the common 
C57BL/6 strain. For other strains, the fibrocyte yield from spleen and blood cells, and 
response to cytokines, could be different, although results similar to C57BL/6 mice are 
expected. 
I found that for optimal fibrocyte differentiation, leukocytes should be isolated 
from the spleen using a collagenase/DNase digest cocktail, followed by passage through 
a cell strainer and lysis of the red blood cells with ACK lysing buffer. The use of the 
digest cocktail led to an increase in the number of fibrocytes, which may be due to the 
release of monocytes attached to the matrix of the spleen. The number of non-red blood 
cells isolated from a spleen is ~ 40 times higher than the number of non-red blood cells 
isolated from approximately 1 ml of the peripheral blood of a mouse. However, the 
percentage ofmonocytes in the spleen cell preparation is 0.5% compared to 1-2% for the 
peripheral blood of C57BL/6 mice (Kile et al., 2003; Swirski et al., 2009). Thus, there 
are ~ 10 times more monocytes obtained from a spleen than peripheral blood. 
Approximately 6 % of the input monocytes from the spleen differentiated into fibrocytes, 
and this percentage increased 4-fold with the addition of IL-13 and M-CSF. For 
peripheral blood, - 8 % of the input monocytes differentiated into fibrocytes. These 
results are comparable to the differentiation in human PBMC, where- 5% of the input 
monocytes differentiate into fibrocytes, and this percentage is increased 4-fold with the 
addition of IL-13 (Pilling et al., 2003 and 2009a; Shao et al., 2008). 
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I further optimized fibrocyte differentiation by plating the cells at high cell 
density. The optimal cell density of 1.75 x 106 cells/ml is significantly higher than the 
optimal cell density of 2.5 x 105 cells/ml we observed for our serum free culture of 
human PBMCs (Pilling et al., 2009a). One possible explanation for the higher optimal 
cell density for spleen cells is that the percentages of monocytes in murine blood and 
spleen are significantly lower than that of circulating monocytes in humans (Kile et al., 
2003; Swirski et al., 2009; Robbins et al., 2010). In addition, the promotion of fibrocyte 
differentiation by high cell density is may be due to both cell-to-cell contacts and soluble 
factors. In fact, T -cells have been shown to be required for the differentiation of spleen 
monocytes into fibrocytes (Niedermeier et al., 2009), and Th2 cells can secrete pro-
fibrotic cytokines such as IL-13, a factor known to enhance fibrocyte differentiation 
(Shao et al, 2008). 
My final optimization was to repeat all assays in the presence of IL-13 and M-
CSF. IL-13 was selected for its ability to enhance fibrocyte differentiation of human 
PBMCs (Shao et al. 2008) and M-CSF to promote monocyte survival (Becker et al., 
1987). Utilizing a combination of factors to promote leukocyte differentiation is a 
standard practice; for instance, GM-CSF and IL-4 are used to promote dendritic cells 
(Inaba et al., 1992; Sallusto et al., 1994), and M-CSF and serum are used to promote 
macrophages (Tushinski et al., 1982). The use ofiL-13 and M-CSF more than tripled the 
number of fibrocytes, while not significantly altering the biological response of the 
spleen cells to differing culture conditions and factors such as SAP and cross-linked IgG. 
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In contrast, IL-4 inhibited fibrocyte differentiation and negated the potentiating effects of 
IL-13 and M-CSF to control levels. We previously found that IL-4 promoted fibrocyte 
differentiation in human PBMCs (Shao et al., 2008), but murine IL-4 has the opposite 
effect when incubated with murine spleen cells, which was also observed by Niedermeier 
et al. (2009). The ability of IL-4 to counteract IL-13 and M-CSF can partially be 
explained by the fact that mouse monocytes are significantly more sensitive to levels of 
IL-4 than IL-13 (Junttila et al., 2008). Additionally, there is biological divergence 
between humans and mice for cytokine activity, such as the differential effects on B cells 
by IL-4 and IL-13 (Mestas et al., 2004), but a possible divergence has not been fully 
explored for fibrocyte differentiation. It is known that IL-4 is non-essential in the 
bleomycin-induced model of murine lung fibrosis (Izbicki, et al., 2002), while IL-13 
deficient animals were protected from FITC-induced lung fibrosis (Kolodsick et al., 
2004). However, both cytokines and their receptors are induced in bleomycin-induced 
lung fibrosis (Jakubzick et al., 2003) 
I was able to culture over 3 x 104 fibrocytes from a single spleen, and this 
number increased to 1.1 x 105 fibrocytes in the presence of IL-13 and M -CSF. This is 
considerably higher than the 4 x 103 fibrocytes we could obtain from the peripheral blood 
of a single mouse ( ~ 1 ml). After 14 days in cultures containing serum, Abe et al. (200 1) 
observed 8 - 40 x 103 fibrocytes from 1 ml of peripheral blood. The higher number of 
fibrocytes observed by Abe et al. (200 1) could be due to the culturing of fibrocytes for 14 
days in serum compared to our culturing of fibrocytes in serum-free medium for 5 days. 
Another possibility is that Abe et al. (200 1) identified fibrocytes using flow cytometry 
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and staining for CD 11 b and collagen I, while I identified fibrocytes both morphologically 
and by marker expression. 
The serum-free culture of mouse spleen cells resulted in the differentiation of 
fibrocytes over a short period of time compared to the typical 14 day period required in 
serum-based cultures. The delay in serum-based cultures is likely due to components in 
serum such as IgG and SAP that can inhibit fibrocyte differentiation. I was able to 
identify conditions to produce a high yield of fibrocytes from a single spleen, and the 
cells were sensitive to factors known to inhibit fibrocyte differentiation. This will allow 
for efficient testing of factors that can affect fibrocyte differentiation in multiple murine 
backgrounds. 
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Chapter 5: Determining which FcyR subtype regulates fibrocyte differentiation. 
5.1 Introduction 
An alternative means to determining how SAP functions is through the deletion or 
knockdown of SAP's only known receptor, FcyR. The current literature is unclear 
regarding how SAP interacts with FcyRs. One group found that human SAP (hSAP) has 
a lower affinity for binding to human FcyRs than IgG, and that hSAP has the highest 
affinity for FcyRI among the different receptor subtypes (Lu et al., 2008). Another group 
found that hSAP has a higher affinity for binding to human FcyRs than IgG, and that 
hSAP binds with highest affinity to FcyRIIa and III (Castano et al., 2009). A third group 
found that hSAP binds with highest affinity to FcyRI and FcyRIIa, and a lower affinity to 
FcyRIIIb (Bharadwaj et al., 2001). 
Human SAP has previously been shown to bind to a 3T3 mouse fibroblast cell 
line expressing specific mouse FcyR subtypes with the relative rank order of FcyiV >Fey 
III ~ Fcyi > Fcyiib (Castano et al., 2009). Also, Castano et al. (2009) determined by 
surface plasmon resonance that human SAP binds with the following order of affinity: 
hFcyRIIA- hFcyRIII > hFcyRI >> hFcyRIIb. Again, there are differences in the biology 
between humans and mice, where human FcyRIIa and III have similar binding affinities, 
while mouse FcyRIV (the equivalent of human FcyRIIA) has significantly higher affinity 
than Fcyiii. Therefore, when determining which receptor subtype is responsible for 
regulating fibrocyte differentiation, I will examine both human and mice cells. 
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Previously, we tested if SAP could act as a therapeutic in cardiac fibrosis-induced 
mice that lack the gamma chain required by all the activating FcyRs (Haudek et al., 
2008). SAP was not able to reduce the level of fibrosis, suggesting that engagement of an 
activating FcyR (1, III, or IV) is necessary for SAP's function. However, this result does 
not reveal which specific receptor is necessary and does not give any information 
regarding the inhibitory receptor's (FcyRIIb) possible involvement in regulating fibrocyte 
differentiation. 
We can use the in vitro fibrocyte differentiation assay from Chapter 4 to measure 
changes in SAP's bioactivity when incubated in mice spleen cells lacking the various 
FcyR subtypes. This will allow us to see more subtle shifts in SAP's bioactivity that 
might not be observable in a more complex biological system such as a fibrosis-induced 
mouse. SAP could act through multiple FcyRs and removing a single receptor subtype 
may not eliminate bioactivity, but would likely cause a noticeable shift in the bioactivity 
curve that could otherwise be missed in vivo. However, the differences in biology 
between human and mice FcyRs means that we should not rely solely on mouse knock 
outs for analysis. I will also be using siRNA against human FcyRs to study any changes 
in SAP bioactivity after knocking down various receptors singly and eventually in 
combination. 
In this chapter, I will use a combination of FcyR KO and siRNA to determine 
which FcyRs are critical for SAP's ability to inhibit fibrocyte differentiation. We know 
that the y chain (FcRy) is necessary for SAP's bioactivity in vivo, so initially the FcRy 
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KO mice and siRNA knockdown of FcRy in human PBMCs can be tested as a positive 
control. Deletion ofFcyRI and FcRy in murine cells and reduction ofFcyRI and FcRy in 
human cells reduced sensitivity to SAP. Together, this suggests that SAP, at least in part, 
uses FcyRI and FcRy to inhibit fibrocyte differentiation. 
5.2 Methods 
5. 2.1 Cell fractionation of spleen cells 
4-6 week male C57BL/6J mice (Jackson Laboratories, Bar Harbor, ME or 
Taconic, Hudson, NY), B6.129P2-Fcgr31ml~v!J mice (Jackson Laboratories), B6.129S4-
Fcgr2btmJTtKN12 mice (Taconic), B6.129P2-FcerllmJRavN12 mice (Taconic) were used 
in this study. FcyRIIIIII/IV knock out mice in C57BL6/J background were kindly 
donated by Dr. Sjef Verbeek at Leiden University Medical Center. Spleen cells from 
FcyRI knockout mice (Ioan-Facsinay et al., 2002) were kindly donated by Dr. Bryce 
Binstadt at the University of Minnesota. All work was done under Rice and Texas A&M 
IACUC approved protocols. Spleens were harvested (~70-100 mg each) and cells were 
isolated by digesting in a cocktail of 450 U/ml collagenase I (EMD, San Diego, CA), 60 
U/ml DNase I, and 60 U/ml hyaluronidase (Sigma-Aldrich, St. Louis, MO) in 1 ml RPMI 
(Sigma-Aldrich) for 30 minutes at 37°C. The digest was then forced through a 100 J.lm 
cell strainer (BD Biosciences, San Jose, CA) using the plunger of a 3 ml syringe (BD 
Medical, Franklin Lakes, NJ) and 5 ml of RPMI. The cells were resuspended in 10 ml 
RPMI and collected by centrifugation at 300 x g for 10 minutes. Cells were then 
resuspended in 940 J.ll ACK lysis buffer (0.15 M NH4Cl, 10 mM KHC03, 0.1 mM 
Na2EDTA; Kruisbeek, 2000) for 3 minutes at room temperature, and the reaction was 
stopped by the addition of 14 ml PBS. The cells were collected by centrifugation at 200 
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x g for 10 minutes, and the PBS wash step was repeated 3 additional times. A final wash 
was carried out by resuspending the cells in 1.5 ml Fibrolife basal rriedia (Lifeline Cell 
Technology, Walkersville, MD) with supplements, and the cells were collected by 
centrifugation at 300 x g for 5 minutes at 4° C. 
5.2.2 Fibrocyte differentiation assay for spleen cells 
Fibrolife serum free media was prepared as discussed in section 4.2.3, including 
the addition of 50 ng/ml murine IL-13 and 25 ng/ml murine M-CSF (Peprotech) for select 
wells. Spleen cells were cultured in flat-bottomed 96 well tissue culture plates (353072, 
BD Biosciences) at 3.5 x 105 cells per well in 200 f ..tl in a humidified incubator containing 
5% C02 at 37° C. Murine and human SAP (EMD-Calbiochem) in 20 mM sodium 
phosphate buffer, pH 7.4, were added to the cells at the indicated concentrations. On day 
3 ofthe incubation, wells with IL-13 and M-CSF were further supplemented with 5 f..ll of 
a cocktail containing 1 f..lg/ml IL-13 and 0.5 f.!g/ml M-CSF in Fibrolife SFM. After 5 
days, plates were air dried, fixed with methanol, and stained with Hema 3 stain (Fisher 
Scientific). 
Flow cytometry 
Mouse spleen cells were subjected to flow analysis as described previously 
(Crawford et al., 2010; Pilling et al., 2009) with the following modifications. Cells were 
stained using 5 f.!g/ml of antibodies against CD3 (clone 17 A2, rat IgG2b, BD 
Biosciences), CD45R/B220 (clone RA3-6B2, rat IgG2a, BD Biosciences), CDllc (clone 
223H7, rat IgG2a, MBL Int., Woburn, MA), CD16/32 (clone 2.402, rat IgG2b, BD 
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Biosciences), CD94 (clone HMa2, rat IgG2a, eBioscience, San Diego, CA), Ly6G (clone 
1A8, rat IgG2a, BioLegend), GR-1 (clone RB6-8C5, rat IgG2b, BD Biosciences), F4/80 
(clone BM8, rat IgG2a, Biolegend), and isotype-matched irrelevant rat monoclonal 
antibodies (Biolegend) as controls. The secondary antibody was a FITC-conjugated 
mouse F(ab')2 anti-rat IgG (Jackson Immunoresearch, West Grove, PA), used at 2.5 
J..tg/ml. After blocking with PBS/10% rat serum (Sigma-Aldrich) for 30 minutes at 4° C, 
cells were collected by centrifugation at 300 x g for 5 minutes, and resuspended in 100 J..tl 
of PBS/4% BSA containing 2.5 J..tg/ml PE-conjugated anti-CDllb antibody (clone 
M1/70, rat IgG2b, eBioscience) and 5 J..tg/ml biotinylated anti-CD45 antibody (clone 30-
F11, rat IgG2b, BD Biosciences). After a 30 minute incubation on ice, cells were washed 
twice with 1.4 ml ice-cold PBS and resuspended in 100 J..tl ice-cold PBS/BSA containing 
2 J..tg/ml streptavidin-APC (Biolegend). After a 30 minute incubation on ice, cells were 
washed twice, resuspended in 100 J..tl ice-cold PBS/BSA, and analyzed using a C6 flow 
cytometer (Accuri, Ann Arbor, MI). 
5. 2. 3 SiRNA knockdown. 
Silencer select siRNA's (Applied Biosystems/Ambion, Austin, TX) were reconstituted in 
H20 to 50 J..tM. Human PBMCs were isolated and purified as described above. 
Transfection of human PBMCs was carried out with Lipofectamine 2000 (Invitrogen), 
following the manufacturer's protocol. 5.25 pmol siRNA was incubated in 25 J..tl Fibrolife 
basal media (Lifeline)+ HEPES (Sigma-Aldrich) with 0.25 J..tl Lipofectamine 2000 for 20 
minutes. The mixture was then diluted in 2.1 ml Fibrolife SFM lacking antibiotics to 
obtain a concentration of 2.5 nM siRNA. 200 J..t1 siRNA was added to the top row of a 96 
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well plate, and 100 J.ll doubling dilutions were carried out using an equal volume of 
Fibrolife SFM lacking antibiotics to obtain 100 Ill of the indicated concentrations of 
siRNA. 100 J.ll ofPBMCs at 5x105 cells/ml in SFM was added to each well, and the plate 
was incubated for 24 hours in a humidified incubator containing 5% C02 at 3 7° C. hSAP 
(EMD Calbiochem) was added at the indicated concentrations 24 hours later in 3 Ill 
aliquots. The plate was returned to the incubator, and after 4 additional days the plates 
were air dried, fixed with methanol, and stained. 
5.2.4 Determination of expressed protein levels of Fe gamma receptors after siRNA 
knockdown. 
SiRNA plates were set up as described above except SAP was not added. After 
2.5 days, the wells were washed with 100 J.ll PBS, fixed with 75 Ill PBS/4% 
paraformaldehyde on ice for 15 minutes, washed twice for 5 minutes with 100 J.ll PBS, 
permeabilized with 75 J.ll PBS/0.1% Triton X-1 00 for 10 minutes at room temperature, 
and washed three times for 5 minutes with 100 J.ll PBS. The wells were blocked with 100 
Ill PBS/4% BSA at 4 • C overnight. Cells were stained for one hour with primary antibody 
or IgG-matched controls (Biolegend and Epitomics) in 50 J . ll PBS/4% BSA using: 5 
J.lg/ml rabbit anti-human FceRI, y subunit (06-727, Millipore), 5 J.lg/ml mouse anti-human 
CD64 (clone 10.1, mouse lgG1, BD Biosciences), 7.5 J.lg/ml goat anti-human CD32a 
(AF1875, R&D Systems), 1:100 rabbit anti-human CD32b (clone EP926Y, Epitomics), 
or 1:100 rabbit anti-human CD16a (clone EPR4333, Epitomics). The wells were washed 
four times for 5 minutes with 100 J.ll PBS. The primary antibodies were detected with 
biotinylated F(ab')2 goat anti-rabbit IgG (Southern Biotech), biotinylated goat F(ab')2 
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anti-mouse IgG (Southern Biotech), or biotinylated F(ab')2 donkey anti-goat IgG 
(Jackson Immunoresearch). All secondary antibodies were incubated for 30 minutes at 
2.5 J..Lg/ml in 50 J..Ll PBS/BSA, and the wells were then washed four times for 5 minutes 
with 100 J..Ll PBS. After washing, the wells were incubated for 30 minutes with 2.5 J..Lg/ml 
of streptavidin-conjugated Dylight-488 antibody (Thermo Scientific). The wells were 
washed four times for 5 minutes with PBS, and the wells were coated with 30 Jll of 
Vectashield mounting media (Vector Labs, Burlingame, CA), containing 4' ,6-diamidino-
2-phenylindole. Immunofluorescence images were captured using an Olympus FV1000 
confocal microscope (Olympus, Center Valley, PA), and ImageJ (Rasband, WS, NIH, 
Bethesda, MD) was used for analysis. Mean fluorescent intensity was measured for each 
cell, excluding sizes smaller than 156 J..Lm2 to eliminate cell debris and lymphocytes. 
5.3 Results 
5.3.1 Murine FcRy and FcyR!mediate sensitivity to SAP. 
Because altering key residues of hSAP at the predicted FcyRIIa binding site (Lu 
et al., 2008) had only a modest effect on SAP bioactivity (Figure 2.13E), other FcyRs 
may bind SAP. The observation that FcRy appears to be necessary for SAP to inhibit 
fibrosis in vivo (2 J..Lg/g for lung or 20 J..Lg/g for kidney) (Castano et al., 2009; Haudek et 
al., 2008), suggests that SAP might activate FcyRI or FcyRIII. To test this, I measured 
the inhibition of fibrocyte differentiation by SAP using cells from mice lacking specific 
FcyRs. I used the plentiful splenic reservoir of monocytes (Niedermeier et al., 2009; 
Swirski et al., 2009) to test for SAP bioactivity (Crawford et al., 2010), as outlined in 
Chapter 4. 
118 
With respect to fibrocyte differentiation, the bioactivity of murine and human 
SAP on FcRy KO cells was significantly reduced compared to the bioactivity on wild-
type cells (Figures 5.1A, 5.1B, and 5.2). These data suggest that fibrocyte differentiation 
is regulated by activating FcyRs and that the mouse spleen in vitro fibrocyte 
differentiation assay is a viable method for studying this effect in KO mice. 
Compared to wild-type cells, FcyRI KO cells were significantly less sensitive to 
murine and human SAP (Figures 5.1C, 5.1D, and 5.2). The shift in bioactivity was 
obfuscated by an overall reduction in total fibrocyte number for the FcyRI KO cells 
compared to WT cells (Figures 5.1C and 5.1D). These data suggest that FcyRI mediates 
some of the effect of SAP on fibrocyte differentiation. 
5. 3. 2 Murine FcyR/Ib reduces sensitivity to SAP. 
FcyRIIb KO and FcyRIII KO cells differentiated into an abnormally low number 
of fibrocytes (Figure 5.3A-D). FcyRIIb KO cells were more sensitive to murine SAP 
than wild-type cells, while FcyRIII KO cells showed a normal sensitivity (Fig. 5.2A). 
These data indicate that neither FcyRIIb nor FcyRIII are critical for the ability of SAP to 
inhibit fibrocyte differentiation. 
5. 3. 3 Cells from FcyR/lbi/IIIIV KO mice have normal sensitivity to SAP. 
As SAP inhibited fibrocyte differentiation from spleen cells of both FcyRIIb KO 
and FcyRIII KO mice, we determined if the deletion of multiple FcyRs affects the ability 
of SAP to inhibit fibrocyte differentiation. Spleen cells from FcyRIIb I FcyRIII I FcyRIV 
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Figure 5.1: Murine FcRy KO and FcyRI KO cells are less sensitive to SAP than 
wild-type C57BL/6 cells. Cells were cultured in the indicated concentrations of mSAP 
(A and C) or hSAP (B and D). After a 5 day incubation, cells were air dried, fixed, 
stained, and the number of fibrocytes was counted. Results are mean ± SEM (n=5 for 
C57BL6, n=4 for FcRy KO, n=3 for FcyRI). (A and B) At concentrations above 24 nM 
for mSAP and concentrations above 8 nM for hSAP, SAP bioactivity was significantly 
reduced for the FcRy KO cells compared to wild-type cells, as determined by t test. *, p < 
0.05 ; * *, p < 0.01 ; * * *, p < 0.00 1. (C and D) At 480 nM, mSAP bioactivity was 
significantly reduced for the FcyRI KO cells compared to WT spleen cells, as determined 
by t test. *, p < 0.05. FcyRI KO spleen cells had significantly fewer fibrocytes in the 
serum free control wells compared to WT spleens (t test, *, p < 0.05). 
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Figure 5.2: SAP ICSO values for the inhibition of fibrocyte differentiation in FcyR 
KO cell cultures. Spleen cells from the indicated strains of mice were cultured in the 
presence of (A) murine or (B) human SAP. Cells were air dried, fixed, stained, and 
enumerated by morphology. Using fibrocyte counts normalized to SFM controls, IC5o 
levels were calculated by fitting SAP bioactivity to a sigmoidal dose response curve with 
variable slope. Values are mean ± SEM (n=5 for C57BL/6, n=3 for FcyRIIb KO and 
FcyRIIIa KO, n=4 for FcRy KO, FcyRI KO, and FcyRIIb/Illa/IV KO). FcRy KO and 
FcyRI KO spleen cells were significantly less responsive to SAP compared to the WT 
strain (1-way ANOVA, Dunnett's test)*, p < 0.05; **, p < 0.01, ***, p < 0.001. If the 
data is also examined by t-test, then FcyRIIb KO and FcyRilb/Illa/IV KO spleen cells 
were significantly more responsive to mouse SAP compared to WT cells (p < 0.05). 
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Figure 5.3: FcyRIIb KO cells have increased sensitivity to SAP, while FcyRIIIa KO 
cells have normal sensitivity. Cells from C57BL/6, FcyRIIb KO, and FcyRIIIa KO 
mice were cultured in the indicated concentrations of mSAP (A and C) or hSAP (B and 
D). Values are mean ± SEM (n=3, except n=5 for C57BL/6). (A and B) FcyRIIb KO 
spleen cells had significantly fewer fibrocytes in the serum free controls compared to WT 
spleen cells, and had an increased sensitivity to (A) murine and (B) human SAP, as 
determined by t test. *, p < 0.05 ; * *, p < 0.0 1. (C and D) FcyRIIIa KO spleen cells had 
significantly fewer fibrocytes in the serum free control wells compared to WT spleens (t 
test, *, p < 0.05). 
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triple KO mice also allowed us to examine if FcyRIV regulates fibrocyte differentiation, 
which we did not have access to as an individual knockout. The triple KO cells 
differentiated into an abnormally low number of fibrocytes (Figures 5.4A and 5.4B). 
However, the IC50 of hSAP in the triple KO spleen cells was comparable to that of WT 
mice (Figure 5.2B), although the triple KO spleen cells were about twice as sensitive to 
mSAP as wild-type cells (Figure 5.2A). The spleen cells from the triple KO mice 
responded to murine and human SAP to the same degree or with increased sensitivity 
compared to spleen cells from WT mice, suggesting that these receptors are not essential 
for SAP's ability to inhibit fibrocyte differentiation. To determine if the reduced 
fibrocyte number was due to a decrease in the number of monocytes in the spleen, we 
analyzed spleen cells for cell markers by flow cytometry. Spleens from the triple KO 
mice had normal numbers of total cells, monocytes (CD45+, CDllb+, GRI+ cells), and 
other leukocytes (Table 5.1). This suggests that the low fibrocyte yield was not due to a 
reduced number of monocytes in the spleen. These data indicate that SAP is still able to 
reduce fibrocyte differentiation in the absence of FcyRII, FcyRIII, and FcyRIV at least to 
the same degree as normal controls; however, the lack of these receptors does affect the 
development of fibrocytes in culture. 
5.3.4 Reduction of FcRy and FcyRI in human cells significantly reduces sensitivity to 
SAP. 
Because of the differences in biology between mouse and human FcyRs, we also 
examined how reducing FcyR expression in human cells using siRNA (Table 5.2) affects 
the inhibition of fibrocyte differentiation by SAP. The siRNAs were transfected into 
A 
150 
t/) 
<l> 125 ~ 
0 t/) e = 100 A_ 
.c B ~ ----"'-
~10 
It- 0 75 
o~ 
'- '-Cl> Ci) 50 
.c Q. 
E 
:::l 
z 
25 *** o:-~ FcyRII/111/IV KO ** ** *** 
0 1 10 100 1000 
mSAP (nM) 
B 
150 
t/) 
<l> 
~ 
(J t/) 
o= 
'- Ci) 
.c 0 
~10 
It- 0 7 
o~ 
'- '-Cl> Ci) 5 
.c Q. 
E 
:::l 
z 
123 
0 1000 
hSAP (nM) 
Figure 5.4: FcyRIIblllla/IV KO spleen cells produce significantly fewer fibrocytes 
compared to WT C57BL/6 cells. Cells from WT C57BL/6 and FcyRIIb/IIIa/IV KO 
mice were cultured in the indicated concentrations ofmSAP (A) or hSAP (B). Values are 
mean ± SEM (n=4 for KO, n=5 for C57BL/6). (A and B) The FcyRIIb/IIIa/IV KO 
spleen cells had a significantly lower number of fibrocytes in the serum-free control wells 
compared to WT spleen cells, as determined by t test.*, p < 0.05; **, p < 0.01; ***, p < 
0.001. 
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Table 5.1: Expression of surface markers on CD45+ spleen cells for wild-type and 
FcyRIIIIII/IV KO mice 
Marker C57BL/6 WT 
Rat IgG Control 0.7 ± 0.1 
CD3 37±2 
B220 46 ± 1 
F4/80 1.6 ± 0.5 
CDllb 9.2 ± 0.3 
CD11c 2.9 ± 0.3 
Ly6G + CD11b 0.9 ± 0.1 
GR-1 + CDllb 2.1 ± 0.1 
CD94 1.6 ± 0.4 
CD16/32 62 ± 6 
FcyRIIIIIIIIV KO 
0.6 ± 0.1 
39±2 
49±4 
1.0 ± 0.3 
8.0 ± 0.1 
2.3 ± 0.3 
1.0 ± 0.4 
1.9 ± 0.3 
1.0 ± 0.5 
0.5 ± 0.1 
Mouse spleen cells were stained with rat monoclonal antibodies and analyzed by flow 
cytometry. Average total cell number isolated from the spleens was 115 ± 6 x 106 for 
C57BL/6 and 110 ± 8 x 106 for the FcyRII/III/IV KO. All samples were gated for CD45+. 
Results are percent positive cells expressed as mean± SEM (n = 3). 
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Table 5.2: Genes targeted for siRNA knockdown 
Target gene ID# Sense 5'~3' Successful 
reduction 
FCER1G (FcRy) s5062 GCUCUGCUAUAUCCUGGAUtt N 
s5064 CCAGCUAUGAGAAAUCAGatt y 
FCGR1A (FcyRia) s5068 GAAAAAGUGGGAUUUAGAAtt N 
s5070 GACUCUGGGUUAUACUGGUtt y 
FCGR2A (FcyRIIa) s5072 CUUCAACCAUUGACAGUUtt y 
s223524 AAACCAUCAUGCUGAGGUGtt y 
FCGR2B (FcyRIIb) s5073 CCUAUUCACUUCUCAUFCAtt y 
FCGR3A(FcyRIIIa) s5078 CAUUCGAAGCUCAACAAGAtt y 
s57396 CCUCCUGUCUAGUCGGUUUtt y 
Scrambled 4390843 N/A 
Succcessful reduction (Y) indicates a significant reduction in the protein levels of 
receptor after the addition of siRNA (p < 0.05; 1-way ANOVA, Dunnett's test). N- no 
reduction, N/ A - not applicable. 
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human PBMCs using concentrations up to 1.25 nM, as concentrations above 1.25 nM 
(scrambled or specific siRNA) nonspecifically inhibited fibrocyte differentiation (data 
not shown). The addition of hSAP to the PBMCs was delayed 24 hours to give time for 
the siRNAs to act. Reduction of levels of FcRy reduced sensitivity to hSAP (Figures 
5.5A, 5.5N, and 5.6A). These effects were not observed with a scrambled siRNA control 
(Figures 5.5A and 5.6A). This suggests that hSAP acts through activating FcyRs in 
regulating human fibrocyte differentiation, which corresponds with the data from FcRy 
KO mice (Figures 5.1A, 5.1B, and 5.2). Reducing the levels of FcyRI also significantly 
reduced sensitivity to hSAP (Figures 5.5A, 5.5C, and 5.6B). This suggests that hSAP acts 
at least in part through FcyRI to inhibit human fibrocyte differentiation. 
5.3.5 Reduction ofFcyRilb in human cells increases sensitivity to SAP. 
Reducing the levels of of FcyRIIa (Figure 5.7A) did not significantly affect 
sensitivity to hSAP (Figures 5.8A, 5.8C, and 5.8D). However, an increase in fibrocyte 
number was observed (Figure 5.8A), suggesting that this receptor could have a modest 
effect on fibrocyte differentiation. Reduction ofFcyRIIb levels (Figure 5.7B) resulted in 
a significant decrease in the number of fibrocytes even in the absence of hSAP (Figure 
5.8B), and an increase in sensitivity to hSAP (Figure 5.8E). This result is similar to the 
increased sensitivity observed in FcyRIIb knockout mice (Figures 5.2, 5.3A and 5.3B). 
Reduction of FcyRIIIa levels (Figure 5.7C) did not significantly alter sensitivity to hSAP 
(Figures 5.8B, 5.8F, and 5.80). These data suggest that FcyRIIa and FcyRIIb may affect 
fibrocyte differentiation, and that FcyRIIb appears to counteract SAP's ability to inhibit 
fibrocyte differentiation. 
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Figure 5.5: siRNA knockdown of FcRy and FcyRI (CD64) in human PBMC 
significantly reduces hSAP bioactivity. Human PBMCs were cultured in the presence 
of siRNA or an equal volume of serum-free medium. After 24 hours, hSAP was added to 
the cultures at 2, 1, and 0.5 ~g/ml. After 5 days, fibrocytes were counted. Results are 
normalized to the number of fibrocytes in the absence of siRNA. Values are mean 
percentage± SEM (n=5 FcRy, n=6 for FcyRI). (A) PBMCs were treated with 0.5 ~g/ml 
hSAP, and the change in SAP bioactivity was measured through fibrocyte counts. siRNA 
knockdown of FcRy and FcyRI significantly increased the number of fibrocytes 
compared to scrambled controls (t test). *, p < 0.05; ** p < 0.01. (Band C) IC50 levels 
were measured for hSAP's ability to inhibit fibrocyte differentiation. siRNA knockdown 
of FcRy and FcyRI significantly increased the IC50 levels of hSAP compared to siRNA-
free controls (1-way ANOVA, Dunnett's test). *, p < 0.05. 
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Figure 5.6: SiRNA knockdown of FcRy and FcyRI (CD64) significantly reduces the 
corresponding protein levels. Cells were stained for FcRy and CD64 and visualized 
with Dylight 488. Results are normalized to the mean fluorescent intensity of cells in the 
serum free control wells, and the results are expressed as the mean percentage ± SEM 
(n=3 for FcRy, n=4 for FcyRI). A minimum of 100 cells was counted per condition. The 
levels of (A) FcRy and (B) FcyRI were significantly reduced in cell cultures treated with 
siRNA (1-way AN OVA, Dunnett's test). **, p < 0.01; *** , p < 0.001. 
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A B 
c 
Figure 5.7: siRNA knockdown of FcyRIIa, -lib, and -Ilia significantly reduces the 
corresponding protein levels. Human PBMCs were cultured for 3 days in the presence 
of siRNA or an equal volume of serum-free medium, and were then stained for the 
associated receptor. Results are normalized to the mean fluorescent intensity of cells in 
the serum free control wells, and the results are expressed as the mean percentage ± SEM 
(n=3). A minimum of 100 cells was counted per condition. The levels of (A) FcyRIIa, 
(B) FcyRIIb, and (C) FcyRIIIa were significantly reduced in cell cultures treated with 
siRNA (1-way ANOVA, Dunnett's test).*, p < 0.05; ***, p < 0.001. 
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Figure 5.8: siRNA knockdown of FcyRIIa and FcyRIIIa does not significantly alter 
hSAP's bioactivity, while knockdown of FcyRIIb increases sensitivity to hSAP. 
Human PBMCs were cultured for 5 days in the presence of siRNA or an equal volume of 
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serum-free medium. At 24 hours, hSAP was added to the cultures at 2, 1, and 0.5 J.lg/ml. 
Results are normalized to the number of fibrocytes in siRNA-free wells, and the results 
are expressed as the mean percentage± SEM (n=3, n=6 for FcyRIIa). (A and B) PBMCs 
were treated with 0.5 J.lg/ml hSAP, and the change in SAP bioactivity was measured 
through fibrocyte counts. siRNA knockdown of FcyRIIb significantly decreased the 
number of fibrocytes compared to scrambled controls (t test). *, p < 0.05. (C - G) IC50 
levels were measured for hSAP's ability to inhibit fibrocyte differentiation. siRNA 
knockdown of FcyRIIb significantly decreased the IC50 levels of hSAP compared to 
siRNA-free controls (1-way ANOVA, Dunnett's test). *, p < 0.05. 
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5.4 Discussion 
To elucidate key components of SAP bioactivity, I examined how the different 
Fey receptors affect the ability of SAP to inhibit fibrocyte differentiation. However, in 
the absence of added SAP, deletion of FcyRIIb in mice and reduction of FcyRIIb in 
human cells both decreased the number of fibrocytes observed in cultures. Deletion of 
other FcyRs in mice, or reduction of their levels in human cells, also affected fibrocyte 
numbers, but there was no correlation between the mouse and human data. 
Deletion of FcyRI or the FcRy chain in mice, and reduction of FcyRI or the FcRy 
chain levels in human cells, significantly decreased but did not abolish the sensitivity of 
cells to SAP. This indicates that FcyRI and the FcRy chain play a major role in the signal 
transduction pathway that SAP uses to inhibit fibrocyte differentiation. However, the 
ability of SAP to inhibit fibrocyte differentiation in cells lacking FcyRI or FcRy suggests 
that SAP activates receptors in addition to FcyRI, and additionally activates a signaling 
pathway that does not require FcRy. 
In wild-type mice, SAP injections inhibit fibrosis, while in FeR{- mice, 
injections of the same amounts of SAP do not inhibit fibrosis (Castano et al., 2009; 
Haudek et al., 2008). Based on my observation that in cultures of FcRy·/- cells, only very 
high concentrations of SAP inhibit fibrocyte differentiation, we would predict that in 
FcRy"1- mice, injections of high concentrations of SAP should inhibit fibrosis. 
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Deletion of FcyRIII in mice, and reduction of FcyRIIa or FcyRIIIa levels in 
human cells (mice do not have FcyRIIa) had no significant effect on the sensitivity of 
cells to SAP. This suggests that FcyRIIa and FcyRIIIa do not play a major role in the 
effect of SAP on fibrocyte differentiation. However, the mutagenesis data from Chapter 
2 for the FcyRIIa-SAP interaction and the slightly increased fibrocyte numbers for the 
siRNA knockdown ofFcyRIIa does mean that FcyRIIa could play a modest role. 
Deletion of FcyRIIb in mice, and reduction of FcyRIIb levels in human cells, 
increased the sensitivity of cells to SAP. This suggests that FcyRIIb may activate a 
pathway that counteracts the ability of SAP to inhibit fibrocyte differentiation. An 
intriguing possibility is that signals that promote fibrocyte differentiation may be sensed 
by this receptor. The increased sensitivity to SAP could also be the result of FcyRIIb 
acting as a decoy receptor for SAP, although SAP does not have high binding affinity to 
FcyRIIb (Castano et al., 2009). 
The FcyRIIb/IIIa!IV triple KO spleen cells retained full sensitivity to SAP. I did 
not have access to the single FcyRIV KO, but the SAP activity in the triple KO mice 
suggests that FcyRIV is not essential for SAP bioactivity. However, the triple KO cells 
differentiated into an abnormally low number of fibrocytes. This suggests that fibrocyte 
differentiation may be regulated by unknown factors that signal using one or more 
pathways that interact with pathways regulated by FcyRIIb/IIIa!IV. Combined with the 
observations that cytokines, angiotensin II, leukotrienes, TLR agonists, and hyaluronan 
fragments regulate fibrocyte differentiation (Haudek et al., 2010; Maharjan et al., 2010, 
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2011; Shao et al., 2008; Vannella et al., 2007), my results showing that SAP uses FcyRI 
as well as other unknown receptors, and FcRy as well as other intracellular signaling 
components, indicates that a complex network regulates fibrocyte differentiation. 
For future directions, we will be testing SAP bioactivity in a quadruple FcyR KO 
to determine if other receptors are involved in the regulation of fibrocyte differentiation, 
including other receptors that utilize FcRy. The y chain is known to associate with the 
FceRI and dectin-2, mediators of the innate immune response involved in allergens and 
fungi, respectively (Sato et al., 2006). Recently, SAP was also found to weakly bind to 
FcaRI with a Kd of 3.2 J.!M, while SAP binds to FcyRs with an affinity in the nM range 
(Castano et al., 2009; Lu et al., 2011). FcaRI activates through the common y chain like 
FcyRs and similarly is expressed by monocytes, but FcaRI relies on engagement of lgA 
to elicit an immune response resulting in phagocytosis, antigen presentation, and the 
release of inflammatory cytokines (Herr et al., 2003). However, neither heat aggregated 
lgA nor heat aggregated lgE were found to inhibit fibrocyte differentiation, suggesting 
that these receptors are not likely candidates (Pilling et al., 2006). There remains some 
possibility, though, as SAP and IgG appear to inhibit fibrocyte differentiation through 
distinct but related pathways (Pilling et al., 2006). 
Chapter 6: Brain Serum amyloid P levels are reduced in individuals that lack 
dementia while having Alzheimer's disease neuropathology 
6.1 Introduction 
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In addition to elucidating SAP's functional domain, we are also interested in the 
bioactivity of SAP in various disease states to further our understanding on how SAP 
functions in vivo. SAP was originally identified as a major component of amyloid 
deposits and is even co-localized with the amyloid plaques associated with Alzheimer's 
(Pepys et a/., 1982; Duong et a/., 1989). Two key neuropathological hallmarks of AD 
are amyloid plaques, formed by extracellular aggregates of beta amyloid (A~) peptide, 
and intracellular neurofibrillary tangles, composed of hyperphosphorylated tau protein. 
Mild cognitive impairment (MCI) is an intermediate state on the path to AD, where 10-
15% progress to full stage Alzheimer's, and MCI individuals have a limited number of 
plaques and tangles (Guillozet et al., 2003). Interestingly, some people with high levels 
of beta amyloid plaques and neurofibrillary tangles, referred to as non-demented with AD 
neuropathology (NDAN), do not develop dementia (Aizenstein et al., 2008; Bennett et 
al., 2006; Reiman et al., 2009). Understanding the mechanism involved in such 
resistance would be important for the future development of novel, effective treatments 
for AD. 
The exact cause and progression of AD is still poorly understood. The hallmark 
amyloid plaques and neurofibrillary tangles are found in the regions of the brain that deal 
with memory and higher cognitive function, such as the cortex, hippocampus, basal 
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forebrain, and amygdala (Mattson et al., 2004). During the course of the disease, the 
patient experiences a loss of synapses, neuronal death, and neuroinflammation that is 
likely caused by soluble A~ oligomers that eventually will form plaques, as well as 
disruption by the hyperphosphorylated tau proteins (Lee et al., 2010). One risk factor for 
Alzheimer's is Apolipoprotein E (ApoE) which helps in the clearance of A~ peptides by 
promoting proteolytic degradation (Jiang et al., 2008). A specific allele of ApoE poses 
an increased risk for AD, APOE-e4, while e3 is neutral and e2 is protective (Corder et al., 
1993). 
SAP does not readily cross the blood brain barrier; however, neurons in the brain 
can produce SAP, and this production is upregulated in AD brains (Yasojima et al., 2000) 
although there is no difference in the cerebrospinal fluid (CSF) levels of SAP between 
AD patients and age-matched normal controls (Kimura et al., 1999; Mulder et al., 2002; 
Verwey et al., 2008). Among AD patients, one study using 70 patients found that higher 
CSF levels of SAP tended to correlate with less dementia (Kimura et al., 1999), while a 
smaller study using 20 patients did not observe any trend (Mulder er a!., 2002). SAP 
potentially contributes to the pathogenesis of Alzheimer's disease through the binding of 
amyloid plaques and neurofibrillary tangles (NFTs) (Coria et al., 1988; Kalaria and 
Grahovac, 1990; McGeer et al., 2001). SAP has been found to enter neurons, and at 
elevated levels can induce apoptosis in vitro and in vivo (Urbanyi et al., 2003; Urbanyi et 
al., 2007). Additionally, SAP was described to stabilize amyloid plaques by preventing 
the proteolysis of A~ fibrils (Tennent et al., 1995); however, other results suggest that 
addition of SAP actually inhibits initial fibril formation and dose-dependently increases 
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the solubility of A~ peptide (Janciauskiene et al., 1995). SAP binds to fibrils in all types 
of amyloid deposits, but SAP is not essential for this deposition (Pepys, 2006). However, 
amyloid deposition throughout the body in reactive systemic amyloidosis is significantly 
delayed in SAP knockout mice, suggesting that SAP plays an important role in the 
pathogenesis of amyloid diseases (Botto et al., 1997; Togashi et al., 1997). 
In this chapter, I show that SAP levels are reduced in the brains of NDAN 
individuals compared to the levels in the brains of AD patients. This reduction can be 
detected in both the hippocampus and frontal cortex. SAP staining is colocalized to the 
amyloid plaques and is reduced in NDAN hippocampal tissue compared to AD. This 
suggests that a reduced presence of SAP associated with senile plaques characterizes the 
amyloid deposits in the brain of individuals who do not develop dementia despite the 
presence of amyloid plaques and neurofibrillary tangles consistent with fully 
symptomatic AD. 
6.2 Methods 
6.2.1 Cases 
Frozen brain tissue samples were obtained from the Oregon Brain Bank at Oregon 
Health and Science University (OHSU) in Portland, OR. Donor subjects were enrolled 
and clinically evaluated in studies at the NIH-sponsored Layton Aging and AD Center 
(ADC) at OHSU. Control subjects were participants in brain aging studies at the ADC. 
Subjects received annual neurological and neuropsychological evaluation, with CDR 
assigned by an experienced clinician. Autopsies were carried out post mortem from 2 to 
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24 hours, with most cases under 10 hours (Table 1). All cases (n=4) classified as 
Alzheimer's fulfilled the National Institute of Neurological and Communicative 
Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association 
criteria for definitive Alzheimer's with histopathologic evidence of amyloid plaques and 
neurofibrillary tangles in the hippocampus and neo-cortex, as well as cognitive 
impairment with a mini-mental state exam (MMSE) score below 10. Control cases did 
not display cognitive impairment (MMSE of 28-30) and had either no or a very limited 
number of amyloid plaques and neurofibrillary tangles. Mild cognitive impairment cases 
had some cognitive impairment with MMSE scores in the mid 20S', and intermediate 
levels of amyloid plaques and neurofibrillary tangles. NDAN cases displayed little to no 
cognitive impairment (MMSE 26 to 30), while having extensive amyloid plaques and 
neurofibrillary tangles in the hippocampus and neo-cortex, comparable to full on-set 
Alzheimer's (Figure 1). 
6.2.2 Western Blot 
0.5 g of hippocampus or frontal cortex was homogenized in 1.5 ml of 0.32 M 
sucrose in 0.1 mM CaClz with 1% protease inhibitor cocktail (Sigma Aldrich, St. Louis, 
MO) and 1x phosphatase inhibitor cocktail (Thermo, Waltham, MA). Samples were 
diluted 1:20 in PBS/0.2% SDS/Triton-X 100, and protein concentration was determined 
by Bradford (Sigma). Samples were normalized to 2 mg/ml in 50 Jll SDS-PAGE sample 
buffer, run on 4-20% SDS-PAGE gels (Bio-Rad, Hercules, CA) and visualized by 
Coomassie stain to further confirm protein concentration. SAP concentration was 
determined by Western blotting as described previously (Pilling et al., 2003) with the 
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Table 6.1: Case studies 
Diagnosis Age Sex PMI Braak Plaque MMSE 
Stage8 Score8 
Control6 82.7 M 14 1 4 N/A 
Controlb 83.1 M 2 1 1 NIA 
Controlb 77.4 F 12 0 4 N/A 
Control >89 F 18 0 4 28 
Control 80 M 2 1 3 30 
Control 28 F 15.5 0 4 N/A 
Control 43 F 10 0 4 N/A 
Control 51 M 9.5 0 4 N/A 
Control 60 F 40.5 0 4 NIA 
MCIC >89 M 23 3 2 26 
MCIC 89 F 20 3 2 22 
MCIC >89 F 12 3 2 27 
MCI >89 F 4 2 3 25 
MCI 79 F 12 2 4 28 
ADb >89 M 3.25 6 1 2 
ADb 61 M 4 6 1 2 
ADb 79 N/A 6 6 1 N/A 
AD 82 F 19 6 2 9 
AD 60 N/A 4.5 6 2 N/A 
AD 64 M 9.25 6 1 1 
AD 62 F 6.5 6 2 7 
AD 87 M 8.75 6 2 N/A 
NDANb 87.8 M 3 4 1 29 
NDANb >89 F 4.5 6 1 27 
NDANC 87 F 2.5 2 3 29 
NDAN 87.6 F 10.5 5 2 29 
NDAN 89 F 2.5 5 2 27 
NDAN >89 F 18 6 4 30 
Abbreviations are as follows: MCI - mild cognitive impairment, AD - Alzheimer's 
disease, NDAN, non-demented with Alzhiemer's disease neuropathology, M- male, F-
female, PMI -postmortem interval in hours, MMSE- Mini-Mental State Examination, 
N/ A - not available. 
a Scoring based on Braak and Braak (Braak and Braak, 1991). 
Tissue sample from hippocampus unless otherwise noted. 
b Frontal cortex tissue only 
c Hippocampus and frontal cortex tissue 
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Ages Sex PMI Braak Plague MMSE 
Control 28- >89 4M/5F 13.7 ±3.8 1 ± 1 4±1 29± 1 
MCI 79- >89 1M/4F 14.2 ±3.4 3±1 3 ± 1 26± 1 
AD 60-87 2M/2F 9.6 ±2.5 6± 0* 2 ± 1 * 6±2* 
NDAN 87- >89 1M/5M 6.8 ±2.6 5 ± 1 * 2 ± 1 * 29± 1 
* denotes values significantly different than control values (p < 0.05; 1-way ANOVA, Dunnett's 
test) 
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Control AD NDAN 
Figure 6.1: Pathological signatures of AD occur in cognitively intact individuals 
(NDAN). Reactivity for A~ plaques (green, top row) and phosphorylated tau (green, 
bottom row) in the dentate gyrus of individuals classified as control (Braak 1, Plaque 3, 
MMSE 30), AD (Braak 6, Plaque 1, MMSE 2), or NDAN (Braak 6, Plaque 1, 
MMSE 27). DAPI mounting media was used to visualize nuclei (blue). Bar IOOJ..Lm. 
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following modifications. Commercially available SAP (EMD Biosciences, Rockland, 
MA) was used as loading controls. SAP was detected using a rabbit anti-SAP antibody 
(Epitomics, Bulringame, CA) at a 1:10,000 dilution. Quantification of band intensity was 
performed via ImageJ (Rasband, WS, NIH, Bethesda, MD) and statistical analysis was 
done with GraphPad Prism (Graphpad Software, San Diego, CA). 
6. 2. 3 Immunohistochemistry 
Five mm sections of the mid hippocampus were brought out of storage at -80 oc 
and equilibrated to -20 °C before embedding in Tissue-Tek O.C.T. compound (Sakura 
Finetek USA, Torrance, CA). 10 f.lm sections were cut and affixed to Superfrost Plus 
slides (Thermo Fisher Scientific, Waltham, MA), for storage at -80°C. After briefly 
equilibrating to room temperature, sections were rinsed in 0.1 M PBS and then fixed in 
ice-cold 4% paraformaldehyde for 15 minutes. After two brief washes in 0.1 M PBS, the 
sections were blocked and permeabilized for 1 hour in 0.1 M PBS containing 10% goat 
serum, 0.03% Triton-X, and 0.1% phosphatase inhibitor (Thermo Fisher). Incubation 
with primary antibodies in 0.1 M PBS containing 10% serum and 0.1% phosphatase 
inhibitor was carried out overnight at room temperature. Antibodies used were 4G8 anti-
beta amyloid (mouse, 1 :800) and pTau (Ser202; mouse, 1: 1000) from Pierce (Rockford, 
IL). Following two PBS washes, the slides were incubated for 1 hour with Alexa Fluor 
488 and 594 secondaries (1 :600; Invitrogen, Carlsbad, CA) in 0.1 M PBS containing 10% 
serum and 0.1% phosphatase inhibitor. Slides were again rinsed twice in PBS and once in 
distilled water before a 10 minute incubation with 0.3% Sudan Black B (EMD 
Chemicals, Gibbstown, NJ) in 70% ethanol to block lipofuscin autofluorescence (Romijn 
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et al., 1999). After two more rinses in distilled deionized water, Vectashield containing 
4',6-diamidino-2-phenylindole (DAPI) was applied (Vector Laboratories, Burlingame, 
CA), and coverslips were mounted. Nail polish was applied to seal the edges. 
For beta-amyloid and SAP staining, the same procedure was followed except that 
the sections were blocked and permeabilized for 1 hour in PBS/4% BSA/0.03% Triton X-
1 00. Sections were incubated overnight at room temperature with 1:800 4G8 in PBS-4% 
BSA. The next day, the slides were briefly washed twice in PBS, and the sections were 
incubated with 1:500 rabbit anti-SAP antibody (Epitomics) for 1 hour at room 
temperature, along with negative control antibodies. After four 5-minute washes, the 
slides were incubated with donkey anti-mouse Dylight 488 and donkey anti-rabbit 
rhodamine red X (Jackson ImmunoResearch) in PBS-4% BSA for 30 minutes. 
6.2.4 Image Analysis 
Images were acquired using a confocal laser-scanning module (Bio-Rad Radiance 
2000 with LaserSharp software; Hercules, CA) mounted on a Nikon E800 microscope 
with a 20x/0.75NA objective (Nikon USA; Melville, NY). Images were acquired with 
488 nm and 568 nm excitation. Images for comparisons were acquired with constant 
settings for laser power, detector gain, amplification gain, and offset. For the beta-
amyloid and SAP staining, DIC and fluorescence images were acquired using an 
Olympus FV1000 confocal microscope with a 20x/0.75NA objective and Micromanager 
software. 
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6.3 Results 
6. 3.1 SAP levels in the hippocampus and frontal cortex of NDAN individuals are 
significantly decreased compared to AD. 
Previously, SAP levels were found to be elevated in Alzheimer's patients. 
(Yasojima et al., 2000). We were therefore interested in looking at the level of SAP in 
NDAN patients who had the serious neurodegenerative hallmarks of AD but never had 
cognitive impairment. We also found that SAP levels were elevated in the hippocampus 
and frontal cortex of AD patients compared to controls with a four-fold increase to 110 
ng of SAP/mg of protein in AD (Figure 6.2A, 6.2B). Our results differ from the 1 J.!g of 
SAP/mg protein previously reported, because we looked at total homogenate, while the 
SAP and total protein concentrations in supernatants after centrifugation of homogenates 
were previously reported (Yasojima et al., 2000). Interestingly, SAP levels were 
significantly elevated in both the hippocampus and frontal cortex for AD patients 
compared to NDAN samples, even though both sets of cases had comparable number of 
amyloid plaques and neurofibrillary tangles that SAP associates with (Figure 6.2A, 6.2B). 
In the NDAN samples, the level of SAP in the hippocampus and frontal cortex were 
comparable to the controls. Levels of SAP in MCI patients were intermediate in the 
hippocampus, while at normal levels in the frontal cortex, which is to be expected due to 
the significantly lower number of plaques and neurofibrillary tangles found in MCI 
compared to AD (Guillozet et al., 2003). 
6.3.2 SAP staining is reduced at AfJ plaques for NDAN hippocampal sections compared 
toAD. 
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Figure 6.2: SAP levels in the hippocampus and frontal cortex of NDAN individuals 
are significantly decreased compared to Alzheimer's. 
SAP levels in homogenized brain tissue were measured by Western blot and compared to 
normal brain controls. Statistical significance was determined by 1-way ANOV A, 
Tukey' s test. *, p < 0.05; **, p < 0.01. Results are mean± SEM (n=6 for control 
hippocampus, n=5 for MCI and AD hippocampus, n=4 for NDAN hippocampus; n=3 for 
frontal cortex). 
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SAP co-localizes with amyloid plaques in the brains of AD patients (Duong et al., 
1989). On stained hippocampal tissue sections, no A~ plaques or SAP staining was 
visible in the normal-age-matched controls (Figure 6.3). NDAN sections had numerous 
plaques with extremely light staining of SAP, also localized to the plaque (Figure 6.3). 
The number of plaques in AD patients was similar to NDAN, but AD tissue sections had 
relatively strong SAP staining co-localized to the plaques (Figure 6.3). 
6.4 Discussion 
SAP levels are elevated in the brains, but not the CSF, of patients with AD. 
These patients have cognitive impairment and a significant number of amyloid plaques 
and neurofibrillary tangles in the memory and cognitive function area of the brain (Lee et 
al., 2010; Yasojima et al., 2000). MCI patients only have slight cognitive impairment, 
fewer amyloid plaques, and significantly less neurofibrillary tangles (Guillozet et al., 
2003). NDAN individuals have extensive amyloid plaques and neurofibrillary tangles 
like AD, while having little to no cognitive impairment (Aizenstein et al., 2008; Reiman 
et al., 2009). Here, I found that NDAN individuals have significantly lower levels of 
SAP compared to AD with levels approaching those of normal age matched controls. 
However, it is not possible at this point to mechanistically link the decreased levels of 
SAP to cognitive rescue. 
SAP is expressed by neurons in the brain, and normal elderly will develop low 
levels of amyloid plaques and neurofibrillary tangles (Bouras et al., 1994; Yasojima et 
al., 2000). Therefore, at least low levels of SAP are expected to be, and were, found. The 
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AD NDAD 
AP 
SAP 
Figure 6.3: SAP staining is reduced at AP plaques for NDAN compared to 
Alzheimer's. Hippocampus sections were stained for A~ (green) and SAP (red). Bar is 
50 !J.ffi. Representative ofn=3. 
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MCI samples showed intermediate levels (between AD and control) of SAP in the 
hippocampus, and in the frontal cortex the levels were indistinguishable from normal-age 
matched controls. This is also expected, since MCI individuals have significantly less 
infiltration of neurofibrillary tangles at that stage of the disease and possibly reduced 
plaque numbers. However, the low levels of SAP in NDAN individuals was not expected 
as high levels of plaques and tangles are located in both sections of the brains and SAP 
readily binds to both. This lack of SAP could therefore reflect biochemical changes 
leading to reduced SAP deposition. Further studies are needed to clarify the exact 
mechanisms involved. 
The lack of dementia and low SAP levels in NDAN individuals could potentially 
be due to a reduced inflammatory response. Typically in Alzheimer's, the presence of 
amyloid plaques and neurofibrillaey tangless activate inflammatory cells, including the 
microglia and macrophages, resulting in the release of cytokines and other inflammatory 
agents (Lee et al., 2010). The microglia could upregulate SAP production, which can in 
tum bind more A~ and result in additional plaques. For NDAN individuals, however, 
SAP could be acting predominantly in its role as an anti-inflammatory agent through 
opsonization and clearance of apoptotic neuronal cells, as well as downregulating the 
activation of infiltrating monocytes and macrophages with local IL-l 0 production 
(Castano et al., 2009). There would be a balance between SAP acting in a positive 
manner as an anti-inflammatory agent and SAP binding to amyloid plaques detrimentally 
as a pattern recognition protein. In the case of AD, the balance is shifted to SAP 
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predominantly binding to fibrils and plaques, while m NDAN individuals SAP is 
predominantly acting to reduce inflammation. 
Additionally, there could be a connection between SAP levels and ApoE, a risk 
factor for AD (Jiang et al., 2008). All NDAD patients in our study expressed the neutral 
APOE E3 allele while the AD patients had a mixture of alleles (personal communication 
with Dr. G. Taglialatela, UTMB). However, SAP is involved in the stabilization of A~ 
aggregates while ApoE promotes degradation of the soluble form (Tennet et al., 1995; 
Jiang et al., 2008). To explore any such connections, the study needs to be expanded to 
more cases. 
The drug CPHPC cross-links SAP pentamers to increase the clearance of SAP 
from the body, resulting in decreased SAP levels in the serum and CSF of Alzheimer's 
patients (Kolstoe et al., 2009). An intriguing possibility is that CPHPC could be used to 
prevent the onset of dementia by removal of SAP from the brain. It remains to be seen 
how CPHPC will affect amyloid clearance in the long term, and if it will help restore 
cognitive function. 
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Concluding Remarks 
As there is currently a large unmet medical need for treatments for fibrosing 
diseases, my work detailing how the potential therapeutic serum amyloid P regulates 
fibrocyte differentiation is of great interest. Fibrocytes have been implicated in two of 
the most prevalent and debilitating fibrosing diseases, cardiac and pulmonary fibrosis. 
We have previously shown that SAP can successfully treat both diseases in mice and rat 
model systems. Understanding specifically how SAP regulates fibrocytes could lead to 
improved or even new therapeutics. 
Although I was not able to determine the specific functional domain of SAP in 
Chapter 2, the work is still of importance in developing an expression system for future 
mutagenesis experiments, and for eliminating two regions of SAP as the major functional 
domain. Expressing bioactive, native SAP was a long and arduous process that many 
commercial companies failed to do (personal correspondence with Promedior), and now 
we can use this method to evaluate new regions of SAP through mutagenesis. When the 
region of SAP was mutagenized that was similar to the IgG 327 ALP APe33 binding region, 
there was no significant change in SAP's bioactivity, suggesting that SAP does not bind 
to the FcyR in the same manner as IgG. There was only a modest change in SAP 
bioactivity when residues were altered that were critical for SAP binding to FcyRIIa in a 
crystal structure. This result suggests that residues 173 and 174 may mediate some but 
not all of SAP bioactivity, and that the critical domain regulating fibrocyte differentiation 
lies elsewhere. 
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In Chapter 3, I developed an assay for measuring receptor binding for when we 
find a mutant that lacks bioactivity, and we want to see if the mutant still binds to the 
receptor. During the development of the assay, we expanded our knowledge of SAP 
biology. SAP has a pattern recognition site to bind apoptotic material or pathogens, and 
such binding does not appear necessary for efficient receptor binding to FcyR, although 
there is the possibility that BSA acts as a very weak ligand to SAP. Additionally, SAP 
does not compete with aggregated IgG for binding to FcyRs in our ELISA assay, 
suggesting that they bind to different locations on the receptor, which also agrees with 
our mutagenesis analysis for the IgG binding region. 
In studying factors that regulate fibrocyte differentiation, we are very limited in 
genetic diversity and in studying diseased states if we only utilize human cells. 
Therefore, there was a specific need for a rapid assay to study such factors in mice, where 
one can knock out genes and/or induce a model diseased state. However, the amount of 
cells one gets from the blood of a single mouse is very limited. In Chapter 4, I solved 
this issue by developing a quick, efficient fibrocyte differentiation assay utilizing mouse 
spleen cells and pro-fibrotic cytokines. We are now able to test factors within a period 
of only 5 days in serum-free media to eliminate any non-specific serum effects. 
Additionally, we can get n=3 using 3 mice instead of the previous requirement of 9 or 
more, which is expensive when dealing with knock out mice. 
152 
Utilizing the assay from Chapter 4, I determined that FcyRI and the FcRy chain 
play a major role in the signal transduction pathway that SAP uses to inhibit fibrocyte 
differentiation. However, the ability of SAP to inhibit fibrocyte differentiation in cells 
lacking FcyRI or FcRy suggests that SAP activates receptors in addition to FcyRI, and 
additionally activates a signaling pathway that does not require FcRy. Additionally, I 
found that FcyRII knock out spleen cells are even more sensitive to SAP, and a similar 
effect was observed in human cells when siRNA was used to knock down the level of the 
FcyRIIb. Using siRNA on the human FcyRs, I obtained results comparable to the 
mouse KOs, suggesting that a result in one system can potentially be extrapolated to the 
other. Overall, this finding of FcyRI as a major receptor in regulating fibrocyte 
differentiation is important since therapeutics could potentially be targeted to the specific 
SAP receptor, and knowledge of the specific receptor will help us investigate fibrocyte 
biology within fibrosing diseases. 
Finally, I determined that SAP levels in NDAN individuals, that lack dementia, 
are significantly lower than Alzheimer's patients, when both have similar levels of 
amyloid plaques and neurofibrillary tangles. My findings are just a preliminary report, it 
is not possible at this time to mechanistically link decreased SAP levels to cognitive 
rescue. However, this finding could eventually be the basis for preventing disease 
progression in AD or used as a biomarker to determine if an individual will develop 
dementia. 
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